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Abstract 
Monitoring changes in protein higher order structure (HOS) is an important regulatory requirement 
for reasons of safety, efficacy and potency of the resultant therapeutic. In particular, as monoclonal 
antibodies (mAbs) emerge rapidly as a dominant class of therapeutics, so does the need for suitable 
analytical technologies to monitor for changes in HOS of these complex large biomolecules. 
Reference materials (RM) serve a key analytical purpose of benchmarking the suitability and 
robustness of analytical procedures for both drug producers and regulators.  Here two different 
model systems, of increasing complexity based on commercially available RMs, have been 
developed  and used to illustrate the assessment of repeatability and reproducibility of a range of 
mass spectrometry based analytical platforms for protein HOS measurements.  The simplest model 
protein RM, recombinant human growth hormone, rhGH, was used to illustrate the development 
and systematic evaluation of more established platforms hydrogen deuterium exchange-mass 
spectrometry (HDX-MS) and ion mobility spectrometry-mass spectrometry (IMS-MS) and a more 
novel platform, fast photochemical oxidation of proteins (FPOP-MS) for protein HOS 
measurements. Both global and localised changes in rhGH HOS, induced due to the presence of 
zinc ligands were identified using the methods developed and cross-platform measurements 
compared. Structural conclusions were underpinned using a statistical approach developed for 
HDX-MS measurements in which measurement variability was differentiated from small but 
significant changes in HOS. These HDX-MS and IMS-MS methods approaches were validated 
using a mAb-based RM from the National Institute of Science and Technology (NISTmAb) and 
two Fc-glycan variants generated using a simple enzymatic protocol and structural changes 
characterised. Measurements reproducibly demonstrated decreases in structural stability as a result 
of loss of Fc-glycan structure. These data promote the use of these, rhGH and NISTmAb RM based 
model systems, for both validating and establishing the sensitivity of analytical methods for the 
detection of HOS changes of mAbs and other protein therapeutics. These data also demonstrate the 
suitability of HDX-MS, IMS-MS and FPOP-MS as valuable analytical methods within the 
biopharma toolbox. 
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Chapter 1 
Introduction 
The introduction of this thesis aims to present established scientific theory to support 
the experimental data presented herein in the later parts of this thesis. The introduction 
can be separated into two sections; mass spectrometry (MS) theory and the application 
of MS methodologies for the measurement of proteins and protein higher order 
structure.  
1.1 Mass Spectrometry theory 
MS is an analytical technique that facilitates the study of gas-phase ions, measuring 
them based on their mass-to-charge (m/z) ratio and intensity.  Measurements can be 
used to abstract masses of single elements, molecules or used to gain structural 
insights into the composition of a molecular ion. It is the ability to provide both 
qualitative and quantitative insights regarding an analyte that makes MS such 
powerful analytical technique. 
In light of the scope of this thesis, the theory presented here will focus on MS  
techniques relating to the analysis of proteins and peptides and the specific MS 
instrumentation used to produce the data described herein.  A general overview of the 
history of MS and the principles of the technique will be provided before discussing 
the technical details of the main components of a mass spectrometer including 
ionisation, mass analysis and detector stages of the instrumentation, and finally the 
hyphenation of ion mobility spectrometry (IMS) apparatus within the MS workflow.  
1.1.1 History and overview 
The development of MS goes back over a century, to J.J. Thomson’s experiments in 
where he used magnetic and electric fields to deflect positively charged canal rays 
within a discharge tube. By evaluation of the deflected parabolas, collected on a 
photographic plate situated at the end of the tube, Thomson was able to obtain the first 
mass spectrum of several elemental ions including H+, H2+ and He ions and the 
isotopes Ne20 and Ne22  [1].   
Developing the instrumentation further, his research assistant, F. Aston, who 
introduced superior velocity focusing, giving birth to the first focusing mass 
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spectrometers, which would later provide the first proof of the existence of isotopes 
[2].   
Mass spectrometers have come a long way since the days of Thomson and Aston, 
though, essentially those founding characteristics of Aston’s first mass spectrometer 
remain. Mass spectrometers can be simplified to three essential elements, a) an 
ionisation source, used to produce gas-phase ions, b) a mass analyser, which sort ions 
based on their mass-to-charge ratio (m/z, Th) via magnetic and/or electric fields and a 
c) detector, measuring the ions in proportion to their abundance (Figure 1).  The 
electrical output from the detector is then converted via data analysis algorithms, into 
a mass spectrum, reflecting the m/z of ions present vs relative intensity.   
To maximise the ion free path, both the mass analyser and detector stages are operated 
at high vacuum (low pressure) allowing ions to reach the detector without undergoing 
collisions with other gaseous molecules preventing unwanted reactions,  
fragmentation or charge loss of the analyte ion. An electrical gradient applied across 
the instrumentation transmits the ions from the source to the detector, though often 
additional ion guides are used.  
 
 
Figure 1. Schematic of the components found in all mass spectrometers, an ionisation 
source, a mass analyser and a detector. 
Though these components described represent the foundation of every mass 
spectrometer, modern day mass spectrometers vary widely in the types of components 
used and the configurations adopted. Such configuration can include the presence of 
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multiple mass analysers, carefully selected to fulfil resolution, mass accuracy, mass 
range and sensitivity requirements for a given analysis of a chemical species.   
1.1.2 Ionisation sources 
As a previously mentioned, the first stage of the mass spectrometer is that on the 
ionisation source. Many types of ionisation sources are available and are typically 
grouped into what is referred to as “hard” and “soft” ionisation sources and are 
selected based on the properties of the analyte being measured. For small volatile 
molecules, “hard” sources such as electron impact (EI) or atmospheric pressure 
chemical ionisation (APCI) are often applied. However for less volatile and larger 
molecules, such as the analytes discussed in this thesis, “softer” ionisation techniques 
are required to produce intact gas phase ions and avoid over fragmentation of the 
analyte mol 
ecules; these techniques include matrix-assisted laser desorption ionisation (MALDI) 
and electrospray ionisation (ESI). The theory of ESI will now be discussed in greater 
detail reflecting the use of the technique to produce the data presented in this thesis. 
1.1.2.1 Electrospray ionisation (ESI) 
Early MS ionisation sources required a gas phase analyte, restricting MS analysis to 
small volatile and stable compounds.  However, the analytical space covered by MS 
was revolutionised by the development of electrospray ionisation (ESI) in 1984 by 
Fenn and Yamashita [8],  which allowed the analysis of analytes directly from the 
solution phase at atmospheric pressures. Importantly, this “soft”  method of ionisation 
induced little or no fragmentation during ionisation, allowing large bio-
macromolecules to survive the transformation from the liquid- into the gas-phase 
intact and facilitating their subsequent MS detection [3].  
The applicability of ESI to wide mass ranges, from several hundred Da up to ~MDa  
[4, 5], combined with the technique’s ability to produce multiply charged ions, i.e. 
[M+zH]z+, has revolutionised the world of bioanalysis giving birth to the “omics” 
fields.   
The production of gas-phase ions during ESI can simply be broken down into three 
main stages a) the production of charged droplets, b) shrinkage of these droplets due 
to evaporation and c) the production of gas-phase ions.  
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During ESI, an analyte solution is flowed through a charged capillary, ~ kV, and into 
an electric field applied at the entrance of the mass spectrometer. Charge accumulation 
occurring at the liquid surface of the capillary tip, causes repulsive forces to build, 
forming what is known as a Taylor cone. These repulsive forces combine with the 
pulling force of the electric field and disperse the liquid into a fine aerosol [6, 7] 
containing smaller droplets with high excessive surface charges and neutral interiors. 
Evaporation caused by applied drying gases (often N2), cause the surface tension and 
coulombic repulsion of these droplets to increase until the Rayleigh limit  is exceeded 
by the surface charge [8], resulting in fission of the droplet into smaller successive 
droplets. These cycles continue until a single desolvated charged analyte ion is 
produced, though the exact mechanism of this final ion formation step is thought to 
be analyte dependent and can be described by the following models and in Figure 2, 
below; 
The ion evaporation model (IEM) [9], describes when the radius of a droplet 
becomes  ≤10 nm,  a small solvated ion is ejected from the droplet surface as a result 
of the high surface charge. Excess solvation of this ion is then lost through collisions 
with background gas ions resulting in a single fully desolvated ion.  This model is 
thought to be the dominating ion release mechanism for small low molecular weight 
species [10, 11].   
The charge residue model (CRM) [12], is widely accepted as the dominant ion 
production mechanism for large globular species, such as natively folded proteins. 
The process describes how nano-droplets containing single analyte ions evaporate to 
dryness. As droplet size decreases during the evaporation process, protons are ejected 
from the surface via IEM, shedding charge as the radii decreases, so as to maintain 
the surface charge within the Rayleigh limit. This process repeats itself until no 
solvent buffer remains and the analyte ion adopts any residual charge on the surface 
as its own.  
The chain ejection model (CEM), was recently proposed by Konermann et al [13], 
as a mechanism for ion production for intrinsically disordered proteins. During the 
drying stages of the droplet formation, a charged hydrophobic region of the disordered 
poly-peptide chain is ejected from the droplet to reduce surface charge, as with in 
IEM. This process continues until the whole disordered polypeptide chain is ejected 
as a charged ion.  
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 Figure 2. The production of gas-phase ions during ESI. Charged droplets are 
produced from an analyte containing solution by a) flow through a charged 
capillary into an electrical field and dispersed via a Taylor cone b) these charged 
droplets then undergo shrinkage due to multiple rounds of evaporation and 
fission until finally producing an analyte ion; c) three different models exist for 
describing the mechanisms of ion release from charged droplets, the ion 
evaporation, charge residue and chain ejection models and vary based on analyte 
type, generally existing for small molecular weight molecules, large globular 
species such as proteins and intrinsically disordered proteins respectively. The 
exact mechanisms are explained in the text, section 1.1.1.   
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The introduction of nano ESI (nESI), using nL/min flow rates, has further progressed 
“soft” ionisation. The smaller capillary orifice produces smaller  droplets, with more 
favourable surface area to volume ratios, requiring less evaporation and removing the 
need for denaturing source conditions [14]. nESI also exhibits higher ionisation 
efficiencies and salt tolerances permitting the use of less volatile buffers, allowing 
more biologically native-like environments for analysis [15].  
Following the generation of ions, the ions are then guided into the mass spectrometer 
to undergo m/z separation in the mass analyser. 
1.1.3 Mass analysers 
A extensive range of mass analysers exist, each operating with an individual ion 
separation principle, varying in mode of action to transmit and separate analyte ions 
based on their m/z. The selection of the most appropriate mass analyser type is a key 
step in the analytical process, dependent on the properties of the analyte post 
ionisation and the context for which the analysis is occurring.   
Mass analysers can be best described and compared based on five fundamental 
characteristics, mass range limit, analysis speed, transmission, mass accuracy and 
mass resolving power;  
Mass range limit, describes the m/z range across which the mass analyser can 
separate ions across and defined in unit of, Th, or u, if an elemental charge is defined, 
such as z =2. This limit can be theoretically limitless, such as with time-of-flight (ToF) 
mass analysers, or be defined to a specific upper mass limitation such is the case with 
a quadrupole mass analyser.  
Analysis speed, is the speed at which a mass analyser can perform measurements 
across a given mass range, and is typically expressed in units per second (u s-1). 
Transmission is the ability of the mass analyser to transmit ions from the entrance of 
the analyser to the detector and is calculated by the number of ions entering the mass 
analyser divided by the number of ions reaching the detector. The transmission of an 
analyser is related to the sensitivity of the mass spectrometer, though ionisation 
efficiency, duty cycle and detector sensitivity are also contributing factors. 
Mass accuracy, describes the accuracy at which the mass analyser is able to measure 
the m/z of an ion (m/z measured) compared with its theoretical m/z value (m/z theoretical), 
and is often expressed, as parts per million (ppm) as; 
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Equation 1 
Mass accuracy (ppm) =  [
𝑚/𝑧 measured −  𝑚/𝑧theoretical
𝑚/𝑧𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙
]  𝑥 106 
 
 
Figure 3. Illustration of the concepts of mass resolution.  Peak width at 50% a) full 
width half maximum (FWHM) and b) two peaks are considered resolved if the 
mass difference between the valley between them ≤ 50% of their height. For 
Orbitrap instruments the valley must be ≤ 10% of their height.  
Mass resolution and/or resolving power, describes the mass analyser’s ability to 
distinguish between signals of two ions of similar m/z (Figure 3 b). Though these 
expressions of mass resolution and resolving power are often used interchangeably, 
they do in fact define two slightly different properties of a mass analyser.  According 
to IUPAC guidelines[16], mass resolution refers to the m/Δm, where m is the mass of 
the ion of interest and Δm is the spacing between two adjacent ions of similar m/z with 
the valley of a defined % threshold between. This percentage threshold is often mass 
analyser specific, for example a ToF mass analyser, a percentile maximum of 50% is 
used (Figure 3 b), whereas for an Orbitrap mass analyser this value is 10% [17]. 
Resolving power, defines the ability of the mass spectrometer to distinguish between 
two peaks of very similar m/z, and is expressed in terms of the peak width in mass 
units.  
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Mass accuracy is intrinsically linked to the mass resolution of the mass analyser, such 
that a low resolution analyser will give poor precision on the m/zmeasured , resulting in 
an inaccuracy of the centroid m/zmeasured . 
Mass analysers can be separated into two main classes based on their ion separation 
principles, scanning devices such as quadrupoles and non-scanning devices such a 
time-of-flight and Orbitrap mass analysers.   
1.1.3.1 Quadrupole mass analysers 
Quadrupole mass analysers [18–20] are scanning devices, using dynamic electric 
fields to filter and direct the transmission of ions, of a particular m/z value, towards 
the detector at a given time. They are generally considered low resolution instruments, 
typically operated at unit resolution, but have high scanning speeds and high 
sensitivity.  
Quadrupoles consist of four cylindrical rods, assembled into two electrically linked 
perpendicular pairs (Figure 4).  To each pair, opposing electric potentials, consisting 
of both direct current (DC), U, potentials and an oscillating radio-frequency (RF), V, 
voltages are applied.  Each of these pair of rods are within phase ( + or -), but in 
opposing phase with the other perpendicular pair, and at any given time, t, the total 
potential applied, ϕT, to each set of poles can be described by;  
Equation 2 
ϕT = U + Vcosωt 
Equation 3 
 -ϕT =  - (U + Vcosωt) 
 
It is these potentials applied to these poles, that dictates if an ion of a given m/z will 
have a stable trajectory through the quadrupole to the detector. Half the distance 
between each pair of hyperbolic rods, is termed ro.  
As an ion enters the mass analyser, it traverses towards the detector along the z axis, 
however, additional oscillation also occurs in both the x and y trajectories in response 
to the applied fields to the rod pairs. These oscillation strengths are dependent on the 
particular m/z of the ion, if there is an unstable trajectory in either x or y planes, 
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collision of the ion with these rods occurs, causing the ion to be neutralised and 
prevented from reaching the detector. In general, lighter ions experience larger effects 
from the oscillating V potential, whilst the U potential dominates for heavier ions [21].  
 
 
Figure 4.  Schematic of a quadrupole mass analyser and detector. As ions, generated 
at the source, enter the quadrupole they traverse towards the detector along the 
z axis whilst also experiencing oscillations in the x and y axis under the influence 
of the opposing electric potentials applied to the two pairs of hyperbolic rods 
that make up the quadrupole.  
To understand whether an ion will experience an unstable or stable trajectory we can 
consider the Matthieu’s differential equations, which models the theoretical stable 
trajectories of a series of ions should no collision with quadrupole rods occur (Figure 
5). For a quadrupole, increasing U and V voltages whilst maintaining them at a 
constant U/V ratio, facilitates the transmission of multiple ions. Figure 5, illustrates 
two scanning lines, presented in blue and red, each line maintaining a constant U/V 
ratio yet the linear rate of potential increase (or slope) is changed between red and 
blue lines respectively. The area underneath each prospective slope indicates those 
ions which have stable trajectories in both the x-z and y-z dimensions, so that their 
trajectories are < ro, preventing collision with the hyperbolic rods and their successful 
transmission to the detector.  
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Figure 5.  Stability areas of a series of ions ( m1 < m2 < m3) as a function of U (DC) 
and V (RF) potentials. Multiple ions are transmitted through the mass analyser 
by a linear increase of potential whilst maintaining a constant ratio of U/V. The 
red and green lines represent two differing scanning modes, stable ion 
trajectories for each slope are indicated by the area underneath the respective 
scanning line.  A lower resolution mode is represented by the green line, in 
which all m1, m2 and m3 ions are transmitted, however due to overlapping 
profiles, m2 and m3 ions are unresolved.  The red line represents a higher 
resolution mode in which m2 and m3 are resolved yet m1 is no longer transmitted.  
Figures adapted from de Hoffman and Stroobart [22].  
If we consider the green slope, m1, m2 and m3 are all transmitted, yet, as a result of  
their overlapping profiles m2 and m3 ions are unresolved. Increasing the scan slope 
from green to red, increases the resolution of the scan, that is the ability to separate of 
the m2 and m3 ions, however prevents the transmission of the m1 ion. Therefore it is 
the scan slope which defines the resolution of a quadrupole MS experiment.  
In contrast, the absence of the applied U potential allows the transmission of all ions, 
yet resolution becomes zero. If we increase V from 0 to past m1, then all ions with 
mass < m1 will experience unstable trajectories, therefore it is the applied V potential 
that dictates the minimum transmission mass of an ion, thus dictating the scanning 
range of the experiments.  
1.1.3.2 Time-of-flight (ToF) mass analysers 
In contrast to quadrupole based mass analysers, ToF mass analysers are other non-
scanning devices transmitting all ions within a m/z range from a single pulse of ions 
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and recording a mass spectrum of all ions present. Theoretically with no upper mass 
limitation, they are particularly amenable to analysing large molecular weight ions, 
and hence ToFs are particularly amenable the analysis of intact large biomolecules.  
The principle of ToF analysers was first described by 1946 by Stephens[23], but it 
was not until 1955, when the designs of Wiley and McLaren [24] were used to produce 
the first commercially available instrumentation that their first practical application 
was realised. 
ToF mass analysers separate ions of differing m/z based on their varying velocities as 
they drift though a field free region, known as a flight tube, following their 
acceleration by an applied electrical field.  The ions are accelerated by an applied 
potential gradient between source and extraction grid, and the ToF mass analyser 
measures the time, t, taken for an ion, of m/z, to move through the flight tube and hit 
the detector situated at the end of the flight tube. Early generation ToF instrumentation 
were based were based on linear ToF mass analysers, such as represented in Figure 6. 
Considering an ion of mass, m, and a total charge of q=ze,  as it leaves the source and 
is accelerated by a potential Vs, its electronic potential energy Eel is converted into 
kinetic energy Ek, as described by; 
Equation 4   
 𝐸𝑘 =
𝑚𝜐2
2
= 𝑞𝑉𝑠 = 𝑧𝑒𝑉𝑠 =  𝐸𝑒𝑙 
This can be rearranged to calculate an ions velocity, v; 
Equation 5  
  𝜐 = (
2𝑧𝑒𝑉𝑠
𝑚
)1/2 
revealing a velocity dependence of the m and z of an ion. So therefore, everything 
being equal, a lighter ion will reach the detector faster than a heavier ion.   
Following the initial acceleration of the ion, the ion travels in straight line at constant 
velocity until it reaches the detector. The time, t, needed to travel the length of the 
path, L, to the detector is given by; 
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Equation 6  
 𝑡 =
𝐿
𝜐
 
Combining Equation 5 and Equation 6, gives us; 
Equation 7 
 𝑡2 =  
𝑚
𝑧
(
𝐿2
2𝑒𝑉𝑠
) 
If path length and applied potentials are constant, a value for the m/z of an ion can be 
calculated from the measurements of t2. 
The resolution of a ToF mass analyser is defined by; 
Equation 8 
𝑅 =
𝐿
2∆𝑥
 
where Δx is equal to the thickness of the packet of the ions approaching the detector, 
and resolution is proportional to flight time and path length. Increasing path length is 
one way to increase the resolution of the instrument, although this can have a negative 
effect on sensitivity of the mass analyser as a result of reduced ion transmission due 
to ion scattering or angular dispersion of ion beam.  
Earlier generation linear ToF instruments were plagued by poor resolution, caused by 
several factors resulting in apparent flight time distributions among ions of the same 
m/z. These factors included; variations in ion formation pulse lengths resulting in the 
formation of ions at differing times (temporal distribution), the formation of ions at 
slightly different positions within the source (spatial distribution) and variations 
existing in the initial Ek of the ions (kinetic energy distributions). To overcome these 
factors leading to significant resolution improvements of ToF instruments, two 
methods in particular, delayed pulsed extraction and use of a reflectron, were 
developed. 
Continuous extraction (Figure 6 a), used in conventional instrumentation, involves the 
immediate acceleration of ions towards detector following ionisation. Any variations 
in Ek, will result in isobaric ions reaching the detector at different times, causing peak 
broadening in the resultant mass spectra.   
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Delayed pulsed extraction, however, allows for the correction of Ek distributions 
amongst isobaric ions by the application of a delay between ion formation and ion 
extraction towards the detector (Figure 6 b). Those ions with lower Ek, situated closer 
to the pulse, experience greater acceleration than those ions with an initially higher 
Ek. This difference in velocities allows both these ions to hit the detector at the same 
time, improving peak resolution of the resultant mass spectra. Delayed extraction can 
be thought of in terms of energy focusing of the ion beam, achieved either by adjusting 
the amplitude of the voltage pulse or by the time delay between ion formation and 
extraction phases. Hence resolution can be optimised by optimisation of both pulse 
amplitude and delay.  
The reflectron consists of a series of ring electrodes and grids which are used to create 
a retarding electric field (Figure 7) [25]. Positioned at the opposing end of the 
pusher/source within the flight tube, the reflectron reflects the ions back through the 
flight tube towards the detector now situated near the source.  The depth at which an 
ion will penetrate the reflectron is dependent on the Ek of the ion. Ions with higher Ek 
penetrate the reflectron further than an isobaric ion of lower Ek before being reflected 
back towards the detector, hence the higher velocity ion will exhibit a longer flight 
time. Tuning of the reflector voltage allows for the point at which two isobaric ions 
of differing Ek react the detector to be aligned, minimising the impact of Ek 
distributions on resolution.  
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Figure 6. Schematic describing two extraction modes within a linear ToF mass 
analyser. Two isobaric ions that differ only in kinetic energy, one high (dark 
blue) and one low (light blue) energy are represented.  During an a) continuous 
extraction mode, this disparity in kinetic energy of the ions, leads to variations 
in flight time and ultimately poor resolution. Using a b) delayed extraction 
mode, a delayed pulse is applied to the ions prior to them reaching the flight 
tube, leading to an increased acceleration towards the detector. The lower energy 
ion situated closer to the source of the pulse, experiences greater acceleration 
resulting in an increased velocity and both ions reaching the detector at same 
time. This leads to subsequent increased resolution of the resulting mass spectra.  
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1.1.3.3 Orthogonal-acceleration ToF mass analysers 
The coupling of ToF mass analysers with pulsed ionisation techniques, such as 
MALDI, is directly compatible, due to their provision of short, defined ionisation 
times and small localised ionisation region. Yet, the requirement of the pulsed 
injection of ions into the flight tube, makes the pairing of linear ToF mass analysers 
with continuous ion sources (i.e. ESI) incompatible.  
However the development of orthogonal-acceleration ToF (oa-ToF) mass analysers 
by Dawson et al. [26], included adaptations to bring the two technologies together. 
These adaptations allow for a continuous ion beam to be transformed into pulsed 
packets of ions, with precisely defined injections times, that are introduced into a 
perpendicularly positioned ToF flight tube (Figure 8). As the continuous ion beam is 
directed from the source it passes into the orthogonal accelerator and across an 
electrical pusher plate, situated opposite to the entrance to the flight tube.  Periodic 
application of an injection pulse voltage creates packets of ions which are pushed 
towards the flight tube in a field free region. As they reach the entrance of the flight 
tube these ions are then accelerated towards the detector using acceleration voltages 
as with conventional ToF. The combination of these two technologies has been 
revolutionary in maximising the high efficiency and compatibility of chromatography 
techniques with continuous ionisation sources whilst achieving the high resolution 
mass analysis of ToF mass analysers. There is however a price to pay for this 
combination, however, and this if in the form of the reduced duty cycle of the oa-ToF 
instrument due to the need to wait for one packet on ions to reach the detector before 
the next pusher event.  
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Figure 7. Schematic of a reflectron ToF instrument. Two types of ion, of the same m/z 
but differing kinetic energy, high energy (dark blue) and low energy (light blue) 
are produced at the source. The greater velocity of the higher energy ion, causes 
the ion to reach the reflectron first and penetrate it further. The lower energy ion 
is reflected back towards the detector at a shorter distance and thus overall has 
a shorter flight path. Appropriate tuning of the reflectron voltage allows both 
ions to reach the detector simultaneously, improving resolution of the mass 
analyser. 
 
 
 
Figure 8. Schematic of an orthogonal accelerator-ToF instrument. Ions from a from a 
continuous ionisation source are pulsed into a ToF mass analyser via an 
orthogonal accelerator.  
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1.1.3.4 Orbitrap mass analysers 
Orbitrap mass analysers are electrostatic ion trapping instruments, that operate on a 
principle of trapping ions based on their attractions to an electrically charged spindle. 
Unlike ToF and quadrupole based instrumentation, they are devoid of a physical 
detector but instead convert the frequency of an ions oscillation within the trap into a 
m/z value via Fourier Transform (FT). The concept of electrostatically trapping ions 
around a central spindle was first described by Kingdon [27] as early as 1920s, yet the 
orbitrap mass analyser was not developed until 1990s by Alexander Makarov [28] and 
not commercialised by Thermo Fisher Scientific in 2005. Like other FT-MS 
instruments, it demonstrates high resolution, high mass accuracy and wide mass 
range.  
The Orbitrap itself consists of two electrodes, an outer barrel shaped electrode of 
which a second central spindle shaped electrode is located at its heart (Figure 9). The 
electrodes are separated by a small gap and a DC potential of several kV applied to 
the central electrode, with the outer electrode grounded. As ions are injected into the 
side of the outer electrode, they begin to rotate around the central electrode. The ions 
also start to oscillate up and down the central electrode, forming spindle like orbital 
oscillation due to the potential and the Orbitrap’s specific geometry. This harmonic 
oscillation along the axis of the applied field, is defined by a specific frequency which 
in turn in converted into the m/z of the ion by FT.  
To describe this process in more detail, we consider the potential inside the trap, U, 
where r and z are cylindrical coordinates of the trap, C is constant, k is field curvature, 
and Rm is the characteristic radius we can obtain: 
Equation 9 
𝑈(𝑟, 𝑧) =  
𝑘
2
(𝑧2 −
𝑟2
2
) +  
𝑘
2
(𝑅𝑚)
2𝑙𝑛 (
𝑟
𝑅𝑚
) + 𝐶 
From this equation it is observed that the voltage gradient in the z direction, is 
proportional to k; 
Equation 10 
𝜕𝑈(𝑟, 𝑧)
𝜕𝑧
= 𝑘𝑧 
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Figure 9. Schematic of an Orbitrap mass analyser. As ions are entered into the 
Orbitrap, the applied potential to the central electrode causes the ions to orbit 
the electrode whilst also oscillating in the z axis, forming a spiral like motion. 
These spiral like motions are of a specific frequency which can be related to the 
m/z of the ions by Fourier Transform.  
Accelerating an ion of mass, m and total charge q=ze, along the z axis, using the force 
from an electrical field, we can consider that electrical force, -qkz, equal to the mass 
times the acceleration, m(d2/dt2): 
Equation 11 
𝐹𝑧 = 𝑚
𝑑2
𝑑𝑡2
=  −𝑞
𝜕𝑈
𝜕𝑧
= −𝑞𝑘𝑧   𝑜𝑟  
𝑑2𝑧
𝑑𝑡2
=  −
𝑞
𝑚
𝑘𝑧 
This equation describes a simple harmonic oscillator, to which an energy factor Ez, 
can be introduced, which is defined by: 
Equation 12 
𝑞𝐸𝑧 =
𝑚
2
(
𝑑𝑧𝑜
𝑑𝑡2
)
2
 
Solving Equation 11 gives; 
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Equation 13 
𝑧(𝑡) =  𝑧0 cos 𝜔𝑡 +  √(2𝐸𝑍/𝑘 sin 𝜔𝑡) 
Where frequency, ω, is equal to 
Equation 14 
𝜔 =  √(𝑞/𝑚)𝑘 
This solutions demonstrates the dependence of the frequency on the m/q of an ion, 
whilst remaining independent of the kinetic energy of the injected ions.  
The oscillation of the ions within the trap induce an image current, which is 
subsequently measured, converted by FT to give individual frequencies of ions and 
intensities. These are solved using  
Equation 13 forming the resultant mass spectrum.  
The wide mass range, high resolution and high mass accuracy of Orbitrap mass 
analysers make Orbitrap MS an attractive technique for the analysis of intact proteins.  
Early generation Orbitrap instruments, however, demonstrated reduced resolution for 
ion mass increases even at constant m/z ratio, as a result of increased ion scattering 
due to collisions with background molecules within the Orbitrap, leading to transient 
decay [29]. Modern Orbitrap instrumentation now have alternative reduced pressure 
modes (~ low 10-10 mbar), which can be operated for intact protein analysis, so as to 
reduce the statistical probability of such unwanted collisions, increasing resolution, 
mass accuracy and sensitivity for these higher m/z ions. Increasingly Orbitrap 
instruments have been utilised in the area of structural biology, where intact 
complexes of proteins have been reported in  4 MDa range  at high mass resolution 
[5]. 
1.1.3.5 Hybrid mass spectrometers   
Multiple mass analysers and/or types can be combined within a single instrument, to 
give hybrid instrumentation, facilitating flexibility of analysis and control of multiple 
MS experiments (known as tandem MS, described later in section 1.1.4) 
simultaneously. Two hybrid instruments, used in this thesis, based on combinations 
of quadrupole, ToF and Orbitrap type mass analysed will now be discussed.  
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1.1.3.5.1 Waters Synapt G2Si  
A common hyphenated instrument, combines quadrupole and ToF mass analysers, 
termed a Q-ToF instrument. This allows for preselection or focusing/guiding of ions 
using a quadrupole mass analyser before m/z separation by oa-ToF. An example of 
one such instrument is that of a Waters Synapt instrument series [30]. Several 
generations of this instrumentation exist (G1, G2, GS and G2Si), and the G2Si in 
particular has been utilised in this thesis (Figure 10). An extra component of this 
instrumentation is that of the travelling wave ion mobility spectrometry (TWIMS) 
cells housed between the Q and ToF mass analysers which shall be discussed further 
in section1.1.6.2, but add further analytical capability to the instrumentation.  
 
 
Figure 10. Schematic of Synapt G2Si Q-ToF instrument. Image taken from Waters 
[31].   
1.1.3.5.2 Q-Exactive Plus 
The Q-Exactive range of MS instruments are hybrid instrumentation that include a 
quadrupole mass analyser positioned prior to the Orbitrap [32]. This feature facilitates 
the preselection of ions in space and capitalises on the fast scanning speeds of 
quadrupoles. The selected ions are then transferred into the C-trap storage device, 
where they can be stored or undergo fragmentation before the final high resolution 
mass analysis in the Orbitrap. Figure 11, gives a schematic of the Q-Exactive plus 
instrument used to produce data in this thesis.   
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This hybrid nature, also extends the variety of tandem MS experiments that can be 
performed using the instrumentation, which is particularly attractive for proteomic 
type MS analysis. The theory of tandem MS will now be discussed.  
 
 
Figure 11. Schematic of Q-Exactive plus Orbitrap MS instrument. Image taken from 
Thermo Scientific [33]. 
1.1.4 Tandem mass spectrometry 
Tandem mass spectrometry (MS/MS or MSn) experiments involve the use of multiple 
mass analysers and refers to when multiple rounds of m/z separation are performed 
within a single mass spectrometry experiment, typically including a dissociation 
process between the rounds of separation [34].   
Typically tandem MS, involves the isolation of an ion (precursor ion) during the first 
round of mass analysis, after which some form of ion activation process is then 
initiated, producing fragment ions (product ions), which are then subsequently 
measured during another round of mass analysis. These processes can be repeated 
giving MSn rounds of experiments.  These types of experiments facilitate specificity 
and vital structural elucidation information of parent ions and are applicable to small 
and large molecules alike. 
MSn experiments can be performed either by separation of the mass analysis stages in 
space or time (Figure 12). Space, refers to the physical coupling of multiple mass 
- 23 - 
analysers separated by a collision cell, such as with triple quadrupole (QqQ) 
instruments or Q-ToFs, and time, refers to when sequential events occur by trapping 
ions within a device, such as with ion trap instruments. 
 
Figure 12. Tandem MS experiments can be performed by separation in space or in 
time depending on the instrumentation. Multiple rounds of tandem MS can be 
performed, termed MSn. 
 
Figure 13. Schematic of the range of ions produced by MS/MS fragmentation of a 
peptide ion.  
A whole plethora of activation processes have been developed to fragment an ion, 
these include collision-induced dissociation (CID) [35], electron-transfer dissociation 
(ETD) [36], electron-capture dissociation (ECD) [37], surface-induced dissociation 
(SID)[38], and photo-dissociation (PD) [39]. These techniques differ in the 
mechanisms of fragment ion production and therefore differ in the type of product 
ions produced. Table 1 describes the types of product ions produced from protein and 
peptide ions by these differing fragment techniques [40], highlighting some of the 
advantages and disadvantages of the techniques within this context [41]. 
- 24 - 
As a result of its high efficiency and sequence coverage yields, CID is the most 
commonly used fragmentation techniques for protein and peptide MS. It is also the 
main fragmentation technique used in the Synapt, Xevo QToF and Orbitrap 
instruments described herein. During CID , a parent ion is collided with inert collision 
gas molecules, within the trap (Orbitrap) or the collision cell (Synapt/Xevo) of the 
instrument. These collision result in the transfer of kinetic energy to the parent ion, 
exciting the parent ion to a higher energy state. This excess internal energy is then 
dissipated via the characteristic fragmentation of the ion, which during CID occurs 
most commonly at peptidic bond, N-C, yielding b and y ions as described in Figure 
13.  If these fragments then undergo further collisions and subsequent fragmentations 
at the peptide bonds, the resulting mass spectra consists of a series of b and y ions 
differing in mass to the next corresponding fragment along the chain by one amino 
acid. Analysis of the mass spectra of these fragmentation series allows the sequencing 
of the corresponding polypeptide parent ion.  
The fragmentation of a polypeptide ion into a series of heterogeneous fragment ions, 
thus facilitating sequencing, is in part directed by the polypeptide sequence and can 
be explained by the model proton theory [42]. The model describes how for 
protonated peptides produced during soft ionisation, the protons are initially localised 
to basic sites of the molecule such as the N-terminus and side chains of basic amino 
acids (arginine, lysine and histidine).  The protons are then able to relocate from these 
sites to less basic sites of the peptide linkages following ion activation processes. 
Following this migration, charge-site-initiated mechanisms occur providing the 
desired fragment ions. 
One major disadvantage of CID is its incompatibility with the analysis of post-
translational modifications (PTMs). The relatively slow transfer of energy during 
CID, causes fragmentation to typically occur at the weakest point, such as is the case 
with PTM groups, which are typically lost as neutral fragments.  
One of the most attractive features of MS/MS, is the diversity of experiments, or 
scanning modes, that can be conducted to gain structural insights into the parent ion 
and hence solve very specific biological questions or provide specificity when 
performing quantitative measurements. 
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Table 1. Summary of the main peptide/protein MS/MS fragmentation techniques.  
Fragmentation 
technique 
Ions 
produced 
Advantages Disadvantages 
Collision-induced 
dissociation (CID) 
bn+ and yn+  
High efficiency, high 
sequence coverage 
and robust 
Labile groups, such 
as post-translational 
modifications 
(PTMs) typically 
lost 
Electron-transfer 
dissociation (ETD) 
c n+ and z●+  
c●+ and z n 
PTMs  retained and 
can be used localised. 
Low efficiency, 
dependence on 
multiply charged 
species 
Electron-capture 
dissociation (ECD) 
c n+ and z●+  
c●+ and z n+ 
PTMs  retained and 
can be used localised. 
Low efficiency, 
dependence of 
multiply charged 
species 
Surface-induced 
dissociation (SID) 
bn+ and yn+ 
High sequence 
coverage 
Labile groups, such 
as post-translational 
modifications 
(PTMs) typically 
lost 
Ultra-violet 
photodissociation 
(UVPD) 
an+ and xn+ 
bn+ and yn+ 
c n+ and z●+  
c●+ and z n+ 
Tune ability of 
fragmentation 
energies, diverse 
fragmentation 
pathways available 
Complicated 
resulting fragment 
spectra and 
requirement of a 
chromophore 
 
1.1.4.1 MS/MS scanning modes 
The most common and relevant MS/MS modes are here described and illustrated in 
Figure 14 ; 
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Product ion scans, the precursor ion of a specific m/z ratio is selected during the first 
mass analysis stage of the experiment, this parent ion is then subsequently fragmented 
and all the product ions separated in a second mass analysis stage, before being 
detected.  
Precursor ions scan, in contrast to a product ion scan, all precursor ions are allowed 
to traverse the first mass analyser and fragmented, but only a specific product ion is 
selected in the second mass analyser. Hence all precursor ions contributing to the 
production of the specific product ion are therefore detected. This type of experiment 
is only applicable for space-based mass spectrometers, such as multiple quadrupole 
instruments.  
Neutral loss scan, both mass analysers are scanned simultaneously, with a constant 
mass offset, corresponding to the mass of a specific neutral loss fragment, applied to 
the scan of second mass analyser. Therefore only product ions which have undergone 
this neutral loss during fragmentation are detected. This type of experiment can be 
useful for determining the parent ion of a PTM-containing peptide, by selection of the 
appropriate neutral loss ion. Similarly this experiment is only applicable space-based 
mass spectrometers.  
Selected reaction monitoring, both precursor and product ions, of a specific 
fragmentation pathway are specifically selected ion the first and second mass analysis 
stages respectively and no scanning of the instrumentation occurs. The removal of the 
requirement of time to scan through ions allows for more time to be spent on the 
detection of specific precursor and product ions. This combined with the removal of 
background ions increasing the sensitivity towards these selected ions, whilst maintain 
specificity of the analysis via the specific fragmentation pathways.  These types of 
experiment are particularly useful for quantitative analysis. 
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Figure 14. Tandem MS scanning modes. Collisional-induced dissociation of the 
precursor ions is indicated by CID, figure adapted from de Hoffman and 
Stroobart [22]. 
 
 
Figure 15. Schematic of ion detection in an electron multiplier detector. 
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1.1.5 Detectors 
The final stage of an ions journey through a mass spectrometer, following production 
at the source and separation in the mass analyser, is its detection and transformation 
into a signal in the detector.  Generally, detectors operate on the principle that an 
incident ion hits the detector, which generates secondary electrons, which are then 
amplified producing a signal of detectable current that is proportional to ion 
abundance. 
There are several types of detectors including electron multiplier (EM), 
photomultiplier, Faraday cup and microchannel plate (MCP) type detectors. The 
Synapt G2Si instrumentation used in this thesis has a “Ultra-fast Electron multiplier 
and ‘‘hybrid ADC’’ type detector, for this reason only the principles of EM type 
detectors will be discussed. It is worth noting that the Orbitrap Q-Exacutive Plus 
instrument also used in this thesis, does not have a physical detector in the traditional 
sense, in contrast ions signals are inferred by the image current produced as ions 
within the mass analyser pass through a pair of photographic plates within the mass 
analyser and generate a circuit  connecting the plates.  
EMs consist of a series of dynodes, which are held at sequentially increasing potential. 
As an incident ion hits the first dynode, secondary electrons are produced, these 
electrons are then incident on next dynode forming further electrons and so on in a 
cascade effect, continuing on until the electrons reach the end of the detector. By 
which point, depending on dynamic range of the specific detector, the signal has been 
amplified by up to ~ 107 and these electrons are now detected as a current. Figure 15 
gives a schematic of an EM type detector.  
1.1.6 Ion mobility spectrometry (IMS) - MS 
Ion mobility spectrometry (IMS) is an orthogonal analytical separation technique 
which allows for the separation of gaseous ions based on the size and shape of ion in 
addition to their charge, yielding increased analytical information of an ion. 
In brief, during IMS, ions are pulled through a drift cell, that is filled with neutral 
buffer molecules, and the time taken for them to traverse the cell, or drift time (tD) is 
measured. As a result of collisions with buffer gas molecules, ions exhibit different 
velocities through the drift cell. These velocities in turn can be related to their size and 
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shape via their collisional cross section (CCS) area, facilitating insights into the three 
dimensional shape of an ion.  
The requirement of a gaseous analyte ion, enables the direct hyphenation of the 
technique with MS (IMS-MS), facilitating a powerful tool for obtaining both 
molecular and three dimensional information of analyte ion. The ability of IMS to 
separate out isobaric ions that differ in CCS, and applicability to a wide range of 
analyte molecular weight including ionic clusters [43], small organic molecules [44], 
peptides [45] and large protein complexes [46] , make the coupling to MS particularly 
attractive. The mode of separation can be used as an alternative to chromatographic 
separation or as an additional orthogonal separation step in the forms of LC-IMS-MS. 
Several instrumental modes of IMS separation exist including drift time IMS (DT-
IMS), differential mobility spectrometry (DMS), travelling wave IMS (TWIMS) and 
trapped IMS (TIMS), the two most common types of ion mobility devices, DT-IMS 
and TWIMS will be discussed herein.  
 
 
 
Figure 16. Schematic diagram of the separation of a large ion (blue) and a smaller 
compact ion (green) in a drift tube IMS (DT-IMS) instrument. A pulsed packet 
of ions are propelled by a low electrostatic field (5-100V) across the drift tube 
whilst encountering collisions with buffer gas ions. Larger ions will experience 
more collisions and drag resulting in subsequent decreased mobility and longer 
tDs across the cell. 
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1.1.6.1 Linear drift tube IMS-MS 
Linear drift tube ion mobility spectrometry (DT-IMS) is the simplest form of IMS. In 
DT-IMS a packet of ions are pulsed into a gas-filled drift cell under a low field 
electrical potential, and the tD measured. As the ions are injected into the cell they 
experience a constant electrostatic force pulling them through the cell, a force that is 
then counteracted by collisions with buffer gas molecules within the cell.  Separation 
of two isobaric ions of differing size occurs as the larger ion with a greater CCS value 
will undergo more interactions with the buffer gas molecules, experiencing a greater 
reduction in drift velocity, vd, and ultimately reduced tD, than an smaller ion (Figure 
16).  The motion of the ion through the drift cell is termed the ions mobility, K, and 
is inversely proportional to the CCS of an ion [47, 48]. This relationship between K 
and CCS only exists at the low field limit (E/N), at higher fields, the mobility of the 
ion can become distorted as a result of alignment between the ion and the field.  
It is worth noting that for a particular m/z ion, a single tD value is not measured during 
IMS experiments, but rather an arrival time distribution (ATD) which describes the 
tDs across the ensemble of isobaric ions pulsed into the cell, the shape and width of 
these ATDs can also be indicative of structure [49].  
An ions mobility, K, can be expressed in terms of its velocity, vD and the applied 
electric field, E.  
Equation 15 
𝐾 =
𝑣𝐷
𝐸
 
If the drift cell length, L, is fixed and known and the tD of an ion measured we can 
express mobility as; 
Equation 16 
𝐾 =
𝐿
𝑡𝐷𝐸
 
 
 
Temperature and pressure can influence mobility of an ion, hence generally mobility 
is expressed as reduced mobility, K0, normalised for standard temperature (273.2 K) 
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and pressure (760 torr), where T and P are the gas temperature and pressures 
respectively.  
Equation 17 
𝐾0 =
𝐿
𝑡𝐷𝐸
273.2
𝑇
𝑃
760
 
 
The Mason-Schamp equation [48], demonstrates how mobility of an ion is inversely 
proportional to its CCS (Ω); 
Equation 18 
Ω =  
3𝑧𝑒
16𝑁
(
2𝜋
𝜇𝑘𝐵𝑇
)
1/2 1
𝐾0
 
where z is the charge of the analyte ion, e is the elementary charge (1.6022 x 1019 C), 
N is buffer gas density, μ is the reduced mass of the ion-neutral drift gas pair, kB is 
the Boltzmann constant. Substituting reduced mobility and rearranging Equation 18 
the in terms of CCS (Ω)we obtain; 
Equation 19 
 
Ω =  
(18𝜋)
1
2
16
𝑧𝑒
(𝑘𝐵𝑇)
1
2
[
1
𝑚𝑖
+ 
1
𝑚𝑛
]
1
2 760
𝑃
𝑇
273.2
1
𝑁
𝑡𝐷𝐸
𝐿
 
 
Where mi and mn are mass of the buffer gas and the ion respectively.  
DT-IMS allows direct measurement of tD, therefore under controlled conditions of 
temperature and pressure, CCS values can be directly abstracted from tD 
measurements. Allowing structural insights into the gaseous ion which can be 
compared with molecular simulations and projections.  However, DT-IMS based 
instruments have long since suffered from low duty cycle and poor transmission, and 
in recent years researchers have turned to TWIMS an alternative form of IMS 
separation  in order to overcome these issues.  
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Figure 17. Schematic diagrams of travelling wave IMS (TWIMS) for ion mobility 
separation of a large ion (blue) and a smaller compact ion (green). The drift cell 
consists of a stacked ring ion guide (SRIG), this SRIG consists of a series of 
stacked ring electrodes with an applied confining radio-frequency field onto 
which a moving DC pulse is applied to consecutive electrode pairs. This DC 
pulse creates the travelling wave upon which the ions can surf. As ions are 
propelled by the wave they will experience an opposing drag force from 
collisions with the buffer gas and roll over the top of the wave.  Ions with a large 
CCS (blue) will roll over the waves more frequently than low CCS (green) ions 
as they experience more drag force, resulting in mobility separation and elution 
from the tube later than their smaller counterparts. 
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1.1.6.2 Travelling wave-IMS (TWIMS)  
First introduced in 2006 [50], the Synapt instrument series incorporated IMS 
separation in the form of a TWIMS device, situated  between the quadrupole and ToF 
mass analysers, allowing for potential pre-IMS ion selection and activation.  This 
region consists of three sections of stacked ring electrodes, or stack ring ion guides 
(SRIG), termed the ‘trap’, TWIMS and ‘transfer’ regions, known collectively as the 
‘Tri-wave’, Figure 10.     
Unlike DT-IMS where a uniform electric field is applied, TWIMS involves the 
application of a travelling wave of oscillating potential that propels the ions through 
the SRIG [51].  A confining RF-field is applied to this SRIG onto which a moving 
DC field is applied onto consecutive electrode pairs. This DC pulse creates the 
travelling wave upon which the ions can surf. The TWIMS drift region is filled with 
a neutral buffer gas, and as ions are propelled by the wave within this region they will 
experience an opposing drag force from collisions with the buffer gas and roll over 
the top of the wave.  Ions with a large CCS will roll over the waves more frequently 
than low CCS ions as they experience more drag force, resulting in mobility 
separation and elution from the drift tube later than their smaller counterparts, as 
demonstrated in Figure 17 
The main caveat of TWIMS is that the very nature of the travelling wave, and lack of 
uniform electric field alters the inverse relationship between tD and CCS [48], 
meaning CCS measurements cannot be obtained directly from observed tD. Instead an 
experimentally derived calibration curve must be generated, using calibrant ions with 
known CCS as measured by DT-IMS [52, 53].  
This can be achieved by modifying Equation 19, for a non-uniform electric field; 
Equation 20 
Ω =  
(18𝜋)
1
2
16
𝑧𝑒
(𝑘𝐵𝑇)
1
2
[
1
𝑚𝑖
+  
1
𝑚𝑛
]
1
2 760
𝑃
𝑇
273.2
1
𝑁
𝐴𝑡𝐷
𝐵
 
Where A and B are correction factors for the electrical field and non-linear effects of 
the TWIMS device respectively [53]. A value of reduced CCS (Ω’) can then be 
expressed as a charge and mass independent quantity, by dividing by reduced mass 
and charge and by grouping constants into a single constant term (A’):  
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Equation 21 
Ω′ = A′𝑡𝐷
𝐵 
This equation can then be plotted in the form y=A’tDB, and a calibration curve 
generated using experimentally measured TWIMS tD values of calibrant ions against 
know Ω’ values from DT-IMS measurements [52]. This allows the subsequent 
abstraction of experimental Ω’ for unknown analyte ions from TWIMS 
measurements, which in turn can then be back calculated to give CCS values using 
the reduced mass and charge: 
Equation 22 
Ω =  𝑧𝑒 [
1
𝑚𝑖
+  
1
𝑚𝑛
]
1
2
Ω′ 
As with DT-IMS measurements, comparisons can then be made between 
experimentally derived CCS values and simulated CCS values generated from 
potential 3D structures via a series of different projection algorithm[54–56].  
Although DT-IMS instruments have superior IMS resolution of around 100 Ω/ ΔΩ 
compared to the 40Ω/ΔΩ of travelling wave instruments, the reduced ion transit time 
due to the faster mode of separation in TWIMS combined with the ability to store and 
pulse ions means an enhanced duty cycle resulting in higher sensitivity compared with 
traditional DT-IMS instruments.  
1.2 MS and protein structural analysis 
Following the introduction of MS theory, the many ways in which MS can be applied 
specifically for the analysis of protein structure will now be discussed.  
1.2.1 Protein structure 
Proteins play a pivotal role in many biological processes in vivo. Gaining an 
understanding of their role and function is key to the expansion of our knowledge of 
health and disease. To fully understand this, we must consider not just the presence, 
absence or amount of a protein in question but also the impact of the protein’s higher 
order structures (HOS) and the role that these structures have on the function and 
activity of a protein. The different levels of protein HOS are illustrated in Figure 18. 
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A proteins primary structure, consisting of the amino acid sequence of the polypeptide 
chain, is the simplest form of its structure. This polypeptide chain can then fold 
locally, through the formation of hydrogen bonds across the amide backbone, forming 
localised three dimensional structures, such as α-helices, β-sheets, which are termed 
secondary structure.  The presence of these localised structures causes the polypeptide 
chain to bend or twist supported by interactions between amino acid side chains. 
These interactions occur so as to achieve a maximum stability or energetic minimum 
of the structure, giving a resulting globular three dimensional shape to the protein that 
is termed the tertiary structure.  If multiple subunits of proteins combine via non-
covalent interactions to form a protein complex this structure is termed quaternary 
structure. Finally further complexity can be present in the form of post translation 
modifications (PTMs), and structural and conformational isomers. Variation in any of 
these including primary, secondary, tertiary and quaternary structures can have a large 
impact on the activity and function of a protein.  
In the last 20 years, the application of the field of proteomics, which involves 
identification and quantification of proteins at a peptide level by MS, has 
revolutionised the way we perform clinical assays and understand complex pathways 
involved in vivo.  These types of MS measurements have typically been based on the 
protein’s primary structure and protein measurement has now become routine in many 
clinical and research contexts. However though now routine, global standardisation is 
required in order to maintain high levels of accuracy, precision and comparability of 
measurements with traditional clinical assays. Over the past decade the metrological 
community, through the development and use of reference materials (RM) has made 
significant progress on the development of methods for quantification of the protein 
primary sequences which are traceable to the System of International Units (SI) [57, 
58]. Yet, the application of these metrological methodologies on the standardisation 
of higher order certified protein RM is lacking, due to the essential need to consider 
the role of PTMs and three dimensional protein structures on any accurate 
measurements made of these higher order RMs.  
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Figure 18. Schematic of the different levels of protein higher order structures. 
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1.2.1.1 Need for protein structural analysis and reference materials 
This relationship between activity and protein HOS is important in the clinical and 
diagnostic areas, however, more recently, with the rapid expansion of drug 
therapeutics based on protein drugs (termed biotherapeutics), it has become 
particularly important in the pharmaceutical area [59].  
In fact, HOS measurement has become a legislative requirement for the 
characterisation of biotherapeutics and biosimilars [60, 61]. Indeed regulation states 
that a series of physical, chemical and biological properties of a candidate drug, 
known as critical quality attributes (CQAs), must be monitored for and maintained 
within predefined limits, ranges or distributions to ensure product quality and 
established pharmacokinetics [60, 61]. CQAs include those properties or 
characteristics of a drug that may affect the identity, purity, biological activity and 
stability of a drug, and include such properties as glycosylation and protein HOS of a 
drug [62].  Protein HOS measurements provide important information on the stability, 
potency, efficacy, immunogenicity and bio-similarity of a bio-therapeutic. Indeed 
insights into the mechanisms of protein-protein interactions, [63, 64], protein-ligand 
interactions [65, 66] and protein aggregation[67], have all been provided by protein 
HOS measurements. 
With these regulatory requirements comes a drive for the development of analytical 
tools capable of providing comprehensive HOS analysis and an understanding of the 
comparability of analytical measurements. Though there are a wide variety of 
techniques available for the analysis of protein HOS, little is known about the 
comparability of the data within like-for-like platforms and even less still about the 
comparability when comparing between different orthogonal platforms. In the clinical 
and diagnostic areas, it has been demonstrated that through the use of RM,  and the 
understanding of measurement comparability, harmonisation of results can be 
achieved [68–70]. Indeed in these clinical and diagnostic areas, such standardisation 
is a recognised requirement. This standardisation is based on absolute quantities, 
therefore requiring SI traceability and harmonisation is based on equivalence of 
relative results. Yet, such international RM and model systems for harmonising and 
standardisation of protein HOS measurements have been lacking and as the area of 
protein HOS analysis expands so does the need for such materials.   
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1.2.1.2 Protein structural analysis techniques 
For decades, nuclear magnetic resonance (NMR), x-ray crystallography (XRC) have 
stood as the gold standard analytical technologies for protein HOS measurements, 
facilitating atomic level high resolution measurements. For XRC, resolutions of < 1 
Å, and 1.1-1.4 Å have been reported for small (10-15 kDa) [71]  and large proteins 
(140 kDa) [72] respectively. More recently, experimental improvements in cryogenic 
electron microscopy (cryo-EM) have led to increased resolution ~ 1.8 Å and these 
measurements have been increasingly adopted in the area of structural biology [73].  
There are several caveats to the analysis of protein HOS using these techniques 
including issues of crystallisation (~ XRC) and extensive sample preparation (~ cryo-
EM) for dynamic proteins,  lack of correlation between solid state structures and 
solution state structures (~ XRC/cryo-EM), poor signal to noise and upper mass 
limitations (~ NMR ~ 50 kDa). These techniques also suffer from heavy data analysis 
requirements and low sensitivity, resulting in a large sample requirement for high 
resolution analysis which in turn can also lead to aggregation issues for NMR in 
particular. In contrast these techniques which provide high resolution data, there are 
a wide range of biophysical analytical techniques that provide lower resolution 
analysis, allowing insights into overall global conformational changes and stabilities 
but with much higher throughput of analysis compared to high resolution 
measurements. These techniques include Fourier Transform infrared spectroscopy 
(FTIR), Raman spectroscopy, circular dichroism (CD), size exclusion 
chromatography (SEC) and differential scanning calorimetry (DSC). Each of these 
techniques can provide different structural information which can, when used in 
conjunction with each other, help to define HOS. These techniques however can often 
be limited in their sensitivity to small subtle structural fluctuations and lack the ability 
to localise the structural change.  
Due to the regulatory requirements for HOS there has been a drive in the development 
of analytical techniques which provide higher resolution structural information whilst 
avoiding some of the limitations of the more established techniques of NMR and 
XRC.  This has led to an increase in the research into the application of MS-based 
structural techniques, where sample requirements are much lower, there is often an 
increased tolerance to excipients and analysis can typically occur directly on solution 
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conformations and hence provide orthogonal data sets to traditional biophysical 
analysis.   
1.2.1.3 MS for protein structural analysis: an overview 
In short, MS for protein structural analysis can be split into two categories (Figure 
19); 
Native MS, where the protein’s folded ‘native’ solution state conformation is 
maintained during gaseous analysis, and; 
Protein footprinting, where the protein’s folded solution state conformation is 
labelled in solution, and its subsequent analysis is performed in a denatured, often 
fragmented, state.   
 
Figure 19. Schematic illustration of some of the range of structural information that 
can be achieved using a variety of MS techniques. 
Classically native MS and protein footprinting can be thought of in terms of global 
and localised resolution for protein structural information respectively, though there 
are exceptions. Often providing complementary structural insights these methods can 
be applied in a standalone manner or in conjunction with one another. The rest of this 
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introduction will now discuss the theory and experimental considerations of these two 
methodologies in context of the data described in this thesis.  
1.2.2 Native MS  
1.2.2.1 History and overview 
It was not long after the advent of ESI, in the late 1980s, that intact proteins were 
analysed by MS for the first time [74, 75].  As well as providing the exact intact mass 
measurement of the proteins primary sequence, it became apparent that structural 
insights of both protein and non-covalent protein complexes could be gained under 
controlled experimental conditions. Observations were made by Loo and co-workers 
[76], that stated that the charge state distribution (CSD) of a protein ion was greatly 
influenced by the solvent composition, which in turn related to the solution state 
structure of a protein during ionisation (discussed further in section 1.2.2.2). The 
mechanism for the production of a natively folded protein/complex during ESI is 
widely accepted as being that of the charge residue model (section 1.1.1)[77].   
Native MS was expanded further by the development of nESI, with its higher 
ionisation efficiencies and lower capillary potential, facilitating reduced sample 
requirements and enhanced preservation of non-covalent complexes. Another driving 
force for native MS has been in MS instrumentation, such as the commercialisation 
of ToF based instrumentation in the 1990s, which were attractive due to their 
theoretical unlimited m/z range, high mass resolution and sensitivity. Increasingly 
instrumental modifications to Orbitrap [78] and FT-ICR type instrumentation have 
also increased their usage in this area.  
Since then, native MS has been used to gain insights into virus assemblies ( ~ 18 MDa) 
[4, 79], aggregation [80], ligand-binding stoichiometry [63] and calculations of 
dissociation constants [81] (Figure 19).  
It is important to note that when studying HOS by native MS, analysis occurs in the 
gas-phase and solution state conformations are inferred, hence great care must be 
taken so that protein solution conformations and any non-covalent interactions are 
retained in the gas phase, some of the experimental considerations that must be made 
in light of this will be discussed in the rest of this section.  
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1.2.2.2 Charge state distribution 
As stated previously, it was observed that amount of charges or CSD accumulated by 
a protein during the ionisation process, correlated with the solution conformation, 
folded or unfolded, of the protein prior during ionisation [76]. Since then many 
additional studies [79, 82, 83] have provided information to support the idea that the 
number of protonation sites of a protein correlates with the solvent accessible surface 
area (SASA) of a protein [82].  
For a more globular, folded protein, the extent of surface protonation is limited due to 
the burial of amino acidic side chain groups within the folded structure, leading to a 
narrow CSDs, low overall charge and higher m/z values (Figure 20). Equally the same 
protein, but in an unfolded conformation, will have more exposed amino acid side 
chains and hence a greater potential for surface protonation, resulting in higher charge 
states, greater CSD distribution and lower m/z. Increased coulombic repulsion as a 
result of increased surface charge is also thought to be a contributing factor towards a 
larger more unfolded protein ion at higher charge states. These ideas correlate well 
with the idea that a protein unfolds, its SASA increases and hence higher charge states 
are observed. 
Though it provides structural insights, caution should be taken with interpreting CSD 
as can also been influenced by experimental parameters such as high instrumental 
voltages and solvent composition. Care should be taken to optimise these conditions 
to ensure the native conformation is retained.  
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Figure 20. Illustration of the theoretical mass spectra of a protein in a denatured 
conformation and native conformation. Spectra represent a protein introduced from a 
solution containing a) 50% MeOH, giving a denatured, elongated protein 
conformation with higher charge, lower m/z and wide CSD, and b) buffering 
ammonium acetate, giving a native folded conformation, with lower charge, higher 
m/z and narrow CSD. For the spectra generated from native solution conditions both 
monomer (●)and dimeric (■) forms of the protein are observed.  Protein illustrations 
are adapted from [84].   
1.2.2.3 Transmission of higher m/z species 
The theoretical unlimited mass range of  some MS instrumentation is one of the most 
attractive features of the technique for structural biology, yet as research progressed 
to larger biomolecules it became apparent that ions ~ >100 kDa exhibited poor 
transmission [85].  These transmission losses occur at the small orifices between ion 
guides, due to the internal energy gains experienced by ions as they are accelerated 
from atmospheric pressure at the source into a vacuum. These energy gains can be 
dispersed both axially and radially and hence affect their transmission through these 
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small orifices. The internal energy gains are proportional to mass, meaning losses are 
more significant for larger molecular weight species and/or can result in the unfolding 
of higher m/z species. Using increased pressures in the source and ion guides of the 
instrument, can minimise these losses, by reduction of the analyte ion’s internal 
energy through increased collisions with neutral gas molecules in a process termed 
collisional cooling [85]. Furthermore reduction in ion speed also allows for greater 
focusing of the ions and ultimately higher transmission. Therefore, modern MS 
instrumentation for native MS, such as the Synapt G2Si instrument used in this thesis, 
are modified to operate at these higher pressures to facilitate such collisional cooling 
and maintaining transmission.  
1.2.2.4 Native IMS-MS 
The coupling of IMS with native MS has been pivotal in understanding protein 
conformation that exists in the gas phase. Comparison of experimentally derived CCS 
values with theoretical CCS values from XRC/NMR, has allowed for many theories 
relating to the preservation of a solution phase structures into the gas phase to be 
validated [3, 5].  
IMS-MS measurements can be used to understand solution state conformations 
(Figure 21 a), such as narrow CSDs being indicative of a single conformation, gas 
phase conformations such as understanding the influence of experimental conditions 
such as trapping voltages on the folding states (Figure 21 b and c).  
Unlike many biophysical techniques for the analysis of proteins and protein 
complexes, IMS-MS is unique as it does not yield conformational averaged data, 
allowing for the true heterogeneity of a sample to be observed [3, 63]. Additionally 
the ms timescale of IMS-MS experiments, is much more applicable to the timescale 
of protein dynamics than those of NMR and XRC facilitating the analysis of dynamic 
nature of protein structures [86]. IMS-MS has been used not only to study 
heterogeneity but also protein-ligand interactions [65], protein-protein 
interactions[63], biosimilarity [49, 87, 88]) and aggregation assembly pathways [67] 
among others.   
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Figure 21. Structural insights of (holo-)transferrin from native IMS-MS 
measurements. a) Mobilogram spectra reveals a single monomeric conformation 
when using low energy internal trapping voltages (20V), b) increased trap 
voltages result in increased resolution of MS peaks however increased voltages 
also result in increased c) drift time indicating gas-phase unfolding of the 
protein.  
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1.2.2.4.1 Arrival time distribution (ATD) 
As mentioned previously, IMS-MS measures the tD of a population of ions, resulting 
in not a single tD value, but an ATD which not only represents the tD through the drift 
cell but any additional space travelled before hitting the detector. Often the centroid 
value of the ATD is used to determine a single CCS value, using the methods 
described in section 1.1.6, however the ATD profile itself can offer insights into 
protein conformation (Figure 22).  If the relevant experimental controls are 
undertaken to ensure no gas-phase unfolding of the protein ions, wide ATDs can be 
indicative of the co-existence of several ensemble populations. Indeed the reporting 
and use of ATD peak width and shape as a metric for IMS-MS publication has been 
increasingly encouraged [49, 89].  
 
Figure 22. Illustration of a series of folding state as indicated by arrival time 
distributions (ATD) of the same m/z ion under differing experimental 
conditions. A single conformation is indicated by a Gaussian-like ATD (black 
trace), a ATD with an increased ATD indicates an increase in the CCS of the 
ion (blue trace) with a non-Gaussian-like shape and increased ATD width (red 
trace) indicative of multiple conformations of differing CCS existing for the ion.  
1.2.2.4.2 Structural insights from CCS measurements  
Classically, structural biology has relied heavily on XRC and NMR data to provide 
information on a protein’s three dimensional structure; however, the ability of IMS to 
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provide both orthogonal data sets and insights into the potential heterogeneity of 
conformations, makes CCS an attractive measurement for comparison and validation 
of solution state conformations. Theoretical CCS values can be extrapolated from 
structures derived from XRC/NMR/cryo-EM measurements or indeed simulated 
structures when such experimentally derived structures are unavailable [3, 63] and 
structures discounted or validated by comparison with experimental measurements.  
Several computational models are available for calculating theoretical CCS values, 
and some of the most established are summarised in Table 2, including some of their 
known advantages and biases. Good correlation between gas phase CCS 
measurements of small monomeric proteins with theoretical projections has been 
demonstrated [90, 91], however the systematic bias of the methods were clear 
emphasising the need to take care when interpreting CCS values obtained by IMS-
MS.   
These systematic biases are particularly important for CCS measurements 
extrapolated via calibration procedures from TWIMS measurements [52, 53]. 
Recently a concentration effect on ATD broadening was reported when deviating 
from published concentration values for calibrants [52], resulting in deviations in 
resulting measured CCS values [92]. 
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Table 2. A selection of computational models available for the calculation of 
theoretical CCS measurements to be made from atomic co-ordinates obtained 
from NMR or XRC. These are all available from the open access programs 
MOBCAL [55, 56, 93, 94] each model provides a slightly different treatment of 
ion-buffer gas collisions.  
Projection 
Algorithm 
PA EHSS TM 
Full title Projection Algorithm 
[54] 
Exact Hard Sphere 
Scattering Algorithm 
[55] 
Trajectory 
Method [56] 
Brief 
summary 
Using fixed interaction 
radii for both buffer gas 
and ion average three 
dimensional CCS values 
are calculated from many 
two dimensional 
snapshots.        
  *A modified update of 
this projection known as 
PSA (projection 
superposition algorithm) 
accounts for concave 
structures [94]. 
Atomic radii are 
modelled as 
overlapping hard 
spheres where the 
radii is equal to hard 
sphere collisional 
distances and 
scattering angles of 
the buffer gas upon 
collision.  
Computation 
follows a similar 
approach to EHSS 
algorithm 
however it models 
interaction 
between buffer 
gas an ion using 
Lennard-Jones 
potentials.  
Advantages Least computationally 
demanding 
Accounts for 
scattering, not very 
computationally 
demanding.  
High accuracy 
model 
Disadvantages Fails for larger systems 
as long range buffer gas -
ion interactions are not 
accounted for. 
Scattering more 
significant for smaller 
proteins which can 
lead to over projection 
Very 
computational 
demanding which 
can limit mass 
range of protein 
of interest 
Applicable to Small proteins Large proteins Small and large 
proteins 
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1.2.2.4.3 Collision induced unfolding (CIU) experiments 
In addition to solely obtaining CCS measurements for proteins, collision induced 
unfolding (CIU) is an IMS-MS method which allows for additional insights into the 
stability and structure of proteins in the gas phase.  CIU-IMS-MS is a collision 
activation method similar to that of tandem MS fragmentation, where an ion is first 
isolated and then activated post ionisation, however, instead of monitoring the 
fragmentation such as with tandem MS, in CIU-IMS-MS the unfolding pathway of an 
ion is monitored as function of collision voltage. These measurements can be 
indicative of protein structure classification [95], protein stability [96] and used for 
the characterisation of protein assemblies [3] and protein-ligand complexes[97, 98]. 
In CIU-IMS-MS, an isolated biomolecule is activated through energetic collisions 
with a background neutral gas (i.e. Argon), if caution is taken to keep the internal 
energy low enough to maintain covalent bonds within the structure, this increase in 
internal energy causes the biomolecule to unfold in the gas-phase. If the activation 
occurs before the drift cell, this unfolding process can be monitored using IMS-MS 
measurements, through increases in CCS or ATD measurement, as a function of 
activation energy, giving an insight into the stability of the biomolecule and/or 
specific domains of the structure (Figure 23). CIU type measurements can be thought 
of as analogous to melting point DSC measurements, though in the gas-phase, and can 
be used to generate fingerprinting data and allowing for high throughput direct 
comparison of protein stabilities and screening type experiments [99, 100]. 
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Figure 23. Schematic of collision induced unfolding (CIU) of an isolated biomolecule. 
Increasing the collision voltage, increased the internal energy of the native 
folded biomolecule (T1†), causing different regions and/or domains of the 
biomolecule to unfold giving rise to a partially folded state (T2†) and a fully-
unfolded state (T3†), which are each indicated by their increase in CCS value. 
1.2.3 Protein footprinting 
In protein footprinting, chemical regents are used to label different features of a 
protein’s primary sequence (Figure 19). The rate of these modifications are altered by 
the  presence of HOS such as secondary [101], tertiary [102] and quaternary structures 
[103] or indeed ligand binding [104], thereby monitoring these labelling modification 
rates, can allow for HOS information to be inferred.  Several different labelling 
strategies exist including hydrogen deuterium exchange (HDX)  [105] hydroxyl-
radical footprinting (HRPF)[106, 107], chemical labelling (using reagents such as 
carbenes and diethylpyrocarbonate) and cross-linking (XL) [108, 109]. 
- 50 - 
Unlike native-MS techniques, where experimental considerations must be made to 
preserve a protein’s solution state conformation into the gas-phase, protein 
footprinting techniques allow the structural behaviour of proteins to be labelled in 
solution prior to MS analysis, which subsequently occurs at either the top-down or 
bottom-up level. At the top-down level the accurate mass of the modified intact 
protein is monitored providing global conformational information. Bottom-up 
approaches rely on proteolytic digestion and subsequent LC-MS/MS analysis of 
labelled peptides to give high resolution localised information, where the labelling is 
located to either a region of the sequence or to a specific amino acid residue. This type 
of analysis can give insights into natively folded proteins or complexes [102, 103], 
define conformational changes [112] and mapping of inter/intra protein contacts 
[113]. 
This thesis will concentrate on just two types of footprinting techniques, one 
reversible labelling technique, HDX, probing the amide backbone structure of a 
protein and the other an irreversible labelling HRPF technique, fast photochemical 
oxidation of proteins (FPOP), probing the structure of amino acid side chain groups. 
These two strategies can be thought of as complementary providing orthogonal 
datasets for protein structure. 
1.2.3.1 Hydrogen deuterium exchange (HDX) 
1.2.3.1.1 History and overview 
HDX was first developed by Linderstrøm-Lang and co-workers in the 1950s, when 
they observed exchange of labile protein hydrogens with tritium (3H) when exposed 
to a tritium containing buffer [101, 114]. This exchange was measured, via density 
gradient tubes, as a function of increased mass of the intact protein. Using insulin as 
a model protein, Linderstrøm-Lang and co-workers first demonstrated reduced rate of 
amide hydrogen exchange as a result of the amide protons involvement in protein 
secondary structures [101, 114].   
Measurement of hydrogen exchange by NMR, at the intact protein level, was later 
introduced in 1982, which allowed the monitoring of single-residue exchange rates 
gaining localised structural information for the first time [115, 116]. The introduction 
of an additional proteolysis step by Rosa and Richards [117], and combination with a 
high performance liquid chromatography (HPLC) separation step, facilitated 
localisation of the isotopic labels at the peptide level. With the advent of ESI a novel 
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workflow [118], was introduced which used deuterium (2H, D), as an alternative 
labelling isotope, and the hyphenation of mass spectrometry for the analysis of 
labelled peptides. These experiments form the basis of HDX-MS experiments that we 
recognise today.  
1.2.3.1.2 Principles of HDX  
The fundamental basis of HDX is that when a protein is incubated in a deuterated 
buffer, labile hydrogens, those bonded to heteroatoms, (N, O and S), within the 
proteins sequence, readily undergo exchange with deuterons in solution. For protons 
present in amino acid side chains and N - /C-terminal groups, this rate of exchange is 
on ~ µs timescales, too fast for most current detection techniques. However the 
protons present in amide bonds of the polypeptide chain (Figure 24), exchange at rates 
spanning from ms - months [119] which are within the time scale of detection 
techniques. This rate of exchange is dependent on two factors: 
The intrinsic rate of the amide proton exchange, of which there is a contribution from 
neighbouring residues [120] and experimental parameters such as pH [121], 
temperature [122] and salt effects[120, 123]. 
Protection of the amide proton, occurring as a result of the participation of the proton 
in hydrogen bonding (secondary structure) or as a result of  reduced solvent 
accessibility due to protein folding (tertiary structure). 
The intrinsic rate of exchange, kex, of an unprotected amide can be expressed as the 
sum of the rate of the acid, kH, base, kOH,  and water, kw -catalysed  rates, as calculated 
in Equation 23 and illustrated in Figure 24.  
Equation 23 
                           𝑘𝑒𝑥 = 𝑘𝐻 [𝐻
+] + 𝑘𝑂𝐻[𝑂𝐻
−] +  𝑘𝑤  
An equilibrium exists between these acid and base mechanisms, creating a pH 
minimum for HDX rates, which for polypeptides occurs in the pH 2.3-3 range (Figure 
25). Here rates of exchange can be reduced by a magnitude of 108 from those observed 
at physiological pH [120], where the base catalysed exchange dominates. 
Temperature also affects HDX rates, with rates increasing around an order of 
magnitude with every increase of ~ 22 °C.  
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Figure 24. Acid (a) and base (b) catalysed mechanisms of HDX of amide hydrogens 
when incubated in deuterated buffer. Acid catalysis can proceed via N-protonation (i) 
or O-protonation (ii).  
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Figure 25.  Dependence of intrinsic rate of exchange (k) of backbone amide protons 
on pH and temperature (solid line, 20 °C, dashed line 0 °C).  
 
Figure 26. Representation of relative HDX rates due to the presence of protein higher 
order structure. HDX rates are fast for loop-like structures with no secondary 
structure and high solvent exposure (blue), rates are reduced due to the presence 
of hydrogen bonding such as β-sheets (pink) and/or burial within tertiary 
structures (red) leading to reduced solvent exposure. Illustration modified from 
PDB: 1HZH [124]. 
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The strong pH and temperature dependence of exchange rates, requires rigorous 
control of these experimental parameters throughout the HDX experiment, 
complicating the experimental set up. Control of pH and temperature, however, 
provide an opportunity to take a snap-shot of the exchange present at a given time. 
This is typically achieved by “quenching” the labelling reaction by a reduction in pH 
within the pH 2.3-3.0 range and a reduction of temperature to ~ 0°C to give slow 
exchange conditions.  
Finally, intrinsic rates of exchange can also be modified by both steric and inductive 
effects caused by neighbouring amino acid side chains in the absence of structure, by 
up to 10 fold [120]. These primary structure effects have been quantitatively evaluated 
by NMR, with the use of unstructured dipeptide standards, revealing the effect of close 
neighbouring amino acids to be additive, permitting prediction of intrinsic HDX rates 
as a function of primary sequence, pH and temperature[120].  
Protection afforded by the folding of a proteins amino acid sequence into secondary 
and tertiary structures, also contributes to the observed exchange rate [125]. Those 
amides which are involved in hydrogen bonding or experience solvent shielding due 
to structural conformations display reduced exchange rates from intrinsic rates, with 
exchange rates potentially extended up to 8 orders of magnitude. The influence of 
protein structure on exchange rates, the presence of amide hydrogens presence across 
the entire length of the polypeptide chain (except at proline residues) and the 
technique's non-perturbative nature, combine to make HDX measurements a very 
sensitive structural probe (Figure 26).  
HDX also allows insights into the dynamic nature of protein folding. In the 
Linderstøm-Lang model, for exchange to occur, a folded protein must repeatedly visit 
unfolded states in which the protected amides protons are free from hydrogen 
bonding/exposed to solvent and can undergo exchange[114, 119].  These unfolding 
fluctuations can be thought of as breathing like motions and are highly dynamic. For 
a stable folded protein in a single conformational state, the rate of refolding of the 
protein is greater than the rate of HDX, resulting in exchange kinetics that increase 
gradually with time, as amides are gradually exposed to deuteration, this instance is 
termed EX2 kinetics.  
However if a protein exists in multiple conformational states and/or a region of the 
protein undergoes an unfolding event whilst in an open conformation during one of 
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these breathing motions, multiple amides are exposed to exchange and all the exposed 
amides exchange before refolding of the protein can occur. In this instance, exchange 
is observed as a bimodal distribution between folded/unlabelled and unfolded/labelled 
states of protein conformation and is termed EX1 kinetics. Most proteins at 
physiological conditions observe EX2 kinetics, though proteins such as intrinsically 
disordered proteins, that lack a stable conformational structure or which have been 
exposed to denaturants to artificially induce conformations observe EX1 kinetics 
[126].  
1.2.3.1.3 MS for HDX measurement 
The use of MS as a detection method for HDX experiments (HDX-MS), offers a 
number of advantages, over classical high resolution structural techniques of NMR 
and XRC.  including sensitivity, protein solubility, speed of analysis, tolerance to 
excipients /impurities and accessible molecular mass range.  
HDX-MS typically only requires nM-pM [127] protein amounts, in contrast to µM 
amounts required for HDX-NMR, which not only reduces sample requirements, 
particularly advantageous during research and development (R&D), but also avoids 
high concentration which may result in unwanted protein aggregation.  
HDX-MS also has a higher tolerance to excipients compared with NMR and XRC, 
due to the opportunity of on-line desalting steps within HDX-MS workflows, allowing 
the technique to be directly applicable to formulated biotherapeutics and indeed study 
such effects of formulations on protein structure [128].  
Additionally, there is a lack of mass limit of MS detection, although practically 
speaking the ability to separate, detect and identify the peptidic products of on-line 
digestion can become a limiting step for very large protein complexes [127]. Large 
proteins may require optimisation of chromatography steps to minimise impacts on 
data quality, see section 1.2.3.1.8 for more detail on this. Due to its applicability to 
large protein complexes, HDX-MS is used regularly to analyse large protein structures 
such as mAb ~ 150 kDa  [129, 130] and viral capsid complexes in ~ MDa range [103, 
131, 132]. These advantages of HDX-MS have resulted in an expansion of the 
application of the technique for protein structural analysis both in academia and 
industry.  
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Figure 27. Schematic of a typical bottom up HDX-MS workflow for analysising 
protein dynamics upon ligand binding. Location of ligand binding is indicated by (L). 
The solubilised protein is diluted in an excess of deuterated buffer, where labile amide 
proton present in unstructured flexible regions exchange readily with deuterium atoms 
in the buffer (yellow). In contrast exchange occurs at much reduced rates for those 
amide protons involved in hydrogen bonding or protected by ligand binding or 
allosteric effects. Quenching of the labelling is induced (rapid decrease in pH, ~ 2.4-
2.5, and temperature) losing the native conformation, however spatial information of 
secondary structure is maintained through the HDX labelling. The protein is then 
subjected to proteolysis using an acid stable protease and liquid chromatography (fast, 
0 ᵒC, often UPLC) mass spectrometry is applied to analyse the rate of deuterium 
exchange over time. Comparison of HDX data between the unbound (Apo) and bound 
(Holo) forms can be indicative of ligand binding effect 
1.2.3.1.4 Back exchange 
A major factor to consider during HDX-MS experiments is back exchange, which 
describes the process in which labelled labile deuterons, located in both the amide 
backbone and side chain, will readily exchange back with protons introduced during 
the quenching, digestion and LC steps, due to the reversible nature of HDX [125]. 
Back exchange can result in fast exchanging amide deuterons being incorrectly 
identified as un-exchanged hydrogens, therefore the process needs to be minimised in 
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order to preserve valuable structural information and the overall sensitivity of the 
technique. Correction factors have been suggested in order to account for back 
exchange[125], however these assume equivalent rates of exchange for all amino 
acids, an assumption which has been since shown to be false [133]. 
Minimising the amount of back exchange that occurs post-labelling, is typically 
achieved by reducing pH and temperature of HDX-MS workflows. These conditions 
represent a key analytical challenge and steps to overcome these challenges will be 
highlighted in the rest of this introduction.  
1.2.3.1.5 HDX-MS workflows 
HDX-MS experiments can adopt a wide variety of forms, labelling can occur in 
solution [117] or even in the solid state [134] and analysis can occur at the peptidic 
level (bottom-up), at the intact level (top-down) or even in cleaved domains (middle-
down). A typical HDX-MS experiment involves the following steps; labelling, 
quenching, proteolysis (if bottom-up), desalting, chromatographic separation and MS 
analysis.   
As it provides the highest resolution of measured exchange data, a bottom-up HDX-
MS approach is the most common workflow, as illustrated Figure 27.  In this example, 
two protein samples are compared,  the unbound protein (Apo) and the ligand-bound 
protein (Holo).  The samples, in parallel, are both incubated in a deuterated buffer for 
a range of defined time points (typically spanning from seconds to hours). Labelling 
is then quenched by reduction of the pH (~2.3-2.5) and temperature (0°C) to “slow 
exchange conditions”. Whilst maintaining the low pH to avoid back exchange, 
proteolytic digestion is then performed either using a solution based or on-line 
approach producing a range of peptides, which are then desalted and separated using 
a rapid chromatographic step before introduction into the mass spectrometer and 
consequently mass analysis. HDX-MS uptake plots are then generated by subtraction 
of the average (centroid) mass of the undeuterated peptide (control at t=0) and that of 
the deuterated peptide (for each incubation time) and plotting the difference as a 
function of time. At the peptide level (bottom-up) labelling sites can be localised to 
specific regions of the protein primary sequence and any differences in relative rates 
between the Apo and Holo forms of the protein can be attributed to changes in 
secondary structure or allosteric effects [135]. In addition, observation of reduced 
deuteration rates can identify ligand binding/epitope sites [111, 113].  
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Similarly the MS analysis can occur at the intact level (top-down approach) by 
removal of the proteolysis step in the workflow, the accurate mass of the intact protein 
is monitored providing lower resolution global conformational information. A 
comparison of the top-down and bottom-up workflows is illustrated in Figure 28.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Schematic of top-down and bottom-up workflows for HDX-MS analysis 
following a continuous labelling experiment. Subsequent analysis of the HDX 
labelling can range from low resolution using intact analysis, medium resolution 
with the implementation of gas fragmentation strategies of the intact labelled 
protein and to high resolution analysis when performed at the peptide level. 
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1.2.3.1.6 Sample handling 
Sample handling refers to the dilution, quenching and injection of deuterated protein 
solution onto the chromatographic system.  
The dilution step, typically ~ 10-50 fold, of the protein sample in deuterated buffer 
initiating exchange can be performed for either a defined time interval (continuous, ~ 
30sec to several hours) or for a short interval (pulsed, ~ tens of ms). Continuous 
labelling gives labelling incorporation as a function of time providing an insight into 
conformational dynamics in solution, whereas pulsed labelling allows access to short-
lived conformations or structural intermediates [136]. Protein labelling is then 
quenched by reducing the rate of exchange by lowering the pH to 2.5 and the 
temperature to just above 0°C. It is often at this quenching stage that any denaturants 
or reducing agents are added to the sample to aid proteolytic digestion efficiency. 
Alternatively, if proteolytic digestion is not performed immediately following 
labelling, the samples can be quenched by flash-freezing in liquid nitrogen and stored 
at -80°C.   
Performing these dilution and quenching steps manually as performed historically, 
was a bottleneck of the technique due to time constraints and questions of 
robustness/reproducibility relating to the operators technical ability.  However the 
introduction of automated robotic sample handling  has been instrumental in removing 
the requirement of the technical operator to be present, increasing experimental 
efficiency and leading to improvements in reproducibility due to the removal of 
operator errors and inconsistencies [112, 137–140].  
1.2.3.1.7 Proteolysis 
In bottom-up HDX measurements, the proteolysis step is key to establishing the 
resolution of measurements to specific regions of a protein’s primary structure.  
Traditional MS fragmentation strategies, such as CID, have prevented the localisation 
of HDX-MS rates at the single amino acid residue level, due to hydrogen scrambling 
( discussed further in section 1.2.3.1.9). Yet, through the generation of many peptides 
overlapping in primary sequence, known as redundant peptides, and subtractive 
analysis of their measurements the resolution of HDX-MS can be extended to just a 
few amino acid residues, or even to a single amide linkage [125]. These factors lead 
to the high dependency of HDX-MS resolution on effective non-specific digestion.   
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The “slow exchange” conditions (pH 2.5 and 0°C) required to quench labelling, 
however are generally not amenable to achieving high rates of digestion, especially 
not on the timescale required to minimise back exchange. Acid tolerant proteases 
including pepsin (EC. 3.4.23.1) [117], protease type XVIII from Rhozpous species 
(E.C. 3.4.23.6) [141], protease type XIII from Aspergillus saitoi species (E.C.23.18) 
[142] and Nepenthes fluid from Nepenthaceae  species  [143], to mention but a few, 
are exploited for their activity under these conditions, and their wide variety of 
enzymatic products. Traditional proteomic enzymes such as trypsin and Lys-C are 
inactive under these conditions.  
Effective digestion during a HDX-MS experiment is reflected in the type of peptides 
produced. These peptides should be a mixture of small and long in length, reflect high 
sequence coverage of the protein’s primary sequence and also exhibit high 
redundancy [144]. Small peptides (~ 5-7 residues) are preferential, allowing for the 
accurate definition and localisation of exchange properties and structural 
interpretations that can be drawn to specific regions of the protein’s sequence.  The 
relatively non-specific nature of pepsin in terms of amino acid cleavage site makes it 
an ideal choice for the production of such overlapping peptides [145], although the 
promiscuity of pepsin cleavage does complicate any subsequent data analysis steps 
significantly, requiring extensive computational analysis.   
Digestion efficiency can be increased further still by the introduction of denaturing 
and reducing agents during the quenching stage, both of which can be optimised to 
the protein of interest  [146], though care should be taken to desalt these additives 
prior to MS analysis due to suppression effects [147].   
Often the digestion step is performed on-line using enzymes immobilised onto a 
column stationary phase [148] and digestion occurs as the quenched labelled solution 
is passed through the column. This approach has been shown to increase digestion 
efficiency [147], increase digestion reproducibility [127, 144] and prevent self-
proteolysis of the enzyme, therefore eliminating self-pyrolysis products from 
downstream analysis. The on-line nature of the digestion also means that desalting of 
the peptidic products can also be performed on-line prior to the LC-MS stage with 
the use of a trap column further increasing the amenability to high through-put 
analysis.  These advantages over in-solution digestion facilitate shorter digestion 
times, subsequently lower back exchange rates and reduced data complexity. For 
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these reasons most current bottom up HDX-MS workflows exploit the use of an on-
line pepsin digestion columns [148], which can be produced in-house [149] but are 
also available commercially. However if using an on-line enzymatic digestion, care 
must be taken to minimise sample carry over [146, 150] as this can result in distortion 
of measured HDX rates, resulting inaccurate measurements and even incorrect 
kinetics identified [151, 152]. 
 
1.2.3.1.8 Chromatography  
Generating a vast array of different peptidic products during the proteolysis step is 
essential for obtaining high resolution HDX-MS data, yet these peptidic products can 
significantly complicate the down-stream MS analysis.  HDX-MS analysis using 
direct infusion of peptidic products has been carried out successfully for smaller 
proteins such as insulin ~ 6 kDa [153] yet for larger proteins a liquid chromatography 
separation step is required before MS analysis in order to reduce the spectral 
complexity and extend dynamic range of the experiment [64].  
Aside from pH control (~ pH 2.5) there are two main strategies employed to minimize 
back-exchange; low temperature (~0⁰C) and rapid chromatographic separation. When 
deuterated amides are exposed to protiated solvents under slow exchange conditions 
the half-life of exchange is reduced to the range t1/2 ~ 30 to 120 min [125], thus 
requiring effective chromatographic separation in a matter of minutes to minimise 
deuterium losses. Achieving this with use of traditional reverse phase (RP)- HPLC 
has been challenging, often producing poor chromatographic separation, resulting in 
losses of MS sensitivity due to ionisation suppression effects, co-elution of peptides, 
increased spectral complexity and ultimately a lower confidence in peptide 
identification.   
The introduction of ultra performance liquid chromatography (UPLC) systems which 
use sub 2 µm particle columns and high pressures (6000 to15000 psi) [127], has 
allowed for fast effective chromatographic separation under these challenging 
conditions in a matter of minutes (~ 1.5 to 6 min) [154], minimising back exchange. 
Typical back exchange rates observed for bottom-up HDX-MS approaches are often 
reported in the range of 10-30% [154–156].  The superior chromatographic separation 
achieved with UPLC over traditional HPLC methods has led to significant gains in 
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sensitivity reducing sample requirements 10-20 fold [127] and opening the door to the 
HDX-MS analysis of much larger and/or protein complexes [130, 131].  
Further to gains observed by UPLC, use of IMS-based separation, prior to the MS 
analysis step  (Figure 29) , has been illustrated to increase peak capacity [157, 158], 
remove issues of spectral overlap [159], increase peptide coverage and data quality of 
HDX-MS measurements, without the addition of analysis time or contribution to 
back-exchange.   
 
Figure 29. Schematic of the integration of IMS separation within HDX-MS workflow, 
figure taken from [159]. 
1.2.3.1.9 MS measurement and identification 
Prior to any labelling experiments, the initial stage of HDX-MS bottom up workflow, 
involves repeat injections/digest of an undeuterated protein sample and MS/MS for 
peptide identification. This process is termed peptide mapping, and forms the basis of 
any subsequent analysis of HDX labelled products.  
As with most proteomic workflows, peptide identification is most typically achieved 
using CID fragmentation and resulting spectral data is then exported to processing 
software such as PEAKS [160], MASCOT [161] or MS-vendor specific software such 
as PLGS (Waters, Milford, USA),  where peptides are identified based on analysis of 
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fragment ions and database comparison. The identified peptides of the peptide map 
are then exported as a list of m/z and retention times onto which HDX-MS data can 
be aligned based on mass envelopes and retention times.  
The fast elution times and co-elution of peptides observed using UPLC conditions 
required for HDX-MS measurements, can result in poor MS/MS using data dependent 
analysis (DDA) based measurements, due to slow scanning speeds and ultimately a 
loss of sensitivity towards low abundanct peptides. 
However, MSE  is a scanning mode, available for the Synapt G2Si instrument used in 
this thesis, which allows for faster MS/MS scanning speeds (Figure 30) [162]. When 
in this mode the instrument switches between low and higher (or elevated as denotes 
the E) ramped collision energies, within the collision cell. The low energy scan, acts 
as a precursor scan and the high energy scan, causes fragmentation and act as the 
resultant product ion scan.  By setting the high energy scan at a voltage range ( ~ kV) 
rather than a specific single voltage, means peptide fragmentation occurs irrespective 
of their intensity or m/z, facilitating very fast scanning speeds. However, as no 
precursor ion selection has occurred there is no instrumental correlation between 
product and precursor ion. Instead this correlation is established post acquisition based 
on the overlap of chromatographic elution profile between precursor and product ion 
using PLGS software. This type of ion scan is used for peptide mapping experiments 
described in HDX-MS experiments performed in this thesis.  
Though useful at the identification stage, due to its high efficiency, traditional CID 
fragmentation cannot be used to localise deuterium labelling to specific amide 
linkages. The high internal energy of CID, leads to the gas phase interchange of labile 
protons/deuterons at exchangeable sites and loss of amide specific site information in 
a process called hydrogen scrambling [163], meaning the deuterium can only be 
located to the specific sequence of the peptide.  
Site specific labelling information can be achieved using alternative fragmentation 
techniques such as ETD [164] and ECD [165], as their reduced internal energies do 
not result in hydrogen scrambling. However both fragmentation techniques suffer 
from low fragmentation efficiencies, lack of software support and increased 
practicality issues [166] limiting their utilisation into widespread HDX-MS 
workflows.  
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Figure 30. Schematic of MSE scanning modes. A full product ion scan is continuously 
acquired whilst switching between i) low collision energy mode resulting in a 
precursor ion measurement and ii) a ramped higher collision energy mode 
producing fragment ion. Alignment between precursor and fragment ions is 
achieved using retention time post-acquisition, allowing for spectra from co-
eluting analytes to be separated.  
 
1.2.3.1.10 Data analysis 
Due to the abundance of heavy isotopes such as 13C and 14N in organic ions,  peptide 
ions are not represented by a single m/z peak, but instead consist of a series of peaks, 
or envelopes (Figure 31) , representing the range of masses (across all isotopes). The 
centroid mass, or the average mass across all isotopes present, is an intensity weighted 
mass measurement based on the m/z (mi) for the given spectral peak (i) within the 
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envelope, the intensity of the spectra peak (Ii) and total intensity of all the ions present 
in the envelope give the centroid mass, calculated from; 
Equation 24 
𝑐𝑒𝑛𝑡𝑟𝑜𝑖𝑑 𝑚𝑎𝑠𝑠 =  
∑ 𝑚𝑖𝐼𝑖
∑ 𝐼𝑖
                                             
Due to the  Δ mass difference of ~ 1 Da between hydrogen and deuterium isotopes, 
the uptake of deuterium increases the average mass of a peptide, shifting the isotopic 
envelope to higher m/z.  HDX-MS exchange rates are therefore measured by the 
average mass of deuterated peptides as a function of deuteration time. This is typically 
calculated by subtraction of the average mass of the undeuterated peptide at time, t=ref 
from the mass of a the peptide exposed to the deuterated solvent at t=exch [125, 167].  
Due to the long list of potential variables within a HDX-MS experiment including 
time, pH, temperature, protein concentration, mobile phases and chromatography, 
comparison of protein states (non-perturbed protein state vs perturbed protein state) 
by HDX-MS, is often performed relatively, termed differential HDX-MS [112, 137, 
168, 169]. This essentially negates the impact of day-to-day variation of the variables 
listed above on HDX-MS measurement. However, when performing a straightforward 
two state protein comparison it is possible to produce hundred/thousands of individual 
measurements when performing just a few replicates at each time point [112, 170].  
Performing this type of data analysis manually is extremely labour-intensive and for 
a long time a lack of software available for HDX-MS data analysis was a limiting 
factor in industrial usage. In addition to this, the complexity of data can often lead to 
practical protein size constraints. Counter to this, however, in the last decade or so, 
there has been an increase in the software available for semi-automated analysis, such 
as HDX Workbench [171, 172], MS Tools [173], DynamX (Waters, Milford, USA), 
HDExaminer (Sierra Analytics, CA, USA),  HX-Express2 [174] and EXMS [175] to 
highlight a few. This automated software still requires specialist analyst knowledge. 
The review by Iacob and Engen [176] gives a comprehensive list of available software 
which is not within the scope of this report.  The combination of good peak picking 
algorithms and high quality data enables high accuracy and precise measurements to 
be obtained in a higher throughput manner.  
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Figure 31. Centroid mass measurement of spectral envelopes gives the average centre 
of mass for analytes across all isotopes present. By calculating the area within 
the spectral peaks using m/z and intensity measurements the centre of mass can 
be calculated for each spectral envelope.  Deuterium uptake is then calculated 
by measuring the difference in centroid mass between the undeuterated peptide 
mass (t = ref) and the deuterated peptide mass (t = exch).  
1.2.3.2 Fast photochemical oxidation of proteins (FPOP) 
An alternative footprinting technology to HDX-MS, oxidative labelling offers an 
alternative analytical method for measuring protein HOS. The theory, workflows and 
experimental considerations of the technique will now be discussed in detail.  
Oxidation of proteins can occur both in vivo, during aging or various disease states,  
and in vitro during sample preparation and processing causing product degradation. It 
has long since been a common amino acidic modification studied in proteomic 
workflows. Furthermore oxidative labelling of proteins and protein complexes, in 
combination with MS analysis of the products, has been exploited as a means for 
proving protein structure [102] and protein-ligand interactions [177], via hydroxyl 
radical protein footprinting (HRPF) techniques (Figure 19).  
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1.2.3.2.1. History and overview 
Oxidative footprinting was first developed in 1986 by Tullius and Dombroski [178],  
as a footprinting technique for DNA,  whereby hydroxyl radicals generated using Fe2+ 
EDTA-Fenton chemistry, were used for studying the interactions between proteins 
bound to DNA. Cleavage of nucleic acids by hydroxyl radicals was observed to occur 
independently of base sequence. This cleavage, however, was mitigated by the 
interaction between that particular nucleic acid with a bound protein, allowing for the 
localisation of protein interaction sites.  
The first reporting of protein footprinting however was not until 1988, by 
Sheshberadaran and Paye [179], who used hydroxyl radicals to non-specifically 
cleave the amide backbone of proteins, when studying the interactions between of 
antigen-mAb complexes, and used SDS-PAGE in order to separate out the proteolysis 
fragments. The coupling of the technique with LC-MS/MS based detection was 
performed by Chance and co-workers [180], dramatically increasing the resolution 
and sensitivity of HRPF.  
A variety of hydroxyl radical sources including water radiolysis [181], and more 
recently laser photolysis [182], have since been applied, facilitating the protein 
labelling on ns - s timescale. Pioneered by Gross and co-workers [182, 183], fast 
photochemical oxidation of proteins (FPOP) utilises laser production of hydroxyl 
radicals on a ns - µs timescale, measuring oxidative footprinting of amino acid side 
chains as a function of solvent accessibility and protein HOS.  The irreversible nature 
of the HRPF,  in contrast to HDX, allows for extensive sample handling post-
labelling, simplifying analysis and making the whole process readily amenable to 
standard bottom-up MS approaches. 
Since its development, FPOP has been applied, but not limited to, the study of protein 
folding [184, 185], membrane proteins [186],  structure elucidation [187] and epitope 
mapping [188], plus the analysis of isolated proteins and protein complexes or even 
in cell and in vivo [189].  
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Figure 32. Representation of potential oxidation sites for hydroxyl radical footprinting 
as function of solvent accessibility, intrinsic reactivity and higher order 
structural effects . Amino acid side chains buried within tertiary structure with 
poor solvent exposure (blue) are unlikely to undergo oxidation compared to their 
solvent exposed counterparts. Aromatic side chains such a phenylalanine (red) 
when devoid of structure have higher intrinsic reactivity towards oxidation than 
other amino acid side chains, such as valine (pink) which will affect the 
oxidation rates observed. Illustration modified from PDB: 1HZH [124]. 
1.2.3.2.2 Principles of oxidative labelling 
Oxidative labelling is an attractive chemical labelling technique, due to the high 
reactivity and relatively non-specific nature of hydroxyl radical labelling [190].  
Though exposure to hydroxyl radicals can result in protein backbone cleavage, the 
reaction of amino acidic side chains is in the order of 10-1000 faster than this cleavage, 
so by tuning hydroxyl radical generation appropriately, amino acidic oxidation is the 
main product of HRPF. By monitoring oxidation rates as a function of the 
corresponding oxidative products, structural insights can be gained.  Though oxidative 
labelling is a direct indication of a residue’s solvent exposure, lack of labelling can 
also indirectly give structural insights. To understand this fully, it should be 
understood that HRPF oxidation of amino acids is dependent on three factors, solvent 
accessibility, intrinsic rates and structural effects (Figure 32): 
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Solvent accessibility, hydroxyl radicals share a similar van-der-Waals radius to that 
of water, meaning a quantitative relationship exists between SASA and the extent of 
oxidative labelling of amino acids  [191, 192]. In the context of protein HOS, residues 
that are solvent exposed, undergo oxidation, in contrast, lack of oxidation or non-
reactive side chains, are indicative of areas that are buried or involved in protein-
protein or protein-ligand interactions and hence protected from modification [193].  
Intrinsic reactivity, with 14 out 20 amino acids undergoing oxidation when exposed 
to hydroxyl radicals, HRPF is often thought of as non-specific, offering structural 
probes over the vast majority of a protein primary sequence. However, in reality, the 
intrinsic reactivity of the amino acids is not equivalent, with the rate constants for free 
amino acids in the range of 107 - 1010 M-1 s-1 [191]. Table 3, describes rate constants of 
free amino acids with hydroxyl radicals, and their chemical reactivity is as follows:  
Cys > Met > Trp > Tyr > Phe > Cysteine > His > Leu ~ Ile > Arg ~ Lys~ Val > Ser ~ 
Thr ~ Pro > Gln ~ Glu > Asp ~ Asn >Ala > Gly. In typical HRPF those amino acids 
with reactivity ≤ Gln, essentially remain unoxidised. This difference in intrinsic 
reactivity is an important factor to consider when inferring structural elucidations of 
HRPF data, and care should be taken not to over interpret data. 
Primary and higher order structural effects, oxidation rates of amino acid residues 
can be influenced by the protein’s primary sequence, due to electron donating or 
electron withdrawing group effects [194]. In addition, local tertiary structures 
surrounding an amino acid residue can influence oxidation rates due to charge-charge 
interactions, charge-dipole interactions, dipole-dipole interactions, and/or 
hydrophobic effects [195]. 
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Table 3. Rate constants for the reaction of amino acids with hydroxyl radicals, 
including the oxidation products observed, table modified with data reported in Xu et 
al. [191].   
Amino Acid 
substrate 
rate (M-1 
s-1) 
pH Oxidative products 
Cys 3.5 1010 7.0 
Cys sulfonic acid (+48), sulfinic acid (+32), 
hydroxy (-16) 
Trp  1.3 1010 
 6.5-
8.5 
Trp hydroxy- (+16, +32, +48, etc.), pyrrol ring-
open (+32, etc.) 
Tyr  1.3 1010 7.0 Tyr hydroxy- (+16, +32, etc.) 
Met 8.5 109 
 6-7 
4.5  
Met sulfoxide (+16), sulfone (+32), aldehyde (-
32) 
Phe  6.9 109 
7.0-
8.0 Phe hydroxy- (+16, +32, etc.) 
His 4.8 109 7.5 His oxo- (+16), ring-open (-22, -10, +5) 
Arg 3.5 109 
6.5-
7.5 
Arg deguanidination (-43), hydroxy- (+16), 
carbonyl (+14) 
Cystine 2.1 109 6.5 cysteine sulfonic acid, sulfinic acid 
Ile 1.8 109 6.6 Ile hydroxy- (+16), carbonyl (+14) 
Leu 1.7 109 ~6 Leu hydroxy- (+16), carbonyl (+14) 
Val  8.5 108 6.9 Val hydroxy- (+16), carbonyl (+14) 
Pro 6.5 108 6.8 Pro hydroxy- (+16), carbonyl (+14) 
Gln 5.4 108 6.0 Gln hydroxy- (+16), carbonyl (+14) 
Thr 5.1 108 6.6 Thr hydroxy- (+16), carbonyl (-2- or +16-H2O) 
Lys 3.5 108 6.6 Lys hydroxy- (+16), carbonyl (+14) 
Ser 3.2 108 ~6 Scr hydroxy- (+16), carbonyl (-2- or +16-H2O) 
Glu 2.3 108 6.5 
Glu decarboxylation (-30), hydroxy- (+16), 
carbonyl (+14) 
Ala 7.7 107 5.8 Ala hydroxy- (+16) 
Asp 7.5 107 6.9 Asp decarboxylation (-30), hydroxy- (+16) 
Asn 4.9 107 6.6 Asn hydroxy- (+16) 
Gly 1.7 107 5.9 - 
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1.2.3.2.3 Oxidative products 
Oxidative labelling can be identified and localised by characteristic mass shifts, which 
in turn can be relatively quantified by LC-MS/MS workflows (described in section 
1.2.3.2.8). However a vast array of oxidative products exist, with the 14 amino acids 
that are oxidised, having the potential to yield  > 50 different oxidative products. An 
extensive summary of the reaction mechanisms of all the different oxidation pathways 
is given in the review by Xu and Chance [191] which have been summarised into 
characteristic modifications/mass shifts in Table 3.  
Most commonly, for aliphatic amino acids  (Ala, Val, Leu, Ile, Pro), oxidation results 
in either the addition of a hydroxyl (+15.99 Da) or carbonyl (+13.98 Da) group to the 
amino acid side chain. For aromatic amino acids (Phe, Tyr, Trp) addition of one or 
multiple hydroxyl (+15.99 Da) groups to the aromatic ring can occur in ortho-, para- 
and meta- ring positions of the aromatic ring. Asp and Glu undergo oxidative 
decarboxylation (-30 Da), basic amino acid side groups give rise to a series of unique 
oxidative products. Sulphur containing residues, Cys and Met, can undergo multiple 
additions of hydroxyl groups (~ +15.99 Da, +31.98 Da) and due to high reaction rates, 
caution should be taken to ensure secondary oxidation has not occurred.  
1.2.3.2.4 Oxidative radical sources 
Hydroxyl radicals can be produced from a variety of sources including Fenton-Fenton 
reactions via metal catalysis [179], radiolysis of water by either γ or x-rays including 
synchrotron sources [185, 192] and laser photolysis of H2O2 [182]. However, only 
laser photolysis of H2O2 and x-ray radiolysis of water produces radicals on a fast 
enough times scale (ms-µs) for unbiased protein measurements.  This times scale is 
faster than unfolding of both tertiary and secondary structures [196], allowing access 
to transient structures permitting possible exploration of dynamic conformations 
[197]. Figure 33, gives the reaction scheme for hydroxyl radical production from laser 
photolysis. In contrast to the expensive and limited access to sources of synchrotron 
radiation, FPOP requires only a modest experimental set up consisting of a UV 285nm 
KrF excimer laser, a syringe pump and a flow system [182], as illustrated in Figure 
34. The experimental workflows will now be discussed in more detail. 
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Figure 33. Reaction scheme for the modification of amino acid side chain groups with 
hydroxyl radicals generated by laser photolysis. 
 
 
Figure 34. Schematic of hydroxyl radical oxidation of proteins using a capillary flow 
FPOP labelling workflow. The protein sample is incubated in low levels of H2O2 
then flowed through a capillary system, where the sample is exposed to a single 
exposure to a KrF laser irradiation through a window on the capillary, producing 
hydroxyl radicals from H2O2. Solvent accessible side chains will be susceptible 
to hydroxyl radical attack and oxidation. The sample is then quenched with the 
addition of the enzyme catalase, and then can be frozen/stored prior to further 
sample treatment and oxidative MS analysis.  
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1.2.3.2.5 FPOP labelling 
Conventional FPOP set-ups use a KrF laser, to produce ns pulses of 248 nm UV light, 
a wavelength sufficient to generate high yields of hydroxyl radicals yet is absorbed 
minimally by proteins in aqueous buffers. The laser is directed to a narrow window a 
fused silica capillary via a series of lenses or optics which, focusing the beam to a tiny 
spot ~ 2 mm x 1mm, covering the height of a conventional capillary ( 100-400 µm 
outer diameter). Figure 34 gives a schematic of the FPOP workflow described. The 
sample (protein + H2O2 + scavenger) is transported  via a sample flow system, 
consisting of a syringe pump, delivering a constant flow of the sample ( ~ µL/min) 
and a capillary of fused silica tubing. This tubing is then held into careful alignment 
with the laser beam via a mounting system and a transparent window formed at the 
point of contact using an ethanol burner.  During the FPOP experiment, the system is 
then irradiated once through this window, in small segments as a result of the laser 
pulse, meaning a small volume of sample in between laser pulses, known as the 
exclusion volume remains irradiated [107]. This exclusion volume, typically ~ 30% , 
can be calculated by capillary dimensions, laser frequency and flow rates to ensure of 
single shot exposure of sample.   
Two specific features of the FPOP set-up ensure that the short lifetime and exposure 
of protein to hydroxyl radicals occurs in the fast sub-ms scale, these are use of 
scavenger reagents and ensuring single irradiation exposure, allowing the FPOP 
footprinting to capture rapid structural dynamics. The generation of hydroxyl radicals 
through a narrow window, ensures the packet of protein passing through the window 
is only exposed once on a ns time scale and removes secondary oxidisation events. 
Secondly the use of scavenger solutions, typically in the forms of free amino acids, 
allows the tuning of hydroxyl radical life time on the 1 ms -100 ns times scale[198].  
1.2.3.2.6 Sample requirements and handling 
In order to abstract meaningful structural conclusions from oxidatively labelled 
proteins, as with all MS structural methodologies, it is critical that oxidation must 
occur while the protein is in its native conformation that is being probed. Controlling 
the extent of oxidation is also critical for data quality and assurance, too low and it 
risks being below the MS limit of detection and quantification, however to high and 
it risks saturation of the modification which can affect the quantification of the 
unmodified forms. Key steps to control these levels of oxidation, other than the 
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experimental set ups described include sample preparation, the FPOP experimental 
process and the sample collection steps.  
A typical FPOP sample contains µM levels of protein (owing to the high sensitivity 
of MS analysis) plus any ligands of interest, any sort of buffering requirements for the 
protein of interest and a tuned H2O2/scavenger ratio. It is worth noting that additives 
within buffers can diminish oxidation induced by the FPOP, particularly free amino 
acids often present in protein formulations or reducing substances such as dithiotreitol 
(DTT), all of which can have quenching effects on hydroxyl radicals produced. Where 
possible additives such as these should be kept to a minimum. Levels of H2O2 should 
be kept ~ 15-20 mM range to ensure sufficient oxidation [199] and radical lifetime is 
controlled using an optimised scavenger solution, which competes with the protein 
for oxidation with the hydroxyl radical. Glutamine, histidine and methionine are 
commonly used as scavengers for FPOP experiments [182, 200]. Measurements by 
time-resolved [181] and lifetime profiles [182] UV spectrometry, suggest that radical 
lifetimes are on the 0.1-1 µsec timescale in the presence of radical scavengers. 
Typically during FPOP experiments the H2O2/scavenger solution is added to the 
protein sample immediately prior to irradiation, minimising any oxidation which may 
occur from low levels of free radicals already present. Alternative set-ups such as one 
in which multiple sample pumps and a micro mixer-Tee are used to mix the protein 
sample and H2O2/scavenger solutions on-line immediately prior to the irradiation 
window have been demonstrated. These workflows have been demonstrated to be 
useful when excessive oxidation levels are a concern [201] and indeed has been shown 
to increase the reproducibility of oxidation levels [184].  Laser-off controls, in which 
the protein sample goes through the FPOP procedure but with no irradiation, should 
also be run in parallel so as to correct for any background oxidation that may occur 
during the labelling procedure or during post-labelling handling and storage.  
The final stage of the flow path is the sample collection tube, such as an Eppendorf, 
which is filled with a quenching solution typically containing the enzyme catalase and 
mM levels of free methionine which remove any unreacted hydroxyl radicals or other 
radical species which can continue to oxidise the protein post FPOP. Following 
completion of the sample flow, the irradiated sample and quenching solution are 
immediately vortexed and samples can now be stored under appropriate conditions 
for further processing and analysis.  
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1.2.3.2.7 MS measurements and identification 
As with all protein footprinting FPOP mediated oxidation can be measured either at 
intact protein or the peptide level, providing global and localised structural 
information respectively (Figure 35). The wide variety of oxidative products ( ~ + 
13.98, +15.99, +32, -30) can then be assigned based on deconvoluted mass shifts in 
MS spectra.  
Intact analysis is the most simple form of analysis, typically including some form of 
desalting or RP-LC step before ESI-MS analysis. The denaturing conditions in RP-
LC however can lead to loss of sensitivity towards low abundant oxidative species, 
due to excessive charging of the protein ions leading to loss of signal-to-noise.  
Oxidation extent can be assessed using the base peak of the protein spectra or by using 
deconvolution software to abstract all the masses of the protein species present.  
Presence of Poisson distribution of the unmodified and oxidated species is indicative 
of a single protein conformation and the absence of secondary oxidation events [196, 
202].  
One of the advantages of covalent footprinting is the irreversible nature of the 
labelling, meaning samples can be stored  and re-analysed in multiple analyses. 
Facilitating more established and sensitive bottom-up proteomic workflows which 
enable peptide and amino acid residue localisation of  modification. Sequence 
coverage across the whole protein can be maximised with the use of single or 
combined proteases (e.g. Trypsin, Lys-C, Asp-N, chymotrypsin) to digest FPOP 
samples, as well as effective chromatographic separation of proteolytic products. 
Extensive fragmentation of modified and unmodified peptides can be ensured with 
use of MS/MS experiments ( eg. CID, ETD, HCD), of which subsequent datasets can 
be analysed using a range of proteomic software packages (e.g PEAKS studio [160] 
and Mascot [161]) to identify peptides and localisation of modification sites.  
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Figure 35. MS analysis workflows of FPOP labelled protein samples. Analysis can be 
conducted at the global level to measure the extent of modification or bottom-
up workflows to localise and measure the extent of modification to specific 
amino acid side chains.  
1.2.3.2.8 MS quantification 
The final stage in the FPOP workflow is that of relative quantification, in which the 
extent of modification is compared to that of the unmodified protein or peptide, and 
modification levels compared between samples (e.g a ligand bound and unbound  
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FPOP labelled proteins). Quantification is performed relatively, expressed as a % 
modified, using the extracted ion chromatogram (XIC) of the exact masses of 
modified and unmodified peptide/protein forms, normalising the fraction of the 
modified peptide against the unoxidised fraction, such as: 
Equation 25 
 % 𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑 =
𝐼(𝑐𝑖)𝑚𝑜𝑑
𝐼(𝑐𝑖)𝑚𝑜𝑑 +  𝐼(𝑐𝑖)𝑢𝑛𝑚𝑜𝑑
 
 
Where I is the intensity or peak area of the XIC for the modified and unmodified 
species. Quantification is considered relative due to differences in retention time 
between modified and unmodified peptides (oxidised peptides often eluting prior to 
the unmodified peak [102]),  which lead to differences in ionisation efficiencies due 
to differing chromatographic compositions. Should multiple forms of modified 
peptides arise due to multiple sites of oxidation at differing amino acid side chains, 
the relative extent of modification can also be expressed at an amino acidic level.  
Modification levels can then be compared across sample types, and use of statistical 
tools such as Student’s t-test applied to identify statistically significant differences in 
oxidation. Relative increases or decreases in the amount (or location) of oxidation 
observed can be interpreted with respect to the SASA of the amino acid residue 
relative to a reference protein state, though intrinsic reactivity and primary structural 
effects should also be considered when interpreting data (see section 1.2.3.2.2). These 
data can be considered in parallel with high resolution datasets such as XRC, NMR 
and HDX. 
1.3 Aims and objectives of work 
High resolution measurement of protein HOS has become increasingly important 
within the biopharmaceutical space from a regulatory perspective. Due to its relatively 
high sensitivity, resolution and applicability to all levels of protein HOS, MS based 
methods have been increasingly utilised as an analytical tool in this space.  Yet, as 
these powerful tools move from academia to industry the quality, reproducibility, 
precision and interpretation of data generated is being challenged. Protocols and 
quality control (QC) materials are needed to validate such methodologies and to better 
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understand comparability of both within-platform analytical measurements and across 
orthogonal platforms. Furthermore, data needs to be produced to discriminate between 
structural changes and measurement variability, to increase confidence in the MS 
measurements and facilitate comparability studies. 
International reference standards have existed in the clinical and diagnostic area for 
decades, for both small molecule and protein measurements, facilitating 
comparability studies and harmonisation of diagnostic assays.  However such 
materials for protein HOS measurement have been lacking and as such understanding 
the comparability and differing sensitivity of platforms for HOS measurement has 
been challenging. This thesis aims to support the metrological gap in these 
measurements by developing reference protocols and model systems to increase 
confidence in MS based HOS measurements and validate new analytical platforms 
for HOS measurements.  
This thesis will seek to apply analytical concepts of repeatability, reproducibility and 
sources of measurement variability to assess three MS based technologies for protein 
HOS characterisation. These include two orthogonal protein footprinting 
technologies, HDX-MS and FPOP-MS, to provide high resolution structural insights 
and use of higher throughput IMS-MS technology, that would be more applicable to 
a regulatory QC environment.  
The specific objectives of this study are; 
- To develop protocols for the generation of modified protein HOS states, known 
as protein model systems, of two commercially available protein RM, for the 
assessment of the sensitivity of differing analytical platforms towards structural 
changes. These modified protein states will be pharmaceutically relevant 
including ligand states (Chapter 2) and glycan variants (Chapter 3).  
- To use these RMs to develop and establish the reproducibility and robustness of 
MS based methods, HDX-MS,  IMS-MS (Chapter 2) and FPOP-MS (Chapter 4) 
for protein HOS measurement.  
- To use these protein RMs to systematically establish and minimise sources of 
measurement variability of MS methods for protein HOS measurement so as to 
optimise their sensitivity towards small structural changes (Chapter 2 and 4). 
- To use HDX-MS and IMS-MS methods developed to validate the model protein 
systems (Chapters 2-3) and characterise the structural changes occurring in the 
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modified protein states. These data in turn will be used to validate more novel 
analysis based on FPOP-MS measurements (Chapter 4) and understand the 
comparability of MS based HOS measurements.  
- To generate data that act as reference datasets of these model systems, that can 
be used to benchmark and optimise more novel analytical technologies, such as 
described for FPOP-MS (Chapter 4). 
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Chapter 2 
Development of a reference protocol for higher 
order structure characterisation of small 
recombinant protein biotherapeutics  
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Chapter 2 
Development of a reference protocol for higher order structure 
characterisation of small recombinant protein biotherapeutics 
2.1 Introduction 
2.1.1 Need for reference standards and model systems for HOS 
measurements 
The availability of reference standards and model systems to assess and validate 
analytical platforms used for measuring changes in HOS is lacking. Further still, 
regulatory guidelines on the most appropriate analytical platform to use when trying 
to define if a protein has undergone a structural change are also wanting. This study 
seeks to address this space by the development of model systems, protocols and 
generating data sets to under pin comparability of measurements across different 
analytical platforms and define their sensitivity towards structural changes.  
An ideal candidate protein for conducting this cross platform characterisation study 
should be stable, bio-pharmaceutically relevant or simulate as such, have a defined 
HOS and be easily sourced with a batch-to-batch consistency. A model system will 
then be developed where the candidate protein exists in a reference HOS state and in 
a “stressed” state, where the protein has undergone some sort of controlled change in 
HOS. These changes should be small, localised and not associated with the total 
unfolding of the reference protein state, so as to truly simulate the type of structural 
heterogeneity that may arise during manufacturing processing.  Better still, ideally the 
magnitude of the HOS change should be controllable, facilitating the use of the model 
system to assess the sensitivity of an analytical platform towards structural changes 
(i.e. the ability to detect both large and small structural changes). 
The WHO material 98/574 is an international RM , consisting of recombinant human 
growth hormone (rhGH), that fulfils the criteria of candidate protein and additionally, 
the well characterised nature of rhGH structure (HDX-MS [203–205], IMS-MS [206], 
XRC [207, 208], NMR [209], CD [210] and SEC [211]) facilitates its use for 
validation of methods developed here.   
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2.1.2 Human growth hormone (hGH)  
Human growth hormone (hGH) is a class-I helical cytokine protein produced in the 
pituitary gland [212], involved in modulation of growth, muscle differentiation, bone 
and cartilage cells and lactogenic signalling [208]. A variety of health implications 
can arise from hGH deficiencies including increased risk of cardiovascular disease, 
growth abnormalities, increased insulin resistance plus decreased muscle and bone 
mass. Since 1984, a recombinant  form of hGH (rhGH, DNA-derived), has been used 
as a biotherapeutic treatment for hGH deficient adolescents and it is an example of a 
well characterised protein therapeutic [204, 208, 209]. 
rhGH consists of 191 amino acid residues, corresponding to a molecular mass of ~ 22 
kDa. Predominantly α-helical in structure, its tertiary structure is based on a four-α-
helix bundle motif observed with class-I cytokines. This bundle of helices, designated 
A-D (Figure 36) is tightly packed, with the first helices, A and B, running in parallel 
with respect to one another followed by the second two helices, C and D, running in 
anti-parallel. These adjacent helices are stabilised by two disulphide bridges and this 
combined with predominantly hydrophobic amino acid residues present in these four 
helices gives rhGH structure a very stable hydrophobic core [207]. rhGH also displays 
regions lacking in defined structure, located in the linker regions between the helices. 
This mixture of regions of very defined HOS and more flexible HOS make rhGH an 
attractive candidate protein to test the capabilities of structural analytical platforms. 
2.1.3 Model system: rhGH and zinc 
The presence of zinc was identified as a reagent for generating a potential “stressed” 
protein state for the rhGH model system based on the literature [208, 213, 214]. The 
presence of Zn2+ has been documented to promote the binding affinity of hGH to the 
transmembrane growth hormone receptors (hGHR) and pro-lactin receptors 
(hPRLR)[214], by up to 8,000 times, a key interaction in modulation in cell growth 
and development. This Zn2+-binding site has been identified by XRC to occur at His18 
and Glu174 residues,  with the His21 side chain contributing towards the binding 
through the co-ordination and stabilisation of Glu174 residue [208]. Binding 
stoichiometry of hGH-Zn2+ complex is reported to be 1:1, and the Kd of the complex 
estimated at ~ 1 µM [213]. Additionally, at high concentrations the presence of Zn2+ 
has been shown to induce dimerization of hGH and the hGH-dimer acts as a possible 
storage form due to the high levels of Zn2+ found in hGH storage granules located in 
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the pituitary glands [215]. The use of Zn2+ has also been explored as a precipitating 
agent in formulation processing of protein biotherapeutics with minor tertiary 
structural changes identified [210].  
 
Figure 36. Higher order structure of hGH based on the crystal structure of PDB 1HGU 
[216].  
 
2.1.4 Defining the sensitivity of HDX-MS measurements 
When moving towards the standardization of an analytical technique, standard 
operating procedures (SOP), QCs, repeatability and reproducibility studies should be 
utilised to understand and minimise measurement uncertainty, and hence facilitate 
both inter and cross-platform comparison of measurements.   
2.1.4.1 Comparability and reproducibility of HDX-MS measurements 
Recently, several commercially available automated on-line HDX-MS platforms have 
become available which allow for automated sample handling, dilution, injection, on-
line digestion and chromatographic separation [127]. There is, however, much work 
to be done in this area with respect to the standardization of HDX-MS measurements. 
Indeed a report published by the International Bureau of Weights and Measures 
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(BIPM) recognized the potential of HDX-MS measurements for the characterisation 
of protein HOS but also the need for standardisation of the methods employed [217]. 
The use of robotic sample handling systems has been effective in creating data sets 
large enough to access the variability of HDX-MS. Studies from Chalmers[137], 
Burkitt [138] and Houde et al. [112] have assessed platforms over a defined time 
period, all of which concluding that robotic set ups aid the reproducibility of the 
system and that inter-day variability was higher than intra-day variability, though 
careful control of variables could result in the variability of percentage deuterium to 
be as low as 1.0-2.2% [138].   
2.1.4.2 Establishing significance thresholds of HDX-MS measurements 
Pharmaceutical regulators require manufacturers to demonstrate the manufacturing 
consistency across batches and process changes, termed comparability, of a drug 
[218]. Traditionally, comparability studies have been performed using biophysical 
techniques such as CD, LC-UV, DSC, isothermal titration calorimetry (ITC) and 
analytical ultracentrifugation (AUC), which provide only low resolution global 
folding profiles of biopharmaceuticals and are known to often demonstrate low 
sensitivity to small structural changes. The high resolution nature of HDX-MS 
measurements make the technique attractive not only in pharmaceutical R&D but also 
in comparability studies. It is worth noting that though HDX-MS measurements 
provide higher resolution, there is a substantial cost in terms of analysis time and 
throughput compared to traditional biophysical techniques. The commercialisation 
and gains in reproducibility from the development of automated set-ups has led to 
increased usage of HDX-MS across academia and industry, particularly the 
biopharmaceutical sector. Yet, measurement reproducibility and/or uncertainty must 
first be established to define significance thresholds before the technique is widely 
exploited for comparability studies.  
Statistical approaches that help define significant structural changes are required to 
support the use of multiple HDX-MS datasets in this comparability area, and indeed 
this has been a small but growing field of research, Table 4 summarises some of this 
published work. Though much of this research, accounts statistically for inter-day 
variability differences between two samples, there is no account for intra-day 
variability nor for measurement variability, reducing the robustness of the approaches.  
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One of the most comprehensive approaches, described by Houde et al. [112], reported 
the use of HDX-MS measurements in a comparability study of several different 
preparations of interferon-β-1a (IFN), by performing a series of lot-to-lot 
comparisons, known as a vial-to-vial study, of seemingly identical samples of IFN. 
The resulting differential HDX-MS measurements were used to establish several 
measurement thresholds above which would define a significant structural change in 
a quantitative way whilst considering the variability of HDX-MS measurements. A 
drawback of this approach is that a single global threshold value was established 
across all the peptides observed for IFN. Potentially this may mask any small 
significant structural change that is experienced by an individual but reproducible (in 
terms of comparability) peptide, decreasing the sensitivity of the approaches towards 
small but real structural changes.  Recently this approach has been extended further 
by Hageman et al. [168], who illustrated the false positives and inaccuracy of using a 
single global threshold limit and how sensitivity and accuracy of structural changes 
could be increased by use of a hybrid statistical approach which assessed the data first 
on a global threshold limited then on an individual threshold basis using a Welch’s t-
test, an unequal variances t-test. This approach was shown to reduce false positives, 
in this study, however is only applicable to discrete HDX-MS labelling times, 
removing any HDX trends that may have a time dependency. 
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Table 4. Summary of some of published statistical approaches for defining the significance of differential HDX-MS measurements.  
Publication 
Software 
incorporation 
Statistical approach Brief description 
Chalmers et al. 
[137]  
HDX-Workbench Two-tailed t-test, Tukey multiple 
comparison procedure 
Devoid of intra-day variability estimation, multiple time points or time-
dependency of HDX 
Houde et al.[112] N/A Single global significance value based 
on  standard error of the mean (SEM)  
Multiple vial-to-vial data sets generated, global significance values 
generated for individual or multiple summed time points of HDX. 
Single global threshold value not peptide specific.  
Rey et al. [219] MassSpec Studio Two tailed t-tests Devoid of intra-day variability estimation, multiple time points or time-
dependency of HDX 
Hourdel et al. [220]  MEM-HDX Linear mixed- effects model Devoid of intra-day variability estimation, replicates considered 
random effects, time dependency and replicate variability considered, 
p-value for ΔD and change in dynamics 
Hageman et al. 
[168] 
N/A Hybrid significance testing approach, 
global significance based on SEM, 
individual significance generated using 
Welch’s t-tests 
Intra-day variability estimation generated from vial-to-vial matrix, 
global and individual significance testing of single time points, no 
testing of multiple HDX time points.  
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2.1.5 Native IMS-MS and comparability studies 
Though providing high sensitivity and high resolution insights into HOS structure, 
HDX-MS comparability studies have several caveats. These include often lengthy and 
complex experimental/data analysis approaches and measurements provide only an 
average measurement of the conformations present in solution, masking differences 
in heterogeniety. Native IMS-MS measurements, however, offer an alternative 
approach for HOS comparison with a much reduced experimental/data analysis time, 
requiring much less sample and the ability to measure and monitor the presence of 
multiple conformational species that could be present in a sample. 
Ferguson et al. [49] systematically assessed the suitability of IMS-MS and CIU IMS-
MS to compare and differentiate between mAb-based biotherapeutics, evaluating the 
reproducibility of several different metrics and applying these to establish lot-to-lot 
variability. These metrics included species drift time (tD), a peak intensity ratio (PIR), 
peak width at 50% maximal intensity (FWHM) and peak width at 10% maximal 
intensity (FWTH). tD measurements were established to be the most reproducible 
metrics (% relative standard deviation, RSD < 1.44%). The utility of IMS-MS and 
CIU-IMS-MS measurements for distinguishing between two mAb based drugs was 
demonstrated for systems with large global changes in structure. However, the study 
questioned the applicability of the technique to compare across biosimilar mAbs from 
two differing manufacturers. The study also compared TWCCSN2 values calculated 
using external calibration required for non-drift tube IMS-MS and concluded that 
considering tD metrics was more sensitive for structural change detection than 
comparison of TWCCSN2 values alone.  
Analytical methods used to support regulation of therapeutic pharmaceuticals must be 
demonstrated to be robust and reproducible [60]. This Chapter reports the use of a 
rhGH RM to optimise and critically assess repeatability and reproducibility of HDX-
MS and IMS-MS measurements. Considering the reproducibility of these 
measurements, these methodologies were then applied to characterise the proposed 
model system of rhGH in the absence and presence of zinc at two rhGH:Zn 
concentrations,1:2 and 1:10, defining any significant structural changes observed 
whilst commenting on the sensitivity of each analytical platform towards structural 
changes.  
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2.2 Materials and Methods  
2.2.1. Materials 
All chemicals and standards were purchased from Sigma Aldrich [Gillingham, UK] 
and were of research grade purity unless otherwise stated. Ultra-pure water (18.2 
MΩ∙cm) was used. Formic acid and TCEP (tris(2-carboxyethyl)phosphine) were 
purchased from Thermo Fisher Scientific [Loughborough, UK]. Acetonitrile was 
Optigrade HPLC Special Grade [LGC Standards, Teddington, UK].  rhGH RM 
(WHO98/574) was purchased from NIBSC [Potters Bar, UK].  
2.2.2. Protein sample preparation 
A 36 µM rhGH stock was prepared by solubilisation of the lyophilised RM in water 
and vortexing for 1 hour at room temperature. Following this the stock was aliquoted 
and stored at -20 °C to be removed for single use.  
2.2.1.1 Sample preparation for HDX-MS and SEC measurements  
A 0.9 mM zinc acetate stock solution was also freshly prepared in water and further 
diluted in 10mM KPBS (pH 7.4) to obtain a series of solutions; solution C (180 µM 
zinc acetate), solution D (90 µM zinc acetate) and solution E (18 µM zinc acetate).  
Prior to analysis, 36 µM stock aliquots of rhGH were defrosted and further diluted to 
7.2 µM (0.16 mg/mL) with 10 mM KPBS or solution D or E to obtain 1:10 and 1:2 
respectively. Samples were left to equilibrate at room temperature for 1h before 
analysis. 
2.2.1.2 Sample preparation for IMS-MS measurements  
For native IMS-MS analysis, zinc acetate solutions were prepared from dilutions of a 
0.9 mM zinc acetate stock solution with a 20 mM ammonium acetate solution. A 
second series of solutions were prepared; solution F (90 µM zinc acetate) and solution 
G (18 µM zinc acetate).  
Prior to buffer exchange and desalting steps, aliquots of 36 µM rhGH stock were 
removed from the freezer and allowed to defrost and equilibrate for 45min. Desalting 
and buffer exchange of the stock sample was performed using Bio-spin micro P6 pre-
packed size exclusion columns (Bio-rad, California, U.S.A) as per the manufacturer’s 
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instructions. In short, excess packing buffer was removed using an 5810R centrifuge 
(Eppendorf, Stevenage, U.K) at 1000 g for 2min. Buffer exchange was then performed 
by loading 500 µL 20 mM ammonium acetate buffer and centrifuging for 2 min at 
1000 g, repeating this step 4 times to ensure 99.9% buffer exchange. 75 µL of rhGH 
stock was then loaded directly onto the centre of the column and centrifuged for 4min, 
collecting the eluent. To maximise desalting the buffer exchange process was repeated 
as described and the sample loaded for a second time. 
The desalted and buffer exchanged rhGH was then diluted to 7.2 µM using 20 mM 
ammonium acetate or zinc acetate solutions F and G to obtain rhGH:Zn 1:10 and 1:2 
respectively. A final sample was prepared by dilution of the desalted rhGH stock using 
a solution of 180 µM of magnesium acetate to give rhGH in the presence of 
magnesium (rhGH:Mg, 1:10). Samples were left to equilibrate at room temperature 
for 1h before analysis. 
Calibrant solutions of 10 µM Beta-lactoglobulin (B-LAC) in 200 mM ammonium 
acetate were also prepared as described by Bush et al [52]. 
2.2.1.3 Preparation of deuterated  and undeuterated peptide mixture  
A peptide mixture containing MRFA [74 µM], bombesin [24 µM], angiotensin II 
[angio II, 191 µM], and glu-1-fibrinopeptide B [glufib, 64 µM], insulin chain B [ICB, 
77 µM] was prepared from stock solutions. This mixture was then diluted 1200-fold 
in either deuterated 10mM phosphate buffer, (pH 7.0) or phosphate buffer, (pH 7.4) 
to act as deuterated and undeuterated peptide mixtures respectively. Both samples 
were shaken at 25 °C overnight to ensure complete exchange occurred for the 
deuterated sample and to take into account potential stability issues. 
2.2.1.4 Preparation of deuterated and undeuterated α1-Antitrypsin  
A 18.5 µM deuterated α1-Antitrypsin stock was prepared by solubilisation of 
lyophilised α1-Antitrypsin in a deuterated buffer containing pre-deuterated 2M urea, 
10 mM potassium phosphate (pH 7.0) solution. To facilitate complete deuteration the 
protein stock was then heated at 30 °C overnight. Prior to analysis protein stock was 
then to 3.7 µM using the pre-deuterated buffer. An undeuterated α1-Antitrypsin 
control stock was also prepared in parallel using undeurated buffers.  
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2.2.3. HDX-MS 
2.2.3.1 Instrumentation 
Sample handling and mixing steps were performed using a first generation LEAP PAL 
system set up for HDX analysis [LEAP Technologies, Carrboro, USA]. Samples were 
injected onto a refrigerated nanoACQUITY UPLC System with HDX technology 
[Waters, Milford, USA] for on-line pepsin digestion and chromatographic separation. 
MS experiments were performed on a Synapt G2Si QToF instrument [Waters, 
Milford, USA]. 
2.2.3.2 HDX-MS experiments 
For the generation of peptide maps and time zero exchange experiments, 15 µL of 
rhGH (0.16 mg/mL) was diluted 10-fold in 10 mM KPBS (pH 7.4). For exchange 
experiments, deuterium labelling was performed by diluting 15 µL of rhGH 10-fold 
in 10 mM KPBS (pH 7.0) prepared in D2O. Exchange times were 0.5, 5, 60, 240 and 
480 min, with the exchange occurring at room temperature (21±2 °C). Triplicate 
analyses were carried out for each incubation. Following the appropriate incubation 
period, exchange was quenched by a 2-fold dilution with 50 µL of 300 mM TCEP, 2 
M Guanidine Hydrochloride (Gnd.HCl) in 100 mM KPBS (pH 2.5) at 4°C.  Following 
a 0.5 min quench delay, a 50 µL sample loop was overfilled with 95 µL of quenched 
sample. 
On-line digestion was performed using an Enzymate BEH pepsin column (5 μm, 2.1 
x 30 mm) [Waters, Milford, USA] at 25 °C and a flow rate was 80 µL/min (mobile 
phase 0.05% v/v formic acid).  Proteolytic peptides were trapped on an ACE C18 
guard cartridge (5 µm, 2.1 mm i.d.) and sequentially chromatographically separated 
on an ACE Excel Super C18, (2 µm, 2.1 x 100 mm i.d, both Hichrom Reading, U.K), 
both trap and analytical column were held at 0 °C. Digestion pressure was held at ~ 
4000 psi using a PEEK restrictor placed post-trap column. Chromatographic 
separation was carried out at 100 µL/min by application of a 7 min linear gradient 
from 92% A / 8% B to 65% A / 35% B.  Mobile phases consisted of aqueous, 0.1% 
v/v formic acid (A) and CH3CN, 0.1% v/v formic (B).  
MS experiments were performed in positive ESI mode using an 80 °C source 
temperature, 2.8 kV capillary voltage, 80 V cone voltage and a desolvation 
temperature of 250 °C. For peptide map generation, data were acquired in MSE 
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continuum mode over a range of 50 – 2000 amu, with a scan time of 0.2 s, inter scan 
time of 0.1s and a transfer ramp of 15-40 V. Exchange experiments acquired in MS 
mode under the same conditions but with no collision energy applied. Mass calibration 
was performed using a 100 fmol solution of Glu-fibrogen, (50% MeOH, 0.1% formic) 
with a lockmass of 785.8426 m/z, mass correction was applied post acquisition. 
2.2.4 Data analysis  
2.2.4.1 Peptide identification  
ProteinLynx Global Server software v 3.02 [PLGS, Waters, Milford, USA] was used 
to generate peak lists by inputting MSE data and searching against a database 
consisting of both FASTA sequences of porcine Pepsin A (P00791, Uniprot) and 
Somatotropin (P01241, Uniprot), see Table A-24, in the appendix for parameters. The 
PLGS outputs were imported in DynamX v3.0 [Waters, Milford, USA] to generate 
peptide maps, file thresholds (peptides observed in x files out of y, n=x/y) of n=3/3 
and n=4/5 were used for digestion optimisation experiments and HDX-MS peptide 
maps respectively. Additional processing parameters included 0.01, minimum 
products per amino acid and 20 ppm, maximum MHP+ error.  
2.2.4.2 Deuterium uptake measurements 
Peptide deuterium levels were calculated as described by Burkitt et al. [138], based 
on the difference between the calculated centroid mass measurement of the isotopic 
distribution of the undeuterated control sample and the deuterated sample at t=x. No 
correction was made for back exchange during deuterium uptake calculations.  
Measurements are expressed as deuterium uptake (in Da) or as percentage relative 
deuterium uptake (rDU), calculated by the division of deuterium uptake (in Da) by 
the theoretical maximum number of exchangeable backbone amide protons in the 
peptide (using the formula, N-2-P, where N is the number of amino acid residues in 
the sequence and P is the number of proline residues not including the first two N-
terminal residues [120] and expressed as a percentage). Differential calculations were 
performed using deuterium uptake (in Da) measurements. 
2.2.4.3 Qualitative assessment of peptide map 
To make a qualitative assessment of the efficiency of digestion under different 
conditions, a parameter called digestion  factor (DF) [221], shown in Equation 26 was 
used, this factor incorporates a weighted average of the sequence coverage achieved 
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(y1), the percentage of potential cleavage sites accessed (y2) and the redundancy (y3), 
a measure of overlapping peptide sequences..  
Equation 26  
DF = 8y1 + 5y2 + 0.6y3 
The sequence coverage (y1) is the proportion of the primary sequence which is present 
in the peptides identified (S) relative to the number of amino acids present in the 
sequence (N).  
Equation 27 
𝑦1 =  
𝑆
𝑁
 
The cleavage rate (y2) shows the proportion of peptide bonds cleaved (C) relative to 
N.  
Equation 28 
𝑦2 =  
𝐶
𝑁
 
The redundancy rate (y3) is the sum of the number of times that an individual amino 
acid is seen across multiple peptides (R) relative to N.  
Equation 29 
𝑦3 =  
∑ 𝑅
𝑁
 
The digestion factor calculation allows for the three components contributing to 
efficient digestion to be evaluated simultaneously, whist still allowing some definition 
in the contribution of these factors, for instance the factor of highest importance, 
sequence coverage, y1, is weighted more than redundancy, y3.  
2.2.5 Size exclusion chromatography 
SEC-UV experiments were performed using an 1100 series LC system with a variable 
wavelength detector [both Agilent technologies, California, U.S.A]. Separation was 
achieved  across a Yarra SEC-X150 column (1.8 µm, 4.6 x 150 mm i.d, Phenomenex, 
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Cheshire, U.K) using an isocratic gradient of a 150 mM PBS, 50 mM NaCl (pH 7.4) 
mobile phase, at a flow rate of 0.18 mL/min for 15 min.  
Triplicate injections of 27.5 µL for each rhGH sample (0.16 mg/mL) were carried out 
and measurements acquired at ʎ=210 nm. A bovine serum albumin solution (BSA, 5 
µL, 1 mg/mL)  was also injected to act as a reference point against rhGH aggregates.  
Integration of chromatographic peaks was performed using ChemStation software. 
Results were reported as relative percentage dimer (%) calculated as the (area of 
dimeric peak)/(area of dimeric peak + area of monomeric peak).   
2.2.6 Native IMS-MS 
2.2.6.1 Instrumentation and experimental settings 
nESI-IMS-MS experiments were performed on a Synapt G2Si Q-ToF instrument 
equipped with a nanoESI source and infused using gold-plated borosilicate capillaries 
prepared in-house. Experimental settings were optimised as follows: source 
temperature 30°C, sampling cone 5 V, source offset 2 V, capillary voltage 1.4 kV, 
trap CE 5 V, trap gas flow 3 mL/min, helium cell has flow 120 mL/min, IMS gas flow 
60 mL/min, trap DC entrance 3 V, trap DC bias 30 V, trap DC 0 V, trap DC exit 0 V, 
IMS DC entrance 20V, helium Cell DC 50 V, helium exit -20 V, IMS bias 3 V, IMS 
DC exit 0 V, transfer DC Entrance 4 V, transfer DC exit 15 V, IMS wave velocity 
1100 m/s, IMS wave height 40 V, transfer wave velocity 89 m/s, transfer wave height 
1 V, stepwave1 RF offset 300, stepwave2 RF wave offset 350. Unless otherwise stated 
all other settings were set to default values. Data were acquired in resolution mode in 
the 500-8000 m/z with a 1 sec scan time for 2 minutes. No cone or purge gas was used.  
Parameters were systematically optimised by infusion of rhGH in IMS-MS mode 
whilst monitoring tD to ensure effective transition of gas ions whilst avoiding 
unfolding of the gas ions within the instrument. 
Mass calibration was performed by infusion of a 1 mg/mL caesium iodide solution in 
the range of 500-5000 m/z.  Data were processed using MassLynx v4.1 and Driftscope 
v2.5 software [both Waters, Milford, USA]. 
2.2.6.2 CIU-IMS-MS experiments 
CIU IMS-MS experiments were conducted using the experimental conditions stated 
above but with the quadrupole selection +8 charge state (2765.5 m/z) of the rhGH 
control and that of the equivalent singly-bound zinc species (2773.5 m/z) for rhGH:Zn 
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1:2 and 1:10 samples.  The trap collision voltage was increased in 2 V increments 
between the range of 6 – 36 V and data acquired for 1 min at a 2 s scan rate for each 
voltage. To avoid any systematic errors which may occur during the course of the 
experiments/spray, IMS-MS spectra experiments were performed in a randomised 
order across the voltage range. 
2.2.6.3 Data Analysis 
Mass spectra, chromatograms and extracted mobiligrams were analysed using 
MassLynx v 4.1. Mobility data were also analysed using DriftScope v. 2.5.  CIU IMS-
MS plots were generated using PULSAR (Protein Unfolding for Ligand Stabilisation 
and Ranking) [98].  
2.2.6.4 CCS measurements and other equations 
Using the methods described by [53] and calibrant reference measurements published 
by Bush et al [52], B-LAC monomer and dimer populations were used as calibrants 
to obtain TWCCSN2 measurements. Briefly using the optimised IMS-MS methods, drift 
time (tD) measurements were recorded for monomeric (+7, +8) and dimeric (+11, +12, 
+13) charge states of B-LAC. Using Microsoft Excel a linear regression model was 
fitted to plots of Ω’ (TWCCSN2 nm2) vs tD’ (ms), using equations described in (1.1.6.2 
~ Equation 20). The subsequent calibration line generated was used to adjust 
measured TWIMS tD of rhGH species.   
An estimation of measurement uncertainty was calculated for each TWCCSN2 
measurement generated, which encompassed measurement error arising from mass 
uncertainties and uncertainty arising from the observed deviation from a linear 
regression calibration  line.  
Equation 30 
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To calculate the theoretical maximum charge, z max, that can be held by a protein of 
mass, m, whilst retaining its native-like conformation, the following equation was 
used [77]: 
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Equation 31  
z = 0.077 x m ½ 
2.2.7 rhGH structural models 
The model used to represent the structure of free rhGH was based on the crystal 
structure of the free wild type hGH (PDB ID:1HGU [216]) solved to a resolution of 
2.5 Å.  The model used to represent the structure of Zn2+-bound rhGH is constructed 
using 1:2 hGH:hGHPLR complex (PBD ID: 1BP3, [208] ), in which a Zn2+ ion is 
present and the structure is solved to resolution of 2.9 Å. Graphics representing this 
three dimensional data have been generated using PyMOL (The PyMOL Molecular 
Graphics System, Version 1.74 Schrödinger, LLC.) as have all further XRC 
documented in this thesis. 
2.3 Results and discussion 
2.3.1 HDX-MS method optimisation 
The key analytical stages involved in production of robust, reliable and reproducible 
HDX-MS measurements were systematically optimised and assessed and described 
herein. 
2.3.1.1 Proteolytic digestion 
In a bottom-up HDX-MS experiment, structural measurements are defined by the pool 
of peptides observed, termed the peptide map, onto which HDX-MS measurements 
are mapped, making optimisation of the proteolytic digestion stage a key experimental 
stage. Peptide map generation involves the production of a series of repeat on-line 
digestions of undeuterated sample, each of which is then desalted and separated by 
UPLC and identified accurately using MS/MS fragmentation. 
High sequence coverage of the protein of interest is critical to generate peptides useful 
for monitoring structural changes by HDX-MS. Furthermore generating a large 
number of overlapping peptides (redundant peptides) is important to increase amino 
acidic resolution for the accurate identification and localisation of induced structural 
changes.  
A range of proteolytic digestion conditions was identified as influencing proteolytic 
digestion and systematically assessed to maximize sequence coverage and 
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redundancy. These included: composition of the quenching solution (reducing and 
denaturing reagents present), temperature, and pepsin column flow rate (effective 
digestion time). Using the on-line digestion set-up described in the Materials and 
Methods 2.2.3.2, these factors were assessed and optimised for peptide map 
generation for HDX-MS experiments.  Samples of rhGH (7.2 µM) prepared in 10 mM 
KPBS (pH 7.4) were diluted 1:10 in KPBS, mixed, quenched and injected on the 
HDX-MS system under a range of digestion conditions. To ensure a robust and 
repeatable peptide map only those peptides observed in 4/5 repeat injections were 
considered in the final peptide map. Peptide maps are qualitatively assessed 
considering the digestion factor (DF) assessment criteria as described in 2.2.4.3, and 
summarised in Table 5. 
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Table 5. Effects of varying digestion conditions on rhGH peptide map. All quench solutions contained 100 mM KPBS (pH 2.5) and any additional 
presence of reducing and/or denaturing reagents are stated. Resulting peptide maps were generated using those peptides observed in n≥4/5 
digests and described considering sequence coverage (y1), cleavage rate (y2) redundancy (y3) and overall digestion factor (DF) score [221].  
Condition number 
Flow rate 
(µL/min) 
Temp (° C) Quench composition 
Coverage 
(y1) 
Cleavage 
(y2) 
Redundancy 
(y3) 
DF 
(DF = 8y1 + 5y2 + 
0.6y3 ) 
i 100 20 - 64.4% 23% 172% 7.3 
ii 100 20 300 mM TCEP, 2M Gnd.HCl 90.6% 36% 279% 10.7 
iii 80 10 300 mM TCEP, 2M Gnd.HCl 82.2% 28% 179% 9.1 
iv 80 25 300 mM TCEP, 2M Gnd.HCl 96.3% 42% 388% 12.1 
v 150 25 300 mM TCEP, 2M Gnd.HCl 94.2% 39% 369% 11.8 
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2.3.1.1.1 Effect of denaturing reagents 
Comparison of resultant peptide maps produced in the absence and presence of 
denaturing and reducing agents (Table 5, conditions i and ii, and Figure 37), 
demonstrates the increased sequence coverage and redundancy due to the presence of 
the reagents. Digestion was increased, particularly around the two cysteine bridges in 
rhGH, positioned at Cys53-C165 and Cys182-189 [208], upon the addition of 
denaturing and reducing agents, as was coverage for the Phe10-Glu30 region and 
redundancy in area of Cys55-Leu75.  It appears that the presence of these reagents in 
the quenching solution has led to the opening of the central α-helical bundle structure 
of rhGH, with the reduction of these bridges allowing for greater pepsin accessibility 
to these areas, resulting in significant increases in digestion of these covalently linked 
areas, as demonstrated. Secondary structures in this region are known to include a turn 
and α-helices; therefore, the reduction of cysteine bridges combined with the 
denaturing of the α-helices has facilitated better digestion. 
2.3.1.1.2 Effect of on-line pepsin flow rate 
During the digestion stage of the chromatography, controlling the flow rate of the 
pepsin column affects the contact time between protein and immobilised enzyme, or 
effective digestion time. Thereby controlling the pepsin flow rate allows efficacy of 
the digestion based on digestion time to be evaluated. Slower flow rates illustrate 
longer effective digestion times, with longer protein to pepsin interactions, compared 
to faster flow rates which have shorter digestion periods and less opportunity for 
interaction between the protein and enzyme. Figure 38 (produced from conditions iv 
and v, Table 5) illustrates a combined peptide map generated from rhGH peptides 
observed using two flow rates, 80 µL/min and 150 µL/min, giving effective digestion 
times of 3.8 and 2 min, respectively. Overall the digestions are similar in terms of total 
digestion factors (DF),  with DF values of 12.13 (y1 – 96.3%, y2 – 42%, y3 – 388%) 
11.75 (y1 – 94.2%, y2 – 39%, y3 – 369%) for  80 and 150 µL/min flow rates 
respectively. Many peptides were observed mutually under both flow rates covering 
some 93% of the sequence.  Average peptide length for each flow rate is similar with 
values of 12.67 and 12.80 for 80 and 150 µL/min flow rates respectively. However, 
considering the standard deviation (SD) across peptide length for each flow rate 
reveals a value of 8.0 for 80 µL/min compared to 5.7 at 150 µL/min illustrating a 
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larger variety in peptide length at the faster digestion times. This is favourable for 
HDX-MS as it could lead to more spatial resolution of any HDX-MS data obtained 
under these conditions. 
 
 
Figure 37. Peptide maps of rhGH generated from pepsin digestion in the a) absence 
and b) presence of 300 mM TCEP and 2 M Gnd.HCl. rhGH samples were 
digested using a flow rate of 100 ul/min and a temperature of 20 °C. Only 
peptides identified in n=4/5 repeats are illustrated. Cysteine residues between 
Cys53-Cys165 (red) and Cys182-Cys189 (black) are indicated.  
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Figure 38. rhGH peptide maps generated with varying on-line pepsin flow rates.Flow 
rates used were  80 µL/min and 150 µL/min, with the presence of 300 mM TCEP 
and 2 M Gnd.HCl at a temperature of 10 °C.  Peptides observed, under both flow 
rates (blue), exclusively at 80 µL/min (green) and exclusively at 150 µL/min 
(red) are illustrated. Only peptides identified in n=4/5 repeats are illustrated. 
This illustration was generated using MSTools [173] . 
2.3.1.1.3 Effect of temperature 
As with many proteases, it has been demonstrated that increased temperatures ( > 0°C)  
increase the digestion efficiency of pepsin [222]. A temperature controlled 
compartment, housing the on-line pepsin column, built within the HDX-MS platform 
allowed digestion temperature to be tightly controlled. Using the optimised digestion 
additives and flow rates, rhGH digestions were performed at both 10 °C and 25 °C. 
(Table 5, conditions iii and iv,  Figure 39). Increase in digestion efficiency across all 
the digestion factor components, was observed at higher temperature, but redundancy 
in particular was effected. A 15 °C increase resulted in peptide redundancy increasing 
from 179% to 388%, further increasing the resolution of any HDX-MS data produced 
under these digestion conditions. Though sequence coverage is relatively high ~ 90% 
with the optimised conditions, there is still 10% of the primary sequence, residues 10-
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15 and 74-93, missing from the peptide maps produced and hence no HDX-MS data 
will be measured in these regions.  
To avoid excessive contributions towards back exchange from increased temperatures 
and long digestion times, a compromise was met under these optimised conditions (25 
°C and 80 µL/min) which attempted to maximise peptide map quality yet allow for 
the conservation of labelling. Though back exchange is generally minimised by the 
short time spent on the pepsin column and pre-cooling of solvents, keeping 
temperature to a minimum yet achieving good digestion is an important consideration 
for peptide optimisation and worth noting. 
 
Figure 39. Peptide maps of rhGH generated from pepsin digestion with varying on-
line pepsin temperatures. rhGH samples were digested using a flow rate of 80 
µL/min, with the presence  of 300 mM TCEP and 2 M Gnd.HCl  and a 
temperature of a) 10 °C and b) 25°C Only peptides identified in n=4/5 repeats 
are illustrated. Disulphide bridges between Cys53-Cys165 (red) and Cys182-
Cys189 (black) are indicated.  
- 102 - 
These data illustrate that in the case of the on-line pepsin digestion of rhGH, elevated 
temperatures, the presence of denaturing/reducing agents, and moderate pepsin flow 
rates are all favourable to producing a high quality peptide map for rhGH HDX-MS 
data. The optimal pepsin digestion conditions were found to be 300 mM TCEP and 
2M Gnd.HCl, 25 °C, 80 µL/min flow rate and were applied to the HDX-MS 
experiments performed herein. 
2.3.1.2 Back exchange assessment 
As aforementioned, controlling the back exchange within the HDX-MS experiment, 
is key to maximising the sensitivity with respect to structural changes and reducing 
measurement variability. A mixture of undeuterated and fully deuterated peptide 
standards (MRFA, bombesin, angiotensin II, glu-1-fibrinopeptide B and insulin chain 
B) were analysed to assess the contribution to the total back exchange of (a) the trap 
and LC column, (b) the pepsin column, (c) the dilution/mixing steps (d) the MS 
source.  
For the back-exchange assessment of the entire system, the mixtures of deuterated and 
non-deuterated peptides were quenched and analysed as described in section 2.2.3.2. 
Total back exchange (%) for the whole HDX-MS system for individual peptide 
standards are displayed in Table 6. To isolate different system components, the 
peptide sample was also injected directly on to the LC system with and without the 
pepsin column in place. Contribution of each component towards back exchange was 
then calculated by comparison of the deuterium uptake across these experiments.  
The most significant amount of back exchange was found to occur across the trap and 
LC column (contributing ~ 76% of the total back exchange), presumably due to the 
overall proportion of time that the deuterated peptides are exposed to protons present 
in the mobile phase. As the temperature and flow rates of the pepsin column are 
critical factors in the optimization of the proteolytic digestion method, their effects on 
back exchange were also investigated by comparing the deuterium uptake of a number 
of peptides observed from a fully deuterated off-line digested sample of α1-
Antitrypsin. It was found that the effect of flow rate on the back exchange was 
proportional to the amount of time the peptides spent on the pepsin column, whereas 
a drop of temperature from 25 to 20 °C during pepsin digestion resulted in no 
significant difference in back exchange (decrease of 0.1 ± 1.5%). An increase to 30 
°C resulted in much greater back exchange (increase of 5.1 ± 1.5% across the peptides) 
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reiterating the need for careful consideration of digestion parameters when developing 
a HDX-MS method. 
Table 6. Details of peptides used for back exchange experiments. Total percentage 
back exchange (across entire system including sample handling, pepsin and 
UPLC stages) observed for each peptide standard assumes complete deuteration 
of the peptides. 
peptide 
primary 
sequence 
m/z 
max exchange 
backbone 
(Da) 
retention 
time  (min) 
back 
exchange 
MRFA MRFA 524.5 2 6.2 24 ± 2.3% 
angio II DRVYIHPF 1046.5 5 7.3 29 ± 1.8% 
Glufib 
EGVNDNEEGFF
SAR 
785.8 12 7.6 33 ± 1.7% 
bombesin 
PQRLGNQTAVG
HLM 
810.4 11 8.0 17 ± 2.3% 
ICB 
FVNQHLCGSHL
VEALYLVCGER
GFFYTPKA 
1165.6 27 9.0 33 ± 1.3% 
 
2.3.1.3 HDX-MS measurements and rhGH structure prediction 
Prior to making any structural comparisons from rhGH HDX-MS measurements, the 
optimised system and methods were validated by comparison of rhGH HDX-MS 
measurements with reported hGH protein structures [203, 205, 209, 216].  
Figure 40 displays the percentage relative deuterium uptake (rDU) rates observed for 
the rhGH control, covering 93% of rhGH sequence. Rates are displayed in relation to 
the known secondary and tertiary structures (Figure 40 a and b respectively), as 
described in the XRC structure of free wild type hGH (PDB ID: 1HGU, [216]). Slower 
rDU rates were observed for all four α- helices present within the structure (Figure 40 
a), residues 9-33 (helix A), 72-89 (helix B), 114-128 (helix C) and 155-186 (helix D), 
as expected due to the protection afforded by the hydrogen bonding in these structures. 
The more flexible linker and loop regions of the structure, such as residues 50-77 and 
130-140, exhibit much faster HDX rates, with their lack of secondary structure 
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facilitating their participation in exchange. Figure 40 b maps the observed rDU, 
represented by a heat colour scale, as slow exchanging peptides displayed as cool 
(blue) colours and fast exchanging as warm (red) colours. Considering this, the effects 
of tertiary structure on rDU were apparent for the residues 15-25, 77-87, 114-117 and 
165-177, positioned within the central cavity of the antiparallel four α-helical bundle 
of rhGH, known to be a central hydrophobic region of the protein. Even after 8 hours 
incubation minimal exchange occurs, due to decreased solvent accessibility as a result 
of the tight packing of the α-helical structures. Overall HDX dynamics observed here 
correlate well with previous studies, both HDX-MS [203–205] and NMR [209], which 
describe a folded, stable structure of rhGH at neutral pH values. These data 
demonstrate the utility of HDX-MS measurements alone, as valuable tool for protein 
structure prediction. 
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Figure 40. Relative deuterium uptake of the rhGH peptides analysed after 0.5, 5, 60, 
480 min incubation periods plotted against a) the rhGH secondary structure and 
b) the rhGH tertiary structure as measured by XRC [216]. Cysteine bridges C1 
and C2, are indicated. HDX-MS measurements are expressed as percentage 
relative deuterium uptake (rDU) values. Amino acidic rDU values are plotted 
according to the shortest localised peptide in the corresponding region. Where a 
residue is covered by multiple peptides the rDU for that given residue is defined 
by the shortest peptide out of those peptides covering that residue. 
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2.3.1.4 Reproducibility and intermediate precision assessment 
To assess the repeatability and intermediate measurement precision (IMP) of the 
optimised HDX-MS methods and system developed here, triplicate within-day HDX-
MS measurements of rhGH control samples ( ~ 0.5 min  deuterium incubation) were 
made across a one year period.  For each experimental dataset, rhGH samples, buffers, 
mobile phases and quench solutions were all prepared fresh. HDX-MS measurements 
across the year period encompass the use of three pepsin columns, four batches of 
rhGH reference material and three analysts that conducted both experimental and data 
analysis stages. 
Considering the 41 peptides observed in all datasets, the repeatability and IMP of the 
rDU were calculated as the mean RSD of the rDU for each peptide within a day and 
over one year period respectively. The repeatability (n=3) was 0.6% and the IMP 
(n=33) was 2.1%. Table 7 displays the rDU, repeatability and IMP for each peptide. 
Comparison of these values with other published reproducibility data from different 
laboratories, albeit produced using difference protein standards, Table 8, demonstrates 
the robustness of the optimised platform and methods developed here [137, 138, 170, 
223]. 
In addition, this in-house dataset was probed for the main sources of measurement  
variability. To visualise any correlation between rDU and precision, a beeswarm plot 
was generated, Figure 41, using the RSD for each peptide and rDU measurements. 
Peptides with higher RSD showed lower rDU for both repeatability and IMP, 
reflecting the effects of small variations in instrumental conditions, different protein 
conformational ensembles in different rhGH samples, temperature, pH and mobile 
phase fluctuations on HDX-MS measurements.  Mobile phases were freshly prepared 
in a controlled environment (uncertainty, pH meter ± 0.01, balance ± 0.00030 g) and 
temperatures were controlled throughout the deuterium exchange experiments 
(temperature uncertainty, PAL ± 1 °C, laboratory ± 2 °C). Those factors were 
therefore considered to be unlikely causes of large measurement variability.  
The contribution of chromatographic reproducibility and pepsin column integrity to 
back exchange [123] were then further evaluated as potential components affecting 
HDX-MS measurement variability. Peptide retention time (RT) reproducibility 
provides an indication of the varying exposure times of eluting peptides in repeat 
injections to protons in the mobile phase. If large enough this variability will 
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consequently affect back exchange rates and ultimate absolute HDX-MS 
measurements. RT RSDs within the one year period, for the 41 peptides considered 
were merely > 1% for 93% of rhGH peptides, suggesting that chromatographic 
conditions such as flow rate, mobile phases, column lifetime variability and 
chromatographic temperature were not the major components affecting measurement 
variability. These data also validate the usage of a 0.5 min window set in DynamX 
processing parameters, matching deuterated and undeuterated peptides in the peptide 
map based on RT, further increasing reliability of deuterated peptide identification 
and reducing need for manual data curation, particularly attractive when considering 
the industrialisation of the HDX-MS methodology. 
On the contrary, fluctuations in back exchange were observed during the life time of 
the pepsin column, with sudden increases in back exchange for rapidly exchanging 
peptides after numerous injections.  During the life time of each of the three pepsin 
columns used in this study, mean RSDs for the rDU across 41 peptides were 15%, 
13% and 14% respectively, similar to the mean RSD of the 41 peptides across the year 
(13%) and all three pepsin columns. This confirms that the major source of variability 
on rDU of the measurements carried out here was within the pepsin column life time. 
Evaluation of the peptide maps generated across the lifetime of the column, showed 
average values of the rhGH sequence coverage and cleavage rate over the one year 
period were 95 ± 1% and 37 ± 3% respectively, indicating that any possible effects on 
deuterium uptake due to column degradation occurred prior to loss of proteolytic 
digestion. In light of this, a QC injection of rhGH incubated in deuterated solvent for 
t=30s was added to the beginning of every HDX-MS run, when large fluctuations > 
10% of back exchange were observed for this sample the pepsin column was replaced 
for new.  
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Table 7. Measurement repeatability (Rep) and intermediate measurement precision 
(IMP) of the 41 rhGH peptides detected in all n=33 experiments carried out to 
calculate IMP over one year period. rDU is the average of the relative deuterium 
uptake percentage and repeatability and IMS expressed as the rDU standard 
deviation, for within-day n=3 and n=33 respectively.  
 
Peptide  
residues 
rDU 
(%) 
Rep (%) IMP (%) 
[rhGH] 1-9 60.6 0.2 7.8 
[rhGH] 2-9 63.0 2.0 9.5 
[rhGH] 3-9 60.7 0.2 8.4 
[rhGH] 15-25 2.3 0.2 0.6 
[rhGH] 16-25 2.5 0.2 0.4 
[rhGH] 26-32 8.5 0.1 0.7 
[rhGH] 31-44 36.0 0.1 1.4 
[rhGH] 32-44 41.0 0.6 1.2 
[rhGH] 34-44 47.3 0.3 1.6 
[rhGH] 35-44 53.5 0.9 1.5 
[rhGH] 45-51 41.9 0.4 4.0 
[rhGH] 45-52 48.8 0.5 2.9 
[rhGH] 53-63 36.4 1.4 2.8 
[rhGH] 53-73 42.2 0.9 2.9 
[rhGH] 54-63 41.9 0.8 1.8 
[rhGH] 54-73 42.4 1.4 3.1 
[rhGH] 55-63 38.1 0.9 2.6 
[rhGH] 55-73 43.5 0.7 3.0 
[rhGH] 64-73 39.3 0.6 2.1 
[rhGH] 93-100 32.0 0.7 1.8 
[rhGH] 98-106 48.7 0.7 1.3 
[rhGH] 98-110 43.8 0.4 2.1 
[rhGH] 101-110 41.5 0.2 2.3 
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[rhGH] 102-110 38.1 0.1 2.2 
[rhGH] 107-113 22.7 0.5 0.7 
[rhGH] 114-124 1.6 0.2 0.6 
[rhGH] 115-124 2.9 0.3 1.0 
[rhGH] 117-124 2.6 0.1 0.8 
[rhGH] 125-138 35.0 0.3 3.2 
[rhGH] 125-139 36.1 0.5 2.4 
[rhGH] 125-146 42.6 1.8 2.8 
[rhGH] 140-146 34.7 2.1 3.2 
[rhGH] 147-156 20.3 0.8 1.4 
[rhGH] 147-157 20.8 0.5 1.1 
[rhGH] 155-163 15.3 0.5 1.2 
[rhGH] 157-163 6.2 0.5 1.2 
[rhGH] 164-175 1.6 0.3 0.9 
[rhGH] 167-176 3.4 0.5 0.6 
[rhGH] 176-182 2.0 0.3 0.8 
[rhGH] 182-191 40.7 0.5 1.8 
[rhGH] 183-191 42.3 0.5 2.0 
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Table 8. Comparison of rhGH HDX-MS measurement Rep and IMP with published 
HDX-MS data [137, 138, 170, 223]. Proteins measured are abbreviated to the 
following: Bovine carbonic anhydrase (BCA), Equine cytochrome c (Cyt. C), 
Bovine ubiquitin (B. Ubiq) and Vitamin D receptor (VDR). Rep and IMP are 
repeatability and intermediate measurement procedure respectively expressed as 
the relative standard deviation of relative deuterium uptake for n replicates. N 
pep is the number of peptides considered in the study. Days is the study duration. 
N/A means that the information was not available 
Protein Rep  (n) IMP (n) N pep Analysts Days 
rhGH 0.6 (3) 2.3 (33) 41 3 360 
BCA [138] 0.4 (4) 1.6 (26) 5 1 60 
Cyt C [170] 1.4 (3) N/A 52 N/A 1 
B.Ubiq [223] 0.9 (20) 2 (60) 39 N/A 37 
VDR [137] N/A 3.9 (127) 34 N/A 240 
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Figure 41. IMP of HDX-MS measurements for 41 rhGH peptides following 0.5 min 
incubation, visualised using a beeswarm plot. Each data point represents the 
relative standard deviation (RSD) percentage of individual peptide HDX-MS 
measurements and points are grouped accordingly to the relative deuterium 
uptake of each peptide.    
 
2.3.1.5 Establishing significance thresholds from differential vial-to-vial 
study 
A statistical differential analysis approach was developed to define rhGH structural 
changes induced by zinc and establish thresholds to discriminate significant structural 
changes from measurement variability [224]. This approach builds on the differential 
analysis method developed by Houde et al.[112] with a modification made to avoid a 
perceived erroneous calculation of the measurement error and to identify individual 
thresholds for each individual peptide in contrast to establishing a single global 
confidence limit, an approach which has been demonstrated to give both under and 
over estimations of error [168].  
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To enable comparability studies and define thresholds, first a vial-to-vial 
comparability study was conducted using the rhGH control [112, 168]. For this 
comparability study, a rhGH control sample was diluted in buffer, allowed to 
equilibrate at room temperature, the sample split into two vials and analysed 
concurrently by HDX-MS using the optimised method described. Replicate vial-to-
vial comparability studies were conducted across three repeat relative experiments 
performed on three different days (n=9). Peptides were given a number, i, based on 
the computed position in the rhGH amino acid sequence of the peptide’s mid-point 
[112]. 
The differential analysis approach developed was first applied to the vial-to-vial 
comparison, to establish measurement thresholds, above and below which structural 
changes can be confidently defined, and then applied to the HDX-MS measurements 
to determine structural differences between the rhGH control (ref) and the rhGH:Zn 
1:2 and 1:10 samples (exp). 
HDX-MS measurements of different rhGH control vials were obtained for each “n” 
rhGH control and only those peptides common to all datasets were considered. The 
data for each peptide were treated as follows: 
For an experiment carried out in a single experiment on one day, the absolute 
differential deuterium uptake at a time point, t, is 
Equation 32 
𝐷𝑡 = |𝑀exp,𝑡 − 𝑀ref,𝑡| 
where Mexp,t and Mref,t represent the mean of triplicate measurements of the deuterium 
uptake at time, t, for the experimental and reference samples respectively. Mean 
values are used because there is no correlation between samples at the repeatability 
level. The precision of Dt depends on the level of replication, and the figures provided 
are for triplicate measurements. If the experiment is repeated over a number of days, 
this will result in a set of values of Dt for each peptide. The correlation introduced by 
day-to-day variation is implicitly taken into account by calculating Dt separately for 
each day. 
For differential analysis, Mref,t represents the reference sample (e.g. rhGH control) and 
Mexp,t represents the perturbed sample (e.g. rhGH:Zn 1:2). In the context of the vial-
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to-vial comparability, reference and experimental states were equal to rhGH control 
vial 1 and vial 2 respectively and are interchangeable between vials.  
The purpose of using absolute values is to ensure that if both destabilising and 
stabilising dynamics (variability in the context of a comparability study) occurred 
across the course experiment for an individual peptide, this would not be concealed 
in final differential thresholds. 
The absolute difference values at each incubation time point, t, are added together to 
produce a differential sum; 
Equation 33 
𝑆 = ∑ 𝐷𝑡
𝑡
 
This is done separately for each day, producing a set of values of S, the variability of 
which represents the intermediate precision of the differential sum. 
A threshold value, SL, can then be defined using the mean and standard deviation of 
S, across the multiple datasets produced, and used to define a limit above which 
structural changes can be differentiated from measurement variability: 
Equation 34 
𝑆𝐿 = 𝑆̅ + 𝑠(𝑆) 
Considering only those peptides, identified in all n data sets, including a final rhGH 
control vs each of rhGH:Zn (1:2 and 1:10) differential study (n = 5 datasets, 10 
samples), measurement thresholds, represented by the dotted lines in Figure 42 a and 
b, were established for 53 (96.3% sequence coverage, 211% redundancy) rhGH 
peptide. For the differential analysis of  rhGH vs rhGH:Zn, Equation 32 and Equation 
33, were applied to each dataset. All raw differential measurements are detailed in 
Table A-25, located in the Appendices.  
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Figure 42. Differential HDX-MS measurements (dark grey bars) between rhGH 
samples. Dotted lines represent the positive and negative individual peptide 
threshold limits (SL) as calculated from vial-to-vial study of rhGH control vs 
rhGH control a) rhGH control and rhGH in the presence of 2 molar equivalents 
of Zn2+ (1:2) and b) rhGH control and rhGH in the presence of 10 molar 
equivalents of Zn2+ (1:10). Those peptides that are considered to demonstrate a 
significant structural change by exceeding the calculated threshold limits are 
highlighted in shaded grey and labelled as regions I, II, III, IV, V. 
 
2.3.1.6 HDX-MS measurements to identify HOS changes induced by zinc 
Relative HDX-MS experiments were carried out to compare the structure of rhGH in 
the absence and presence of zinc, and differential analysis performed (applying 
Equation 32 and Equation 33). Differential values were compared with thresholds, SL, 
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calculated from the rhGH control vial-to-vial, allowing structural changes from 
measurement variability.  
Figure 42, shows the differential sums for each peptide calculated for the comparison 
a) rhGH and rhGH:Zn 1:2, and b) rhGH and rhGH:Zn 1:10 . Table 9 summarises those 
peptides identified as showing significant changes due to the presence of zinc at two 
and ten molar equivalents.  
Table 9. rhGH peptides identified as showing significant changes due to the presence 
of zinc, by HDX-MS differential analysis. Changes are expressed as HDX 
increases (+) and decreases (-) relative to rhGH control, with no significant 
change is indicated by blank input.  
Identifier Relative HDX change 
Peptide, i Peptide ID Sequence Zn 1:2 Zn 1:10 
1 1-9- FPTIPLSRL 
 
- 
2 2-9- PTIPLSRL 
 
- 
4 14-25- MLRAHRLHQLAF 
 
+ 
5 15-25- LRAHRLHQLAF + + 
6 16-25- RAHRLHQLAF 
 
+ 
7 26-32- DTYQEFE + + 
26 93-100- LRSVFANS 
 
+ 
34 114-124- LKDLEEGIQTL 
 
+ 
35 115-124- KDLEEGIQTL 
 
+ 
36 117-124- LEEGIQTL 
 
+ 
51 178-191- RIVQCRSVEGSCGF 
 
- 
52 182-191- CRSVEGSCGF 
 
- 
53 183-191- RSVEGSCGF 
 
- 
 
Two peptides exceeded the threshold limits localised for rhGH:Zn 1:2 sample 
comparison, indicating structural changes, corresponding to the residues 15-25 and 
26-32 (region II in Figure 42). Both of these peptides are located in the helix A of 
rhGH with peptide 15-25 including the residues His18 and His21, that are two of the 
three residues reported to be involved in the Zn2+ ion binding to rhGH [208, 213].  
Increased rates of deuteration for both these peptides suggest that Zn2+ binding 
disrupts the hydrogen bonding of helix A, possibly shifting the orientation of the 
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hydrophobic α-helix region outwards and increasing the incidence of deuterium 
exchange. Although the two peptides demonstrate a continuation of the same primary 
sequence, the magnitude of increased deuteration rates is highest for the peptide 
corresponding to residues 26-32, ~ -0.9 Da, suggesting that long range structural 
changes, positioned away from the zinc binding site, are greater than those correlating 
to zinc binding interactions alone. This further promotes an idea of the orientation of 
the hydrophobic α-helix region outwards or disruption of the hydrogen bonding 
between helix A and D.  
By increasing the concentration of zinc to obtain a ratio rhGH:Zn equal to 1:10, 
thirteen peptides exceeded the threshold limits defined for rhGH. The structural 
differences identified for the rhGH 1:2 were confirmed and further differences were 
identified (Figure 42 b, Figure 43 c and Table 9). Particularly the structural changes 
observed in region II for the rhGH:Zn 1:2 sample were confirmed and two additional 
peptides at residues 14-25 and 16-25 also exhibit structural changes.  
In addition, a decrease in deuterium uptake in regions I and V was observed at earlier 
incubation periods (0.5 and 5 min) suggesting further long range structural changes. 
For region I, considering overlapping peptides and loss of two N-terminal amides 
during back exchange [125], data suggest that the structural changes were located in 
residues 5-9 and for region V, a larger magnitude of change is observed for peptide 
178-191. Considering the magnitude of decreased deuterium rates for the three 
overlapping peptides 178-191 ( ~ 0.88 Da) , 181-191( ~ 0.70 Da)  and 182-191( ~ 0.50 
Da), this would tend to suggest the structural changes to be occurring across both the 
N- and C-terminal regions of the 180-191 sequence.  
A possible cause for these decreased HDX rates at the N and C-terminal could be an 
outward movement of helix A upon zinc binding orientating the two termini closer 
together and therefore decreasing their solvent accessibility. Region III corresponding 
to residues 98-106, located in the loop region between helix B and helix C, also 
exhibits a very small, ~ 0.2 Da, increase in deuteration uptake at the early incubation 
points. Finally, region IV shows increased deuteration rates in the presence of zinc. 
Two overlapping peptides in this region, 115-124 and 117-124, show an increase in 
uptake from residue 115 to 117, localising the structural changes observed to residues 
119-124 of helix C. All regions identified as showing structural changes due to the 
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presence of zinc appeared to exhibit EX2 kinetics in both the absence and presence of 
zinc suggesting stable folded conformations.  
 
Figure 43. Structural changes of rhGH induced by zinc. a) XRC of rhGH in the 
presence of zinc (adapted from PDB 1BP3 [208]). Regions of significant 
structural change due to the presence of zinc as identified by HDX-MS 
differential analysis are highlighted in terms of deuterium uptake in presence of 
zinc, as reduced uptake (blue) and increased uptake (red). Labelled regions 
include the following residues: region I [1-9], II [14-32], III [98-106], IV [114-
124], V [178-191]. b) Zinc binding residues His18, His21 and Glu174 are 
illustrated by stick representations. c) Uptake plots of deuterium uptake (Da) 
against incubation time (min) are displayed for five peptides located in those 
regions of structural change. 
The benefits of defining individual thresholds for each peptide were demonstrated by 
comparing the results here discussed with the results obtained by using the approach 
described by Houde et al. [112] and the DynamX software approach utilised by many 
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users for data analysis, respectively. Applying the approach described by Houde et al. 
[112] a single unique threshold for all peptides was calculated as the standard 
deviation of the mean differential sum value across all peptides, corresponding to ± 
0.98 Da. When this threshold was applied no structural changes were observed for the 
rhGH:Zn 1:2 comparison and only one difference was observed in the rhGH:Zn 1:10 
comparison (peptide 26-32). Hence this approach would lead to an over estimation of 
measurement variability for many peptides and therefore reduce the sensitivity of the 
differential approach to detect small but statistically significant structural changes.   
 
Figure 44. Plot of mean differential HDX-MS measurements (dark grey bars) from a 
rhGH vial to vial study. Individual peptide threshold limits are plotted as 
calculated using a 3σ criterion approach (red line) and in-house approach (dotted 
line) to differential vial-to-vial measurements 
A generic approach to establishing differential data analysis measurement threshold 
limits can be taken using the software DynamX based on a “3σ”, where σ represents 
SD of measurements. The thresholds limits calculated by applying the 3σ approach 
and the threshold approach developed here, are represented in Figure 44 . Those 
regions identified as showing a structural change demonstrated high similarity when 
comparing the 3σ approach with the statistical method here developed, with general 
trends of measurement variability consistent across the two methodologies. However 
for a number of peptides, the 3σ criterion underestimated the measurement variability, 
probably due to the fact that through the DynamX approach, it is only possible to 
compare data generated from an intra-day comparison. Furthermore the proprietry 
calculations performed by DynamX limits its use in combining data from different 
analyses. 
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2.3.2 Size exclusion chromatography 
The presence of Zn2+ has been indicated previously as inducing dimerisation of hGH 
[213]. To rule out any overinterpretation of HDX-MS measurements as a result of 
such aggregation, SEC-UV experiments were carried out to monitor for the potential 
formation of rhGH aggregates in the presence of increasing concentrations of zinc ( 
1:2, 1:10 and 1:20; rhGH:Zn). A bovine serum albumin (BSA) sample was also run 
in parallel, to act as a standard for differentiating between different sized species, 
using BSA monomers and dimers observed.  
Three distinct peaks are observed in all the SEC-UV chromatograms for rhGH and 
1:2 and 1:10 samples (overlaid in Figure 45), and were attributed to a rhGH dimer( ~ 
7.9 min), a rhGH monomer ( ~ 8.5min) and excipient present in the samples ( 10.2 
min).  The small dimeric peak eluting prior to the main monomeric form of rhGH was 
observed in all samples, and quantified as corresponding to ~ 0.5% of total rhGH, 
regardless of the absence and presence of zinc (Figure 46). The consistent percentage 
of dimers in the samples, even at the elevated 1:20 ratio, indicates that increasing 
amount of zinc under these operative conditions doesn’t induce formation of 
aggregates that may bias the HDX-MS results. 
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Figure 45. a) Overlay of SEC-UV chromatograms of rhGH containing samples. rhGH 
control, rhGH:Zn 1:2 and rhGH:Zn 1:10 (blue, red and green traces respectively) 
rhGH dimer, rhGH monomer and sample excipient peaks were observed across 
all samples, with retention times of 7.9, 8.5 and 10.2 min respectively. b) Zoom 
of dimeric peak.  
 
 
Figure 46. Relative percentage of dimer present in rhGH samples as calculated by 
SEC-UV. 
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2.3.3 Native IMS-MS  
Unlike HDX-MS measurements which are representative of solution average of 
conformations present in a sample, one of the key attractions of native-IMS-MS is the 
technique’s ability to measure multiple isobaric copopulated protein populations that 
differ in physical size or shape. Native IMS-MS measurements were applied to the 
rhGH model system, providing a complementary dataset to HDX-MS measurements 
and assessing the applicability of the technique to detect the small structural changes 
observed for the candidate model system. 
2.3.3.1 Sample buffer optimisation  
Several experimental conditions and instrumental parameters were optimised for 
IMS-MS measurements of rhGH. Two differing buffer conditions, 20 mM and 200 
mM ammonium acetate, were assessed, representing relatively low and high levels of 
buffering concentrations. Native IMS-MS spectra obtained under these conditions are 
presented in Figure 47.  
Both spectra exhibit similar CSDs at both high and low buffering conditions, 
suggesting stable and “native-like” conformations are retained [4, 76, 82, 83]. 
Increased peak broadening is observed under higher buffering conditions, observed 
particularly at the +8 base peak, with the 20 mM ammonium acetate buffer giving a 
more optimal and cleaner spectrum with less peak broadening. Higher concentrations 
of buffer ions offer greater protection to the protein during ionisation, yet cause beak 
broadening due to protein binding and ultimately decreased signal to noise of the 
spectra. It is therefore advantageous to optimise these buffering conditions to ensure 
that native like structures are maintained whilst simultaneously maximising signal to 
noise and spectra quality.  
Additionally, the lower molarity buffering conditions of 20 mM ammonium acetate 
are more analogous to the 10 mM KPBS used in HDX-MS experiments making 
drawing parallel conclusions across platforms more representative. For all further 
IMS-MS experiments, samples were introduced in 20 mM ammonium acetate buffer.  
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Figure 47. Native IMS-MS spectra of rhGH in a) 200 mM and b) 20 mM ammonium 
acetate. 
2.3.3.2 Native IMS-MS measurements and rhGH structure prediction 
The native IMS-MS spectra of the rhGH control (Figure 48) revealed multiple (~3) 
Gaussian CSDs, indicating the presence of multiple conformations of rhGH. The most 
abundant distribution is centred around the +8 charge state, with another centred 
around the +11 charge state, suggesting the presence of a compact and extended 
monomeric conformation for each respectively. A final, much smaller dimer 
distribution is also observed centred around the higher ~3400 m/z range.  
Analysis of the mobilogram for the rhGH control (Figure 49), confirms the presence 
of a small dimer conformation (+12 to +14, Figure 49 i) plus compact monomer (+7 
to +11, Figure 49 ii) and extended monomer (+10 to +13, Figure 49 iii) conformations 
at lower and higher charge states respectively. Additionally, a final very small 
distribution of a further extended conformation (> +14) was observed in the tD 
measurements that was not observed in native IMS-MS spectra, however the signal-
to-noise of the mobility measurements meant that data quality is poor and extracting 
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tDs unreliable. Overall the relatively narrow CSDs observed are consistent with a 
globular-like folded protein conformations [77].  
These observations are also in accordance with previous published IMS-MS 
measurements of rhGH [206] and solution based studies [225] which identify the 
existence of  > 1 folded monomeric populations of rhGH, that differ in tertiary 
structure whilst maintaining a stable secondary structure [226]. The observation of an 
extended monomeric conformation for charge states in excess of +11, is in accordance 
with the calculation (Equation 31) that the maximum charge that can be theoretically 
carried by a protein of rhGH’s size, ~ 22 kDa, as equal to 12 [77].   
 
Figure 48. Native IMS-MS spectra of rhGH control. Multiple Gaussian CSDs suggest 
the presence of multiple conformations are indicated by the red dotted lines. 
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Figure 49. Mobilogram of rhGH control IMS-MS measurements. Drift time 
measurements reveal multiple conformations and are highlighted: i) dimer, ii) 
compact monomer, and iii) extended monomer species.   
2.3.3.3 IMS-MS reproducibility  
To assess the measurement variability of the optimised IMS-MS method, triplicate 
(within-day) repeat measurements of the rhGH control made across a series of three 
days (intra-day, IMP) were considered. For each given day a fresh aliquot of rhGH 
was removed, desalted and buffer exchanged into the optimised buffer.  
Observed tD measurements were assessed in terms of within-day repeatability and 
IMP, by considering the RSDs of average measurements. These values are expressed 
in Table 10 . Very high reproducibility was observed for both within-day repeatability 
(0.1-1.1% RSD) and IMP (0.0-1.8% RSD) measurements demonstrating both the 
IMS-MS measurements to be reproducible but also the conformations present in the 
rhGH sample to be consistent across the time span of the experiments and 
preparations. 
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Table 10. Measurement variability of IMS-MS measurements of rhGH control. 
Average observed tD and RSDs for compact monomer, extended monomer and 
dimeric species are expressed for triplicate, n=3,  intra-day (Rep) and inter-day 
(IMP) measurements.  
   
Rep IMP 
 Charge state (z) m/z tD RSD tD RSD 
compact monomer 
 
7 3160.7 14.0 0.3% 14.0 0.0% 
8 2765.6 11.2 0.2% 11.2 0.3% 
9 2458.3 9.4 0.2% 9.4 0.3% 
10 2212.5 8.6 0.4% 8.7 1.2% 
11 2011.3 8.5 0.3% 8.4 0.5% 
extended monomer 
 
10 2212.5 9.9 1.1% 10.2 1.8% 
11 2011.3 9.5 0.4% 9.7 0.3% 
12 1843.7 8.6 0.5% 8.6 0.0% 
13 1701.9 8.2 0.1% 8.2 0.2% 
Dimer 
12 3687.5 15.0 0.1% 15.0 0.3% 
13 3403.8 13.1 0.4% 13.1 0.1% 
14 3160.7 12.0 0.2% 11.9 0.4% 
 
2.3.3.4 TWCCSN2 measurements 
Conversion of tD to 
TWCCSN2 measurements is common practice, facilitating the 
comparison of ions gas phase structures within theoretical structures or structures 
measured by XRC and also allowing for direct lab-to-lab comparison of IMS-MS 
measurements.  
TWCCSN2 values for average IMP IMS-MS measurements described in Table 11 were  
calculated post-acquisition as described in 2.2.6.4. Taking an average of CCS across 
the charge states observed for a given species, TWCCSN2 measurements of rhGH are 
as follows ; rhGH compacted monomer ( 2519 ± 303 Å2), rhGH extended monomer 
(3216  ± 271 Å2) and rhGH dimer ( 3957± 179 Å2).  
Uncertainty was also calculated for each measurement including a contribution from 
the calibration line established.  These uncertainty values appear relatively high for 
these types of measurements [206] and given the very high reproducibility of the 
extracted tD measurements the main source of uncertainty of the TWIMS-MS 
measurements performed here is the contribution from the calibration.   
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For TWCCSN2 calculation, calibrants of known 
TWCCSN2 values are selected to bracket 
the molecular size of the compound of interest and measurements performed under 
the native conditions of the compound. The availability of such calibration values 
however is limited [52, 227–229]. A potential cause for the poor calibration fit could 
be the source of the calibrant TWCCSN2 values. The 
TWCCSN2 calibrant reference 
values used  here, as reported by Bush et al. [52], where obtained using a modified 
earlier generation Synapt G1 TWIMS instrument of the, in which the TWIMS drift 
tube was replaced with a linear drift tube. Although the Synapt G2Si instrument used 
here is of similar instrument lineage, additional components such as the step-wave ion 
guide [30], mean the gas phase ions will experience non-identical voltages to those 
described by Bush et al. [52], which were acquired on an earlier generation instrument. 
This is corroborated by the fact that the TWCCSN2 measurements performed here for 
rhGH are consistently ~20% larger than previously published values  which were 
performed using a Synapt G1 instrument [206]. This raises questions about the 
appropriate use of these calibration reference values for non-identical TWIMS 
instrumentation, which is beyond the scope of this thesis. In addition, recently, it has 
also been reported that space charge effects due to concentration deviations, can affect 
peak broadening and measured ATD peak tops, ultimately affecting the quality of 
CCS calibration in TWIMS [92, 230].  
This is in accordance with the observation by Ferguson 2016 et al. [49], that CCS is a 
less sensitive metric for comparison of TWIMS measurements than tD alone, similarly 
highlighting the need for better calibrants, or for HOS measurements to be performed 
relatively purely on tD based metrics. Considering this, comparison of observed tD was 
deemed more appropriate for HOS comparison across differing protein samples 
(rhGH and rhGH:Zn) in this work, aiding increased sensitivity towards smaller 
structural changes.  
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Table 11. TWCCSN2 values calculated for compact monomer, extended monomer and 
dimeric species  of rhGH. The uncertainty of each measurement (U) is also given 
and expressed as a relative %.  
 
 
 
 
 
 
 
 
 
 
2.3.3.5 IMS-MS measurements to identify HOS changes induced by zinc 
Though structural changes were observed due to the presence of zinc using HDX-MS 
measurements, rhGH binding to zinc was only inferred. Comparison of spectra 
obtained from native IMS-MS measurements performed of rhGH control, rhGH:Zn 
1:2 and 1:10 (Figure 50) confirm zinc binding to rhGH using the preparative 
conditions described.  
Although a 1:1 binding stoichiometry (rhGH:Zn) was observed for the rhGH:Zn 1:2 
sample, a significant portion of rhGH appears to be unbound (Figure 50 b ii). In 
contrast, both stoichiometric ratios of 1:1 and 1:2 are observed for the rhGH:Zn 1:10 
sample, with a reduced presence of unbound rhGH, and the 1:1 species the most 
abundant, suggesting a greater proportion of bound rhGH-Zn. These findings are 
consistent with the reported Kd of ~ 1uM for the 1:1 rhGH:Zn complex and of positive 
co-operative binding of a secondary zinc molecule, of which no Kd is reported.   
In order to rule out non-specific binding of Zn2+ to rhGH as a result of the ionisation 
process [231], a rhGH sample containing ten molar equivalents of Mg2+ (rhGH:Mg 
1:10), an analogous small covalent bi-anion, was also analysed by native IMS-MS. 
Though some non-specific binding of Mg2+ was evident spectra revealed a greatly 
   rhGH 
 Charge 
state 
m/z 
TWCCSN2  
(Å2) 
± U (rel%) 
compact 
monomer 
7 3160.7 2170 343 (16%) 
8 2765.6 2321 267 (12%) 
9 2458.3 2481 162 (7%) 
10 2212.5 2682 221 (8%) 
11 2011.3 2940 239 (8%) 
extended 
monomer 
10 2212.5 2794 188 (7%) 
11 2011.3 3057 229 (8%) 
12 1843.7 3217 249 (8%) 
13 1701.9 3436 320 (9%) 
Dimer 
12 3687.5 3783.2 585 (16%) 
13 3403.8 3949.6 535 (14%) 
14 3160.7 4140.5 495 (12%) 
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reduced binding affinity of the Mg2+ compared to Zn2+ (Figure 50 b iii and iv) 
confirming the specific binding of zinc. 
Comparison of tD measurements showed no significant differences between rhGH and 
rhGH-Zn bound samples (both 1:2 and 1:10). This would suggest that under the 
conditions used here, there is no overall large differences in globular structure as a 
result of the binding of zinc and that the tertiary structure of the protein is largely 
consistent. Figure 51 illustrates the overlaid extracted mobilograms for each rhGH 
and rhGH-Zn charge state, these in turn are separated into relative conformer groups 
of dimer (+12 to +14), compact monomer (+7 to +10) and extended  monomer (+11 
to +13).   
Considering the extracted mobilograms for each individual charge state, it is possible 
to observe multiple conformations for some charge states are evident and separated 
by IMS (Figure 51, D11+, M7+, M8+, M10+ and M11+). Comparison of the relative 
abundancies of these conformations reveal a predisposition towards the more folded 
monomeric conformations (Figure 51, M8+ and M10+ and M11+) and dimeric 
species (Figure 51, D11+, M7+) for Zn2+ containing samples relative to the rhGH 
control. This data suggests a shift towards more compact and dimeric species due to 
the presence of Zn2+, which could arise due to a potential stabilisation in HOS by Zn2+. 
This idea is supported by the correlation of the amount of Zn2+ present in the samples 
and the relative shift towards more compacted species, rhGH:Zn 1:10 > rhGH:Zn 1:2 
> rhGH control, illustrated by the overlaid traces in Figure 51. Though no significant 
differences in tD were observed across the samples this potential stabilisation in HOS 
was explored further using CIU-IMS-MS experiments.  
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Figure 50. a) Native MS spectra of rhGH samples. i) rhGH, ii) rhGH:Zn 1:2, iii) 
rhGH:Zn 1:10, iv) rhGH Mg 1:10, b) zoom of +8 base peaks of rhGH and rhGH-
bound species. 
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Figure 51. Overlay of extracted mobilograms associated with each species identified 
in IMS-MS measurements of rhGH control (blue), rhGH:Zn 1:2 (black) and 
rhGH 1:10 (red) samples. Each mobilogram is annotated as either dimer (D) or 
monomer (M) and the charge state indicated. Grey panels highlight the arrival 
time distribution of the species/charge state indicated.  
2.3.3.6 CIU-IMS-MS comparisons  
Previous studies [49, 95, 232] have illustrated that CIU-IMS-MS experiments are 
more sensitive than CCS measurements alone for comparing and differentiating 
between proteins with small differences in HOS. In light of this, CIU-IMS-MS 
experiments were perfromed on rhGH and rhGH:Zn samples. To avoid any bias 
associated with charge-state selection, the +8 charge state was selected for all samples 
( ~ 2765.5 m/z for rhGH and 2773.6 m/z for the rhGH-zinc bound species for zinc 
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containing samples) and the trap voltage increased at 2V increments  across the 6 – 
38V range.   
Similar unfolding pathways were observed across all three samples during the CIU 
experiment, in which at low collision voltages ~ 6 – 18 V, a single Gaussian ATD was 
observed, indicating a native folded state (T1‡, Figure 52 a-c) with a tD ~ 11.3 ms.  As 
voltages are increased a CIU event occurs, indicated by an additional species with an 
increased tD, T2‡ ~ ~ 13.6 ms.  The CIU event appears to proceed via a transitional 
voltage range where the folded and elongated conformer co-exist simultaneously. 
Though the unfolding profiles across the samples are similar,  the appearance of the 
elongated  ~ 13.6ms species (illustrated as T2‡ in Figure 52) occurs at a higher voltage 
for both rhGH-Zn bound species (22V) compared to the rhGH control (20 V) as 
represented in mobilograms Figure 52 d and e.  Comparison of the relative proportion 
of T1‡/ T2‡ states at the transition point of 20 V also suggests a general trend of 
increased proportion of T2‡/ T1‡ observed across rhGH:Zn 1:10 > rhGH:Zn 1:2  > 
rhGH. These data indicate that under these conditions, not only does zinc-binding 
stabilise the globular structure of rhGH, representative of a difference in HOS between 
rhGH and rhGH-Zn, but that the amount of stabilisation is proportional to the amount 
of zinc in the sample. These data are in accordance with HDX-MS measurements 
which indicate higher structural changes at increased zinc concentrations. These data 
suggest that CIU IMS-MS experiments are also sensitive towards small structural 
changes, which is particularly attractive due to the high throughput nature of the 
experiments relative to HDX-MS measurements.  
Differential HDX-MS analysis indicated two regions of increased HDX in rhGH:Zn 
1:2 samples relative to rhGH. If these increased rates were solely due to the unfolding 
of helix A due to zinc binding, and hence decreased hydrogen bonding, one might 
expect a relative decrease in globular stability or CCS, yet, these CIU-IMS-MS data 
suggest the stabilisation of the structure due to zinc. This would therefore be in 
accordance not with the unfolding of helix A, but in fact the disruption of hydrogen 
bonding across either helix A and D or within the central cavity of the protein due to 
the presence of zinc. It is possible that the zinc ligand stabilises the structure overall 
through side chain interactions which is not reflected by the amide hydrogens 
monitored during the HDX-MS experiments described here.   
Similarly for rhGH:Zn 1:10 differential measurements a mixture of both destabilising 
and stabilising changes in secondary structure  were observed, though this time at a 
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much greater magnitude with six regions showing structural changes, illustrating the 
increased localised structural insights that can be achieved using HDX-MS relative to 
IMS-MS.  The observed rhGH:Zn binding stoichometries of 1:1 and 1:2 revealed by 
native IMS-MS measurements of rhGH:Zn 1:2 and 1:10 samples respectively, support 
that ligand binding is indeed not saturated at the lower zinc concentration and the 
increased structural changes observed at higher zinc concentrations by both HDX-MS 
and IMS-MS. These data demonstrate the value of using multiple analytical 
techniques which span multiple HOS levels in order to maximise structural insights.  
As aforementioned there is greater potential for use of IMS-MS measurements within 
a high throughput environment, and though lower resolution than HDX-MS 
measurements, these type of cross-platform validation suggest that this analytical 
technique is indeed applicable in a QC type environment such as those required using 
drug manufacture, in which HDX-MS may not be appropriate.  
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Figure 52. CIU-IMS-MS plots of a) rhGH control b) rhGH:Zn 1:2 and c) rhGH:Zn 
1:10. Quadrupole selection of +8 charge state of free rhGH and rhGH-Zn bound 
states was performed and trap cell activation induced using a voltage range of 6 
- 36 V. Data are displayed in three dimensions as arrival time (ms), trap cell 
collision voltage versus normalised intensity. Arrival time distributions (ATD) 
are indicated for two folded states compact (T1‡) and unfolded (T2‡) state. A 
decreased stability towards unfolding can be observed for rhGH (blue) relative 
to rhGH:Zn 1:2 (black) and rhGH:Zn 1:10 (red) when looking at the overlayed 
mobilograms for CIU-IMS-MS measurements at a) 20V and b) 22V, indicated 
by an increased relative amount of T2‡ state with an increased ATD. CIU-IMS-
MS plots (a-c) were generated with use of PULSAR processing software [98].  
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2.4 Conclusions  
With use of a commercially available RM (rhGH), a protocol to induce structural 
perturbations based on zinc ligands has here been developed. This RM has been used 
to systematically optimise a HDX-MS experimental methodology. A new statistical 
data analysis approach was developed to determine thresholds that enable 
discrimination between measurement variability and HOS changes and are specific 
for each peptide. The statistical approach proposed here is a generic methodology 
applicable to any protein of interest, that can be applied to improve sensitivity of 
measurements and increase confidence when defining structural changes detected by 
HDX-MS measurements. This approach was then applied to the rhGH and zinc model 
system, to evaluate sensitivity to structural changes of HDX-MS methods developed. 
The data here generated also provide detailed indications on what can be expected 
from an optimised HDX-MS system in term of back exchange, precision and accuracy 
and a comprehensive investigation of the major components affecting measurement 
uncertainty carried out. 
Similarly the RM system was used to assess the applicability, reproducibility, 
robustness and sensitivity of IMS-MS measurements towards structural changes. 
Though structural changes were identified by IMS-MS measurements due to the 
presence of zinc, the sensitivity was lower than that of HDX-MS. HDX-MS 
measurements also provided much higher localised resolution towards structural 
changes. This model system is widely applicable to other analytical methodologies, 
which will allow the assessment of sensitivity and subsequent across platform 
comparisons. Outside the scope of this thesis, work is currently underway to validate 
this approach through the conduction of a cross-platform inter laboratory comparison 
based on defining structural differences of the rhGH model system [233].  
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Chapter 3 
Application of higher order structure characterisation 
methodologies to a reference protocol  for generation of NISTmAb 
Fc-glycan variants 
3.1 Introduction 
3.1.1 Monoclonal antibodies as biotherapeutics 
The development of monoclonal antibodies (mAbs), was first introduced in 1975 by 
Kӧhler and Milstein [234], when they described using a clone generated from a single 
parent cell to produce a single antibody type, a feat that would later result in a share 
of the 1984 Nobel Prize for medicine and physiology.  
Since the introduction of the first FDA approved mAb based drug, OKT3 
(Muromonab-CD3), on the market in 1986, more than 60 therapeutic mAbs had been 
approved by 2017 with many more in the development pathway. Their therapeutic use 
supports treatment in areas such as oncology, inflammatory and autoimmune diseases, 
infectious diseases, and cardiovascular indications. The high specificity, low toxicity, 
long serum half-life and relative ease of manufacture of mAbs have since led them to 
become the major leading class of the therapeutic market [59] and such their 
characterisation is of great interest to industry and regulators. 
3.1.2 Immunoglobulin (Ig) structure 
Due to their prolificacy within the circulatory system, immunoglobulins (Igs) have 
become the dominant protein platform for the development of mAbs. These ~ 150 
kDa glycoproteins facilitate an immune response by the recognition of and binding to 
a specific foreign antigen, resulting in the ultimate destruction of the antigen. Igs are 
“Y” shaped hetero-proteins made up of two identical units of a heavy chain (~ 50 kDa 
each) and two units of light chain (~ 25 kDa each) (Figure 53).  
Across the Ig protein-class, slight variances in the heavy chain sequences exists, 
creating several different subclasses (Ig- A, D, E, G and M), these subclasses are 
diversified further still with two additional light chain subclasses (κ and λ) [235]. IgG 
type mAbs are by far the most abundant, accounting for some 75% of all circulatory 
Igs, and four further subclasses exist for IgG type mAbs, IgG1-4, in which subclass 
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varies based on the number of disulphide bonds present.  The vast array of Ig based 
structures available are what facilitate the specificity of the antigen immune response, 
and of all these various isoforms, IgG1 are the most predominant species.  
The structure of Igs consist of twelve repeating units, or domains, each made up of 7-
9 anti-parallel β-sheet structures which are further stabilised by intra-chain disulphide 
bonds [236, 237]. Four and two of these domains link up to form both heavy and light 
chains respectively, and the entire structure is then unified by additional inter-chain 
disulphide bonds at the centre of the complex termed the hinge region. Figure 53  
displays the conventional structure of an IgG based mAb.  
 
 
Figure 53 a) Structure of IgG1 mAb. Domains are represented in blue (heavy chain) 
and pink (light chain), black lines represent inter-chain disulphide bonds, b) 
crystal structure of constant light chain domain (adapted from PDB: 5k8a [238]) 
The top half of the molecule consists of two identical antigen binding fragments (Fab) 
each containing one variable (VH/VL) and one constant (CH1/CL) domain from both 
heavy and light chains. The bottom half of the molecule, the crystallisable fragment 
(Fc), contains two constant domains (CH2 and CH3) from each heavy chain present.  
Recognition of the antigen occurs via interaction with the complementary-
determining regions (CDR), which are loop-like structures, found in the variable 
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domains of the Fab structure. Sequence and inherent structural variation of these 
CDRs are what yield the high specificity of mAbs.  
3.1.3 Issues of heterogeneity  
Further to sequence variation and subclasses mAb heterogeneity also arises in the 
form of PTMs and aggregation, introduced during the complex synthetic pathways 
used in their production. These PTMs can include glycosylation, oxidation, 
deamidation, isomerisation, N-terminal pryo-glutamine cyclization and incomplete 
disulphide bond formation, to mention but a few. Though their presence can be 
advantageous, by offering the opportunity to tune the properties of a candidate drug. 
when they arise in an uncontrolled manner during manufacturing processes, they can 
lead to differences in stability, efficacy and potency of a therapeutic mAb. For these 
reasons, there must be a tight control of product quality and batch-to-batch 
consistency, and these heterogeneities deemed CQAs which must be monitored for 
regulatory requirements [60–62].  
Characterisation of this array of heterogeneities and understanding their impact 
represent a real analytical challenge for the biopharmaceutical industry, both during 
the high resolution characterisation performed in developmental stages and high 
throughput monitoring during QC. As aforementioned in the introduction (section 
1.2.1.1), the availability of RM, standards and protocols to ensure the effectiveness of 
the analytical methods developed and help support regulatory documentation for a 
therapeutic drug are needed for mAbs.  
To address this, the first mAb based reference material, RM 8761 (NISTmAb RM), 
was commercialised in 2016 by the National Institute for Standards and Technology 
(NIST) with the intended purpose of use for system suitability tests and establishing 
analytical method performance, variability, comparability and ultimately the 
qualification of new methodologies for determining physicochemical and biophysical 
attributes of mAbs.  To support the use of this RM, reference analytical datasets have 
been published through an ACS book series as a collaborative effort across 
governmental, academic and bio-industrial settings [239–241].  
3.1.4 NISTmAb reference material 
The NISTmAb RM is a recombinant humanized IgG1κ, with the purpose of 
simulating a ‘drug-like’ mAb, which, as a part of RM validation, has been 
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characterised in detail by established analytical platforms [239–241]. These data are 
inclusive of the determination of NISTmAb primary structure [242], sequence 
variance analysis [243], structural elucidation of PTMs [244] and N-glycan structure 
[245], separation science analysis of CQAs [246], biophysical characterisation of 
HOS [247], a developability assessment [248], particle/aggregate analysis [249–251] 
plus host cell protein and process-related impurity analysis [252]. In addition, the 
NISTmAb RM, has been used as a case study to highlight the potential use of state-
of-the-art and emerging technologies for mAb characterisation including  assessment 
of multiple bioinformatics workflows [241, 253, 254]. HOS structural information 
datasets have been produced using technologies including NMR [255, 256], XRC 
[238], HDX-MS [256], oxidative footprinting [257], chemical XL [257], IMS-MS and 
high resolution Orbitrap mass spectrometry [258]. Though these provide reference 
datasets, the published manuscripts do not offer methodologies for assessing the 
sensitivity of these technologies for use in comparability studies of mAbs, such as 
detecting HOS changes occurring as result of storage induced degradation and 
changes in manufacturing processes.  
 
 
Figure 54. Schematic representation of the most abundant N-glycan structures found 
in the NISTmAb RM. Nomenclature corresponds to the following oligiosaccharide 
residues Gal, galactose; GlcNAc, N-acetylglucosamine, Man, mannose; Fuc, fucose. 
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3.1.5 Glycosylation of IgG1 
N-linked glycosylation is present in many native and recombinant mAb 
biotherapeutics.  The complex biosynthetic pathways involved mean producing a 
single glycoform in vivo is almost impossible, hence any glycosylation present is 
almost always heterogeneous, further adding to the mAbs structural heterogeneity. 
Variation in N-glycosylation is significant as it has been demonstrated to influence 
both antibody-dependent cellular cytotoxicity and complement-dependent 
cytotoxicity (CDC) [259],  meaning this type of heterogeneity can ultimately affect 
therapeutic dosage of mAbs in the clinic. Variance in mAb glycosylation has also 
been demonstrated to have significant impact on a wide range of critical attributes 
including product stability [260], immunogenicity [261, 262], serum clearance [263], 
pharmacokinetics [264] and potential anti-inflammatory response [265, 266] of 
biotherapeutics. For these reasons, glycosylation is defined as a CQA of mAb based 
biotherapeutics by regulators. Furthermore understanding the impacts and 
mechanisms of glycan variation on the therapeutic use of mAbs is of great interest to 
the biopharmaceutical industry, for exploiting potency and hence minimising 
manufacturing costs of a drug.  
For IgG type mAbs, glycosylation is often present as N-linked glycosylation at the 
Asn300 residue of the Fc region. Typically this is in the form of a biantennary 
complex type oligosaccharide, with a core fucose (Fuc), bisecting N-
acetylglucosamine (GlcNAc) structure and terminal β-1,4-galactose (Gal) residues. 
The batch-to-batch heterogeneity of these terminal β-1,4-galactose linkages is 
considered to be one of the most common glycan modifications in humanized IgGs, 
with variation the number of terminal (0, 1 or 2) Gal residues, termed G0F, G1F and 
G2F glycan isoforms (Figure 54), present on both of the two heavy chains. Slight 
variations in pathology, culturing and species of the chosen cell expression lines can 
generate changes in the glycan structure such as the number of terminal Gal residues. 
These types of variations have been shown to have implications of a biotherapeutics 
immunogenicity, effector function modulation [267] and CDC [259]. Structural 
analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and 
structural integrity [268, 269]. Similarly complete absence of glycan structure alone 
is known to affect immunogenicity, thought to be as a result of enhancement and 
stabilisation of the CH2 domain necessary for FcγR binding [269].  
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3.1.6 Alternative proteases for on-line digestion of mAbs 
The resistance to proteolysis often observed for mAbs [270], particularly by the light 
chain [271], is known to make obtaining HDX-MS peptide maps of sufficient 
resolution to give high resolution HOS insights, challenging.  For this reason it was 
anticipated that the use of alternative acidic proteases to pepsin may need to be 
considered when optimising HDX-MS peptide mapping of NISTmAb RM to 
circumvent the known specificities of pepsin [142, 145, 272, 273] or to maximise the 
potential spatial resolution achieved when using a single protease.  Examples of such 
alternative proteases used in HDX-MS workflows include:  aspergillopepsin (protease 
type XIII, EC 3.4.23.18) [141, 273, 274], rhizopuspepsin (protease type XVIII, EC 
3.4.23.6) [141, 272, 273], and plasmepsin (EC 3.4.23.39) [275].  Contrasting data 
from studies that compare the performance of different proteases [141, 142, 272, 276], 
tend to suggests a lack of a one-shoe-fits-all approach for the selection of an ideal 
protease to digest a protein of interest. Yet several studies have suggested the 
attractiveness of the short peptides produced by aspergillopepsin for yielding higher 
resolution of HDX-MS measurements[141, 276].  
Nirudodhi et al. [277] demonstrated the effectiveness of using a commercially 
available co-immobilized enzymatic column, containing both pepsin and 
aspergillopepsin, for the digestion of IgG2s, compared to pepsin immobilised alone. 
It was thought that the close proximity of the proteases and complementary cleavage 
preferentiality of the enzymes facilitates more superior proteolysis, with high 
digestion coverage and redundancy (≥95% and ≥ 6.5) also observed for IgG1 based 
mAb using the dual protease column. Similarly the benefits of multiplexing proteases 
for increased resolution of HDX-MS measurements have been demonstrated in other 
studies [272, 273]. 
3.1.7 Model system: NISTmAb RM and Fc-glycan variants 
The N-linked glycan structure of the NIST mAb RM has been characterised 
extensively [245] and has been indicated as having an ensemble population of G0F, 
G1F, G2F isoforms, as illustrated in Figure 54. Recently a study by Arbogast et al. 
[255], demonstrated, using the application of multivariate analysis of 2D NMR  data, 
that enzymatically induced changes in the glycosylation pattern of the NIST mAb RM 
led to changes in HOS. 
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The work described the use of simple enzymatic bio-chemistry to generate Fc-glycan 
variants of NISTmAb RM,  in the form of deglycosylation (complete glycan removal) 
and degalactosylation (removal of terminal Gal residues), simulating such 
heterogeneities that may exist as a result of changes in manufacturing processes or 
cell culture lines. These model systems were then used to validate a statistical 
approach for screening 2D NMR fingerprinting data for significant changes in HOS, 
a potential methodology for industrial comparability studies. 
Although structural changes were identified, the high spectral complexity and absence 
of a 15N labelled protein resulted in unresolved amino acidic chemical shifts and 
hence the data gave no resolution as to where the HOS  changes occur. Using the 
enzymatic methodology described, a model system consisting of the 3 Fc-glycan 
variants of NISTmAb, (control, deglycosylated and degalactosylated)  has here been 
described and used to test, validate, and build on the analytical methodologies (HDX-
MS and IMS-MS) developed in Chapter 2, using a more complex and potentially a 
more biologically relevant molecule to the biopharmaceutical industry as a whole. 
Additionally these data are used to provide localised and globular resolution to 
changes in HOS as a result of Fc-glycan variation previously reported by NMR [255]. 
These data will ultimately provide a reference data set to support use of NISTmAb 
RM model system for use in the validation and assessment of analytical 
methodologies ability  to detect changes in HOS of biotherapeutic mAbs [224].  
3.2 Methods 
3.2.1 Materials 
All chemicals and standards were purchased as stated in section 2 unless otherwise 
stated.  The NISTmAb RM 8761, humanized IgG1κ mAb, was purchased from NIST 
[Gaithersburg, Maryland, USA] and ammonium hexafluorophosphate (AHFP) was 
purchased from ACROS Organics [Fisher scientific, Loughborough, UK].  
3.2.2 Protein sample preparation 
3.2.2.1 Generation of Fc-glycan variants 
A stock solution of 67 µM NISTmAb RM 8761 (10 mg/mL) IgG1ĸ mAb in 12.5 
mmol/L L-histidine, 12.5 mmol/L L-histidine HCl (pH 6.0), was received and split 
into 50 µL aliquots upon arrival before storage at -80°C for single use.  
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3.2.2.2 Generation of Fc-glycan variants 
Endo-deglycosylated (DeGly) NISTmAb was prepared by dilution of 50 µl of 
NISTmAb RM stock (67 µM) in 50 µL 100 mM potassium phosphate buffer saline 
(KPBS, pH 7.4) and incubated with 4 µL peptide:N-glycosidase (PNGase F) [10 
ku/mL, Promega, Southampton, UK] at 37 °C for 24 hours.  Exo-degalactosylated 
(ExoGal) NISTmAb was prepared by diluting 50 µl of NISTmAb stock (67 µM) in 
50 µL 1X GlycoBuffer (50 mM sodium acetate, 5 mM CaCl2 pH 5.5) and incubated 
with 4 µL β 1-4 galactosidase [8 ku/mL, both New England Biolabs, Ipswich, 
Massachusetts, USA] a ratio of 1mg:0.07 KU protein:enzyme at 37 °C for 72 hours 
[255].  
PNGase F (~36 kDa) and β 1-4 galactosidase (~ 94 kDa) were removed from their 
respective samples via ultrafiltration using Amicon Ultracel-100 regenerated cellulose 
membranes with 100 kDa molecular weight cut-off [Sigma-Aldrich, Dorset, UK] and 
a 5810R centrifuge [Eppendorf, Stevenage, UK]. The membrane filter was 
preconditioned using 400 µL 10 mM KPBS (pH 6.2) and centrifuged at 4 °C at 13,000 
g for 8 min, as were all ultrafiltration steps. Following filter conditioning, 200 µL 
sample was loaded followed by two sequential washing steps consisting of 200 µL 10 
mM KPBS (pH 6.2). Post centrifugation and sample concentration, samples were 
diluted to 13.2 µM sample concentration using 10 mM KPBS (pH 6.2). 
For both enzyme treatment procedures, a control glycosylated (NISTmAb RM) 
sample was treated in parallel, where in place of the relevant enzyme 4 µL of 
equivalent incubation buffer was added. All prior sample handling, heated incubation 
and ultrafiltration steps between the enzyme containing and control samples were 
otherwise identical. These samples will be referred to as “DeGly NISTmAb control” 
and “ExoGal NISTmAb control” herein.  
3.2.2.3 Sample preparation for IMS-MS measurements 
Prior to native IMS-MS analysis, NISTmAb RM, DeGly NISTmAb and ExoGal 
NISTmAb samples were desalted and buffer exchanged twice into 50 mM ammonium 
acetate as described in section 2.2.1.2, using Bio-spin micro P6 pre-packed size 
exclusion columns. Following desalting samples were diluted further to 5 µM in 50 
mM ammonium acetate.  Samples were left to equilibrate at room temperature for 1h 
before analysis. For inter-day measurements each sample was freshly buffer 
exchanged and analysed on the same day.  
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3.2.3. Intact analysis of Fc-glycan variants 
Glycosylation, deglycosylation and degalactosylation was verified at the intact protein 
level by LC-MS analysis as described below.  
3.2.3.1 Chromatography 
Chromatography was performed using a Vanquish UHPLC system [Thermo Fischer 
Scientific, Bremen, Germany]. 1.5 pmol of sample was injected onto an Aeris 
Widebore XB-C18 column [2.1 x 100 mm, 3.6 µm, Phenomenex, Torrance, 
California, USA] and chromatographic separation achieved using a 350 μL/min flow 
rate, 50 °C column temperature and a linear gradient starting from 95% A/ 5% B to 
2% A/ 98% B over 6 minutes. Mobile phases consisted of aqueous, 0.5% formic acid 
(A) and 0.5% formic, CH3CN (B). 
3.2.3.2 MS conditions 
Following chromatographic separation intact mass analysis was performed a Q-
Exactive Plus Orbitrap instrument, using a HESI-II probe source [both Thermo 
Fischer Scientific, Bremen, Germany] in positive ESI mode. Source conditions 
included a 320 °C source temperature, 3 kV capillary voltage, 90 S-lens RF, 25 a.u. 
sheath gas, 12 a.u. aux gas, 80 V in-source CID. MS experiments were performed 
using the following parameters; 200 ms maximum IT, 3E6 AGC target value, 10 
microscans, high mass resolution (HMR) mode. Data were acquired in a resolution 
mode of 17.5 K over a range of 1700 – 4500 m/z. The instrument was calibrated in 
the high mass range of 1000 – 5000 m/z using a 1 mg/mL solution of AHFP.  
3.2.3.3 Deconvolution of intact protein measurements 
Protein deconvolution was performed using BioPharma finder v 2.0 software [Thermo 
Fischer Scientific, Massachusetts, USA] using the ReSpect™ algorithm for 
isotopically unresolved spectra. Deconvolution was performed in the 140-150 kDa 
range, considering 10-100 charge states, a range of 6-10 minimum charge states and 
a target mass of 148 kDa.  
3.2.4. HDX-MS experiments 
3.2.4.1 Instrumentation and experimental settings 
Sample handling and mixing steps were performed as described in section 2.2.3 unless 
otherwise stated. 13.2 µM protein sample solutions were diluted 10-fold in 10 mM 
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KPBS (pH 6.2). For exchange experiments, deuterium labelling was performed by 
diluting 15 µL of protein 10-fold in 10 mM KPBS (pH 5.8, uncorrected for isotope 
effect) prepared in D2O. Exchange times were 5 and 60 min with the exchange 
occurring at room temperature (21 ± 2 °C) and each incubation period run in triplicate. 
Following the appropriate incubation period, exchange was quenched by a 2-fold 
dilution with 50 µL of 1 M TCEP, 8 M Urea in 100 mM KPBS (pH 2.3) at 4°C.  
Following a 5 min quench delay, 95 µL of quenched sample was injected onto a 
refrigerated nanoACQUITY UPLC System with HDX technology for on-line pepsin 
digestion and chromatographic separation, as described previously.  
Method variation in digestion conditions from section 2.2.3.2 include a digestion 
temperature of 15 °C, a flow rate of 70 µL/min (mobile phase 0.5% v/v formic acid) 
and a digestion pressure of ~ 7000 psi applied using a PEEK restrictor placed after the 
trap column. Otherwise chromatographic separation, MS and data analysis workflows 
were followed as described previously in sections 2.2.3.2 and 2.2.4.  
3.2.4.2 Alternative protease evaluation 
Using the final optimised peptide mapping conditions described above an additional 
commercially available on-line proteolysis column, a 2.1 x 30 mm protease column 
containing a 1:1 mixture of immobilised pepsin and aspergillopepsin (Type XIII 
protease) [NovaBioAssays, USA] was also evaluated. All sample handling, quenching 
and repeats were as previously described. Lower pressures of ~ 800 psi were applied 
for the NovaBioAssay column due to manufacturers recommendations.  
3.2.5. Native IMS-MS experiments 
3.2.5.1 Instrumentation and experimental settings 
nESI-IMS-MS experiments were performed as described in section 2.2.6.1 unless 
otherwise stated. Experimental settings were optimised as follows: source temperature 
30°C, sampling cone 75 V, source offset 50 V, capillary voltage 1.4 kV, trap CE 3 V, 
trap gas flow 3 mL/min, helium cell has flow 180 mL/min, IMS gas flow 60 mL/min, 
trap DC entrance 3 V, trap DC bias 45 V, trap DC -2 V, trap DC exit 0 V, IMS DC 
entrance 10 V, helium Cell DC 25 V, helium exit -5 V, IMS bias 3 V, IMS DC exit 0 
V, transfer DC Entrance 4 V, transfer DC exit 5 V, IMS wave velocity 800 m/s, IMS 
wave height 40 V, transfer wave velocity 47 m/s, transfer wave height 4 V, stepwave1 
RF offset 300, stepwave2 RF wave offset 350, 200 µsec mobility trapping release 
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time; 20 V trap height; 0 V extract height. Data were acquired in resolution mode in 
the 2000-8000 m/z range, using a 2 sec scan time for 2 minutes. No cone or purge gas 
were used.  Parameters were systematically optimised by infusion NISTmAb RM to 
ensure effective transition of gas ions whilst avoiding unfolding of the gas ions within 
the instrument. 
3.2.5.2 CIU-IMS-MS experiments 
CIU-IMS-MS experiments were conducted using IMS-MS experimental conditions 
stated above but with the quadrupole selection of the + 24 charge state.  The ions 6180 
m/z, 6050 m/z and 6180 m/z were quadrupole selected during CIU-IMS-MS 
experiments for NISTmAb RM, DeGly NISTmAb and ExoGal NISTmAb samples 
respectively. The trap collision voltage was increased in 1 V increments between the 
range of 30 – 55 V rate and 5 V increments between 55-100 V and the data acquired 
for each voltage. Data processing was carried out as described previously in section 
2.2.6.2.  
3.2.6. NISTmAb structural models 
Due to the current unsolved XRC status of the intact NISTmAb RM, two solved XRC 
IgG1 fragment structures of both the Fab (PDB:5K8A [238]) fragment and a 
fucosylated-Fc (PDB:3AVE, [278]) IgG fragment are herein used to represent the 
structure of NISTmAb RM and Fc-glycan variants.  These structures were solved to 
1.99 Å and 2 Å for Fab and Fc respectively and the PyMOL fragments combined to 
illustrate a complete structure using Inkscape 0.92.3 (Copyright (C) 1989, 1991 Free 
Software Foundation, Inc.) 
3.3 Results & Discussion 
3.3.1. Intact protein characterisation of Fc-glycan variants 
Intact LC-MS of the NISTmAb RM and Fc-glycan variants was performed to confirm 
the presence of the expected glycoforms for NISTmAb RM and the successful 
enzymatic generation of deglycosylated and degalactosylated forms.  Subsequent 
spectra were then deconvoluted to experimental intact masses (Figure 55), which were 
compared with theoretical and previously reported masses [242] as stated in Table 12 
and Table 13. 
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The presence of all five major expected glycoforms (Figure 54) was observed upon 
deconvolution of the NISTmAb RM sample, with the most abundant being G0F/G1F 
type. Complete deglycosylation due to PNGase F treatment was confirmed for the 
DeGly NISTmAb sample.   
For the ExoGal NISTmAb sample, treatment with β 1-4, galactosidase saw a shift 
from the predominant species of G0F/G1F type towards predominantly G0F/G0F 
type, indicating removal of both terminal galactose residues at both CH2 glycoyslation 
sites present in NISTmAb RM.  Complete absence of all glycosylated species 
containing both terminal galactose residues (G2F type, Figure 54) was observed, and 
though there was evidence of the presence of single terminal glycan species (G1F 
type), this G1F type was evident with reduced abundancy to that of the NISTmAb 
RM control, this is similar as previously reported [255]. The degalactosylation 
demonstrated here simulates the type of micro heterogeneity that can arise as a result 
of differing manufacturing practices (such as changed cell lines) which could result 
in subtle but real changes in HOS of mAbs [268, 279].  
Comparison of the deconvoluted masses with theoretical masses[242], average Δ 
mass tolerances were found to be within Δ ~ 5.8-22.8 ppm across all the glycoforms 
and Δ ~  9.1-22.3 ppm for the deglycosylated sample.   
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Table 12. Average deconvoluted (n=3 measurements) intact masses of glycoforms 
observed in LC-MS analysis of the a) NISTmAb RM control and ExoGal 
samples. Measurement error (standard deviation) from theoretical values are 
stated in ppm. * Theoretical masses are taken from Formolo et al. [242].  
  
Deconvoluted Mass (Da) Error (ppm) 
Isoforms Theoretical * NISTmAb RM control ExoGal control ExoGal 
G0F/G0F 148036.4 148038.4 148038.7 13.5 15.3 
G0F/G1F 148198.6 148200.7 148200.9 13.9 15.2 
G1F/G1F 148360.7 148361.8 148361.4 7.3 4.5 
G1F/G2F 148522.8 148521.9   -5.8   
G2F/G2F 148685.0 148681.8   -21.8   
 
Table 13. Average deconvoluted (n=3 measurements) intact masses of  main isoforms 
observed in LC-MS analysis of the DeGly NISTmAb samples.  Measurement 
error (standard deviation) from theoretical values are stated in ppm.  * 
Theoretical masses are taken from Formolo et al [242].  
 Isoforms Theoretical* Deconvoluted Mass (Da) Error (ppm) 
DeGly 145148.5 145150.1 11.1 
 + Hex 145310.6 145311.9 9.1 
 + 2Lys 145404.0 145407.2 22.3 
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Figure 55. Deconvoluted intact mass spectrum of a) native glycosylated NISTmAb 
RM, b) β-1-4,-galactosidase treated (ExoGal) NISTmAb and c) PNGase F 
treated (DeGly) NISTmAb. The abundant glycoforms are indicated which are 
of biantennary complex type oligosaccharides (GXF), that varying the number 
of terminal β-1,4-galactose residues as indicated by numbers (X = 0,1 and 2), a 
hexose (hex.) containing impurity is also indicated.  
 
 
- 150 - 
3.3.2. HDX-MS method optimisation 
As described for the rhGH protein in Chapter 2 the peptide mapping stage was 
optimised for NISTmAb. Systematic initial screen of a range of digestion conditions 
was made for the on-line pepsin digestion of NISTmAb RM, including variation of 
chemical denaturing agent concentration, digestion pressure, temperature and flow 
rate, assessing the resulting peptide maps using the digestion factors previously 
described section 2.2.4.3.  
3.3.2.1 Optimisation of peptide mapping of NIST mAb RM 
The peptide maps produced for both heavy chain (HC) and light chains (LC) under 
each of the various digestion conditions screened are summarised in Table 14 . 
Increased molarity of chemical denaturants, Gnd.HCl (4M and 6M) and TCEP 
(200mM, 400mM and 600 mM), Table 14, conditions i-iv, facilitated higher sequence 
coverage and redundancy for both HC and LC of the protein. However, even under 
these relatively strong quenching conditions there was still incomplete digestion of 
both HC and LC  (~ 85%  and ~ 93% sequence coverage, Table 14 , condition iii).  
Additionally, there was evidence of protein carry-over (data not shown) during the 
organic washing stage of the chromatographic separation, indicating not only 
incomplete digestion but the presence of carry-over can have significant impact on 
the magnitude and reproducibility of measured deuteration rates due to contributions 
towards back exchange and ultimately isotopic distributions [280].  
An increase in HC redundancy was observed when increasing the digestion 
temperature from 15 to 20 °C, (Table 14, conditions iv and v), though little gain in 
sequence coverage was observed. Yet, at 20 °C,  there was an apparent slight decrease 
in number of LC peptides produced,  though poor reproducibility and low digestion 
efficiency observed under both these conditions at both temperatures. In light of this 
15 °C was deemed a more appropriate digestion temperature to use.  
Increasing pepsin flow rate across 70, 90 and 115 µL/min (Table 14, conditions vi-
viii) led to a decrease in percentage sequence coverage of the HC, due to reduced 
effective digestion caused by the increased flow rate, though LC sequence coverage 
was less significantly affected by the change in flow rate. Digestion indicators for the 
LC peptide map were still poor and combined with the presence of intact LC in the 
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chromatograms produced as described previously, suggested incomplete LC 
digestion.   
Increased sequence coverage and redundancy were observed when the digestion 
pressure was increased from 4000 to 7000 psi (Table 14, conditions v and ix) with use 
of a PEEK restrictor after the trap column.  
Comparison of initial condition i with resultant condition ix shows a significant 
improvement in peptide map coverage through simple screening of conditions.  
However peptide map coverage was still ~ 90% for LC and HC and intact undigested 
protein was evident upon appraisal of the resulting chromatograms. This was 
considered to be most likely due to incomplete reduction and denaturation of the 
protein, therefore optimisation of the quench hold time [281], that is the time protein 
is held in the quench solution, was explored as a potential way to facilitate better 
digestion. 
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Table 14. Summary of the resultant peptide maps produced from the on-line digestion of NISTmAb using a range of initial screening conditions. 
Only those peptides observed in n ≥ 4/5 injections were retained for peptide map.  
Conditi
on  
Quenching 
composition 
On-line digestion conditions Heavy chain Light chain 
Gnd.H
Cl 
(M) 
TCEP 
(mM) 
Tem
p. 
(°C) 
Flow rate 
(µL/min) 
Pressure 
(psi) 
# 
Peptide
s 
Sequence 
Coverage (%) 
Redunda
ncy 
# 
Peptide
s 
Sequence 
Coverage (%) 
Redunda
ncy 
i 4 200  15 70 4000 106 74.0 4.15 11 40.4 1.65 
ii 4 400  15 70 4000 97 73.1 4.05 19  57.7  1.74  
iii 4 600  15 70 4000 129 85.1 4.82 29 93.4 2.09 
iv 6 400  15 70 4000 108 82.7 4.04 33 85.4 2.59 
v 6 400  20 70 4000 116 83.8 4.44 31 77.5 2.42 
vi 4 600  20 70 4000 117 92.7 3.85 30 73.2 2.41 
vii 4 600  20 95 4000 123 82.2 4.7 31 73.7 2.47 
viii 4 600  20 115 4000 85 73.1 3.62 24 62.0 2.11 
ix 4 600 20 70 7000  137 86.7 4.81 43 90.1 3.03 
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3.3.2.2 Effect of quench holding times 
Peptide maps were produced using 0.5 and 5 min quench hold times and further 
variation of reducing and denaturing reagents and these are summarised in Figure 56.  
Much improved digestion was observed for both HC and LC across all digestion 
factors, when quench hold time was extended from a default 0.5 min to 5 min (Figure 
56 conditions i and ii), suggesting incomplete denaturation and reduction of the 16 
disulphide bonds present when using the shorter quenching hold times.  
Increasing the molarity of the TCEP reducing agent from 600 mM to 1 M (Figure 56, 
conditions iii and iv ) gave further gains in all digestion indicators, corroborating that 
at the lower molarity, there was indeed still incomplete reduction of disulphide bonds 
present within the NISTmAb structure. Almost complete sequence coverage, 99% and 
98% HC and LC respectively, was maintained when the denaturing agent was 
switched from 4 M Gnd.HCl to 8 M urea, yet a 1.4 fold increase in redundancy and 
1.2 fold increase in the number of peptides was observed with use of urea.  
In hope of reducing any further unreduced disulphides and/or preventing any 
reformation of reduced disulphides during the pepsin digestion stage, a low molarity 
of TCEP (8 mM, Figure 56 condition v) was added to the on-line pepsin mobile phase. 
However, this resulted in a detrimental effect on all digestion indicators, likely due to 
increased ion suppression of the MS signal and hence a lower number of peptide 
identifications made from the resultant spectrum.  
Overall increasing quench hold time, reducing agent molarity and the use of an 
alternate chaotropic agent resulted in an increase of sequence coverage, redundancy 
and number of peptides for the NISTmAb HC by 20%, 50% and 62% respectively. 
More significant gains were observed for the LC with values of 40%, 165% and 245% 
respectively, demonstrating a far superior pepsin digestion, peptide map coverage and 
ultimately significantly increased resolution of HDX-MS measurements using these 
optimised conditions.  
3.3.2.3 Effect of back exchange rates 
To check for negative effects on back exchange due to increased quench hold times, 
a sample of NISTmAb was incubated in deuterium for 5 minutes before being 
subsequently quenched using both 0.5 and 5 min quench hold times, and analysed 
using bottom-up HDX-MS workflow.  
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Considering all peptides observed in both data sets produced across both quench hold 
times, increased relative uptake measurements were in the range of 0.04 – 5.33% for 
NISTmAb analysed using the 0.5 minute quench hold time, with a mean increased 
value of 0.7% across all peptides. 
The large gains observed in peptide map quality due to increased quench holding were 
therefore deemed to outweigh a small increase in back exchange. Unless otherwise 
stated, for all proceeding HDX-MS on-line digestion was performed using  a quench 
containing 8 M Urea, 1M TCEP, a quench hold time of 5 min, 15°C and a flow rate 
of 70 µL.   
Figure 57 and Figure 48 illustrate the resultant peptides maps produced for NISTmAb 
using these optimised conditions.  
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Figure 56. Representation of NISTmAb RM peptide maps from on-line pepsin 
digestion under a range of digestion conditions (i-v). Peptide maps are evaluated 
in terms of a) sequence coverage percentage b) redundancy c) number of 
peptides identified. Quenching composition, quench hold time  and pepsin 
mobile phase were varied to optimise pepsin digestion. Digestion conditions 
were i) quench - 4 M Gnd.HCl, 600 mM TCEP, 0.5 min quench hold time  ii) 
quench - 4 M Gnd.HCl, 600 mM TCEP, 5min quench hold time iii) quench - 4 
M Gnd.HCl, 1M TCEP, 5min quench hold time iv) quench - 8 M Urea, 1M 
TCEP, 5min quench hold time v) quench - 8 M Urea, 1M TCEP, 5min quench 
hold time, 8 mM TCEP pepsin mobile phase. 
- 156 - 
  
 
Figure 57. Peptide map of NISTmAb RM HC, using optimised conditions. These 
conditions include; quenching solution containing 8 M Urea, 1M TCEP, a 5min 
quench holding time, 15 °C, 70 µL/min. Only peptide observed in n=4/5 repeat 
injections are displayed. In total some 182 peptides are displayed, giving 98% 
sequence coverage and redundancy score of 7.36.   
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Figure 58. Peptide map of NISTmAb RM LC, using optimised conditions These 
conditions include; quenching solution containing 8 M Urea, 1M TCEP, a 5min 
quench holding time, 15 °C, 70 µL/min, Only peptide observed in n=4/5 repeat 
injections are displayed. In total some 63 peptides are displayed, giving 100% 
sequence coverage and redundancy score of 5.02.    
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3.3.2.4 Alternative protease evaluation 
Two commercially available on-line proteolysis columns, one containing only 
immobilised pepsin and the other containing a 1:1 mixture of immobilised pepsin and 
Type XIII protease (from Aspergillus saitoi), referred to as Enzymate™ and 
NovaBioassay respectively herein, were also evaluated for the digestion of NISTmAb 
RM.  
Table 15 summarises the resultant peptide maps produced from repeat injections 
(n=5) of 10 µM NISTmAb RM solution using both columns. Both columns 
demonstrated high sequence coverage with HC and LC coverage in excess of 90 %, 
consistent with application of the proteases to on-line mAb digestion mAbs in 
previous studies [277]. However, the NovaBioassay dual protease column yielded a 
higher number of peptides and higher redundancy rates, 6.37 and 5.56 for HC and LC, 
respectively, compared to 5.57 and 3.93 redundancy scored for the pepsin column 
alone. These increased proteolysis and redundancy rates reported are consistent with 
previous studies [277].  
In light of the similar sequence coverage and high redundancy achieved using both 
columns and ultimately due to lab practicalities and costs, the Enzymate™ column 
was selected for all further experiments described in this Chapter.   
Table 15. Summary of the resultant peptide maps produced of NISTmAb RM using 
two different commercially available on-line protease columns. Peptide maps 
are summarised by the number of peptides identified, the percentage sequence 
coverage and redundancy score. 
 
Heavy Chain Light Chain 
Pepsin 
column 
# 
Peptid
es 
Sequence 
coverage (%) 
Redund
ancy 
# 
Peptid
es 
Sequence 
coverage  
(%) 
Redund
ancy 
NovaBioa
ssay* 
176 93.1 6.37 82 94.4 5.56 
Enzymate
™ 
136 91.1 5.57 48 96.2 3.93 
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3.3.3 HDX-MS measurements and NISTmAb RM structure prediction 
Using the optimised peptide mapping method described, HDX-MS measurements 
were made for the NISTmAb RM control and the uptake measurements were 
interpreted and compared against known structures for the protein.   
Following manual curation of the exchange data, sequence coverage was 89.6% and 
91.1% for HC and LC, respectively.  Relative HDX-MS peptide rates were mapped 
onto the solved XRC structures of the NISTmAb Fab (PDB:5K8A [238]) and an Fc-
fragment  (PDB:3AVE, [278]] solved for an alternative IgG1, as illustrated in Figure 
59. Overall regions of predominantly lower relative exchange (cooler colours) was 
observed, suggesting a relative high amount of structure, consistent with the high 
levels of secondary structure in the form of the β-sheets known to exist in each 
domain. However there are some regions of higher relative exchange (warmer 
colours) tending to populate the bottom of the CH3 domain and the lower region of 
the CH1 domains.  
Very low exchange rates (dark blue) were measured for peptides spanning HC 95-99 
and HC 221-230 suggesting high structure and/or low solvent accessibility (indicated 
in Figure 59). Considering this in the context of the XRC structure confirms indeed 
these peptides are buried within the Fab domain of the crystal structure (Figure 59).  
Other regions of low exchange kinetics include HC 84-94, HC 111-117, HC 150-159, 
HC 315-322, HC 394-408, LC 72-74 and LC 173-201; this is in accordance with low 
kinetics observed during a previous HDX-MS study of NISTmAb RM [256].  
Higher kinetics were measured for the following regions: HC 190-220, HC 280-303, 
HC 352-359, HC 385-394, LC 5-11, LC 142-160, LC 201-214, with these regions 
consisting of a mixture of loop regions plus β-secondary structures within the constant 
region of the Fab. Albeit, differences observed in exchange conditions, back exchange 
rates and peptides make direct and absolute comparisons of relative HDX-MS 
measurements between different laboratories difficult, though general trends of 
kinetics can be observed across laboratories.  
Considering the 3D heat map, overall higher structural rigidity was observed for the 
Fab region compared to the Fc region of the NISTmAb RM, in particular the variable 
domains appeared to have more structural rigidity compared to the constant domains 
in the Fab region. This rigidity could reflect the need of residual structure for 
specificity of binding at these variable regions which house the CDRs, the associated 
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antigen-binding regions. Additionally lower relative exchange rates were measured 
for those residues within the central cavity of the Fc-region compared to those residues 
located on the outside and C-terminal end of the domain, reflecting the lower solvent 
accessibility experienced by residues within the cavity.  These data are in good 
accordance with predicted and published data for the structure of NISTmAb RM 
validating the effectiveness of the HDX-MS method optimised [256].
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Figure 59. Relative deuterium uptake mapped on to crystal structure of combined Fab (PDB:5K8A[238]) and Fc (PDB:3AVE [278]) regions of IgG1 
structure and for two deuterium incubation periods of 5 and 60 minutes. Relative uptake is represent by the colour scale ranging from low uptake 
(blue) to high uptake (red). Black regions indicate regions of sequence not identified in HDX-MS experiments. 
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3.3.4 HDX-MS measurements to identify changes in HOS of Fc-glycan 
variants 
3.3.4.1 Definition of significance thresholds for NISTmAb RM 
Changes in HOS structure as a result of deglycosylation and degalactosylation of 
NISTmAb have been reported previously as measured by multivariate analysis of 2D 
NMR [255]. In this study, however, the specific resonance shifts were not resolved at 
an amino acid level and localised characterisation of these changes is therefore 
incomplete.  It was hoped that relative HDX-MS measurements of this model system 
could be able to provide localised insights into where these structural changes occur, 
validating the applicability of the model system.  
Prior to this comparison, as demonstrated by the rhGH model system described in 
section 2.3.1.5, confidence and sensitivity towards small structural changes in HOS 
are increased by definition of measurement thresholds using vial-to-vial 
comparability studies. Prior to the measurement of Fc-glycan variants, first a vial-to-
vial HDX-MS comparability was performed using a series of NISTmAb RM control 
samples.  
To account for any structural changes that could occur during the digestion and 
centrifugal clean-up of the NISTmAb Fc-glycan variants, a sample of the NISTmAb 
RM control sample was first subjected to heated incubation (minus enzymatic 
treatment), centrifugal clean-up and dilution, before splitting into two equal vials and 
HDX-MS measurements from both vials performed concurrently. As for rhGH vial-
to-vial, each measurement was performed in triplicate on the same day and a relative 
vial-to-vial comparison was repeated three times on three different days (n=9 in total 
measurements). 
So as to put the data into context with the final Fc-glycan variant HDX-MS 
comparison, only those peptides, i, identified in all datasets including a final 
NISTmAb RM vs DeGly NISTmAb differential study (n = 4 datasets, 10 samples) 
were considered. Measurement thresholds were then generated from the vial-to-vial 
comparability measurements using the statistical approach previously described in 
section 2.3.1.5. Following manual curation of HDX-MS measurements across all 
datasets, measurement thresholds, represented by the dotted lines in Figure 60 and 
Figure 61, were established for 87 (76.2% sequence coverage, 200.9% redundancy) 
and 34 (84.5% sequence coverage, 116.4% redundancy) peptides observed for NIST 
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mAb samples for HC and LC respectively. All raw differential measurements are 
detailed in Table A-26 located in the appendices.   
3.3.4.2 Comparability of NISTmAb RM and DeGly NISTmAb HDX-MS 
measurements 
Comparison of differential HDX-MS measurements between the NISTmAb RM 
control and DeGly NISTmAb with thresholds established from the vial-to-vial 
comparability study (Figure 60 a, Figure 61 a and Table 16), revealed seventeen HC 
peptides and a single LC peptide exhibiting statistically significant structural changes 
following deglycosylation. All other regions appeared unaffected and the large 
majority of the HOS structure was unchanged.  
Figure 61 a highlights these regions identified as exhibiting significant structural 
changes on the XRC structures of NISTmAb RM Fab and Fc regions. Two distinct 
regions within the CH2 domain of the Fc region (Figure 60a regions III and IV) 
revealed increased structural flexibility as a result of deglycosylation, corresponding 
to 11 peptides spanning residues HC 238-254 and HC 265-280. Relative changes in 
HDX-MS rates for these specific peptidic sequences, as a result of deglycosylation, 
are illustrated in Figure 62 b. Located within the hinge and CH2 domains, all six 
peptides monitored within the HC 238-254 region exhibit increased exchange kinetics 
(S ~ between 0.79 – 1.011 Da) following deglycosylation. Resolution afforded by the 
overlapping peptides, lack of exchangeable amides in proline residues and loss of 
deuteration of the two N-terminal residues during analysis [125], suggest these 
changes in kinetics are most significant for residues Phe-246, Lys-249, and residues 
251-255 (Figure 62 b).  
Increased HDX-MS rates upon deglycosylation have been attributed previously to the 
loss of an interaction between the phenyl ring present in Phe-246 and the GlcNAc 
moiety present within the glycan structure [282]. Removal of this interaction indeed 
seems to lead to reduced stabilisation of these residues which in turn leads to greater 
flexibility across the HC 238-254 region. Increased flexibility of the specific sequence 
FLFPPKPKDTLM (residues 244-255, Fc-region) is widely reported in the literature, 
in the HDX-MS analysis of other IgGs, as a result of undergoing a variety of other 
perturbations including distal Fc Met-oxidation [129, 283] and chemical 
destabilisations [284]. These data are concurrent with the identification of this Fc 
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region as a potential aggregation spot [285] and reported increased aggregation rates 
as a result of mAb deglycosylation of mAbs [286]. 
Further still, increased structural flexibility was measured for residues HC 265-280, 
situated between the CH2 and CH3 domains of the Fc region, revealing that the loss of 
this stabilising carbohydrate interaction appears to also have long-range effects 
(Figure 62 b and c). Structural changes, in the form of increased flexibility of the CH2 
domain of IgG1-based proteins upon deglycosylation appears to be a repeated 
observation [130, 279, 287, 288] demonstrating not only the homology of structure 
across the IgG1 class but also the reproducibility and robustness of HDX-MS 
measurements for protein conformation dynamics.  
Three regions of the Fab portion of the NISTmAb RM, HC 5-20, HC 159-177 and LC 
122-131 also show increased structural flexibility as a result of deglycosylation 
(Figure 60 a, regions I and II and Figure 61 a, region I). Of particular interest is the 
increase in structural flexibility in the region of HC 159-177, situated in the CH1 
domain (Figure 62 a). This region has previously been indicated as being involved in 
the interaction between an IgG1 in its native glycosylated form and an FCγRIIIa type 
receptor  by both HDX-MS [258,] and FPOP-MS studies[279]. If this region is indeed 
part of the epitope of this interaction, then loss of structure in this area is consistent 
with the well documented loss of activity observed between an IgGs and FCγRIIIa 
type receptors upon deglycosylation [282]. 
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Figure 60.  Differential HDX-MS measurements across the heavy chain sequence of 
NISTmAb RM between the native NISTmAb RM and a) Degly NISTmAb and 
b) ExoGal NISTmAb. Dotted lines illustrate the measurement thresholds for 
each peptide, i, calculated from a vial-to-vial comparability study using the 
NISTmAb RM. Those differential measurements which are in excess of these 
thresholds demonstrate robust structural changes and are highlighted in grey and 
correspond to the following residues a) I) HC 5-20, II) HC 159-177, III) HC 
238-254 and V) HC 265-280 and b) I) HC 5-20, II) HC 66-82, III) HC 159-177 
and V) HC 248-255.  Error bars represent standard deviations of triplicate 
measurements. 
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Figure 61. Differential HDX-MS measurements across the light chain sequence of 
NISTmAb RM between the native NISTmAb glycosylated control and a) Degly 
NISTmAb and b) ExoGal NISTmAb. Dotted lines illustrate the measurement 
thresholds for each peptide, i, calculated from a vial-to-vial comparability study 
using NISTmAb glycosylated control. Those differential measurements which 
are in excess of these thresholds demonstrate robust structural changes a) region 
I corresponding to residues LC 122-131. Error bars represent standard 
deviations of triplicate measurements. 
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Figure 62 a) Resolved areas of structural change upon endo-deglycosylation of 
NISTmAb mapped onto Fab and Fc crystal structures (PDB:5K8A [238] and 
3AVE [278] respectively). Regions identified as showing reduced (blue) and 
increased (red) HDX rates are highlighted; residue Phe-246 is highlighted in 
green sticks, indicated to stabilise the CH2 domain via interaction with GlcNAc 
residues. b) Overlapping fragments of interest monitored by HDX-MS. 
Differential measurements between NISTmAb RM and DeGly NISTmAb are 
indicated in Da. c) Relative uptake plots of two peptides in which structural 
changes were identified. Data presented show NISTmAb RM vial 1 (grey), 
NISTmAb RM vial 2 (black), DeGly NISTmAb (purple) ExoGal NISTmAb 
(cyan), standard deviations of triplicate measurements are represented by error 
bars. 
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3.3.4.3 Comparability of NISTmAb RM and ExoGal NISTmAb HDX-MS 
measurements 
Comparison of differential HDX-MS measurements between the NISTmAb RM 
control and ExoGal NISTmAb with thresholds (Figure 60 b, Figure 61 b and Table 
16), revealed eight HC peptides exhibiting statistically significant structural changes 
following β-1,4-degalactosylation. None of the LC and all other HC regions appeared 
unaffected, demonstrating the large majority of the HOS structure was unchanged. 
These regions of structural change are indicated in Figure 63.  
Increased structural flexibility for the region HC 248-255 (Figure 60 b, region IV) 
located in the CH2/CH3 domain interface was also observed for the NISTmAb RM 
upon degalactosylation, though with HDX rates increased between 0.44-0.57 Da less 
magnitude relative to Degly NISTmAb. No structural changes were observed for HC 
238-245 and HC 265-280 (Figure 63), in contrast to the DeGly NISTmAb, suggesting 
that the conservation of the interaction between the phenyl ring of Phe-246 and the 
GlcNAc moiety results in better overall stabilisation of the CH2 domain. In spite of 
this conserved interaction, the data suggest a small destabilisation of structure for the 
HC 248-255 region consistent with the loss of an interaction between the terminal 
galactose moiety and Lys-249 residue [268]. In contrast to the effect of total glycan 
removal for the Degly NISTmAb study, dynamics in the Fab region, HC 5-20, HC 
66-82 and HC 159-177 (Figure 60 b regions I, II and III), appear to be decreased due 
to galactose removal. Figure 61 b illustrates that NISTmAb RM degalactosylation has 
no significant change on LC HOS structure.  
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Figure 63. Resolved areas of structural change upon β 1,4-degalactosylation of 
NISTmAb RM mapped onto Fab and Fc crystal structures (PDB:5K8A [238] 
and 3AVE [278] respectively). Regions identified as showing reduced (blue) 
and increased (red) HDX rates are highlighted; residue Phe-246 is highlighted 
in green sticks, and glycan structure in yellow. 
3.3.4.4 Effect of glycosylation on intrinsic HDX-MS rates 
The acetoamido groups and N-linking asparagine of the N-glycosylation site will 
undergo deuteration during HDX [279, 290], and in light of the absence of both of 
these in the DeGly NISTmAb peptides that contain the glycosylation N300 were 
therefore not considered in the overall differential HDX-MS analysis.  
However comparing the uptake of the peptide HC 281-303 (Figure 64), which spans 
the glycosylation site Asn300,  we observe, as expected, increased uptake for the  
NISTmAb RM and ExoGal NISTmAb samples compared to that of the DeGly 
NISTmAb.  
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It is worth noting deuterium incorporation was equivalent across the two different 
glycosylation states, this is consistent with the experimental and theoretical 
observations that the major glycoforms present across the NISTmAb RM and ExoGal 
NISTmAb samples both share 5 acetoamido groups known to incorporate deuterium 
(Figure 54) [290]. These data would tend to suggest also that structural changes within 
the CH2 domain, associated with removal of galactose residues are conserved to the 
HC 248-255 region and do not affect the glycosylation site directly. 
 
 
Figure 64. Deuterium uptake plot for the Fc-glycan site of NISTmAb RM. Data 
presents the uptake rates for the HC peptide spanning residues 281– 303 for the 
NISTmab RM (black), ExoGal NISTmAb (blue) and Degly NISTmAb (purple) 
following incubation in deuterium for 5 and 60 min, error bars represent 
standard deviations (n=3). 
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3.3.4.5 Comparability of HDX-MS measurements of Fc-glycan variants 
Comparison of the localised relative structural changes induced by variation in Fc-
glycan structure of the NISTmAb RM as identified in both NISTmAb DeGly and 
ExoGal NISTmAb samples (Figure 62 a and Figure 63, Table 16), demonstrates a 
larger HOS change as a result of complete removal of the glycan structure.   
Structural changes were identified in both Fc and Fab portions of the molecule for 
both Fc-glycan variants, indicating potential stability and efficacy implications for the 
two portions respectively. Such as in the Fab region, where contrasting structural 
changes, of increased and decreased flexibility for regions HC 5-20 and HC 159-177 
were observed for Degly and ExoGal samples respectively, both of which could 
influence the interaction with FCγRIIIa type receptors [268, 289]. However, increased 
flexibility of the region situated at the CH2/CH3 domain interface was observed in both 
samples, demonstrating the significance of the interaction between the terminal 
galactose moiety and Lys-249 residue for the HOS of IgG1s.  In the degalcosylated 
form, the HOS remains unchanged for HC 238-255, a region associated with IgG1 
structure degradation, implicating potential different stabilities across the two 
variants.  
Overall the variation in number and magnitude of structural changes observed across 
the variants, i.e. larger HOS changes upon deglycosylation compared to 
degalactosylation, promotes the use and suitability of this model system for 
establishing the sensitivity of analytical technologies towards structural changes.  
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Table 16. NISTmAb RM peptides identified as showing significant changes due to 
variation in Fc-glycan structure by HDX-MS differential analysis. Changes are 
expressed as increases (+) and decreases (-) of HDX relative to NISTmAb RM, 
with no significant change is indicated by blank input. 
Identifier Relative HDX change 
Peptide, i Peptide ID Sequence DeGly ExoGal 
1 HC 5-17- RESGPALVKPTQT  - 
3 HC 5-19- RESGPALVKPTQTLT + - 
4 HC 5-20- RESGPALVKPTQTLTL + - 
14 HC 66-82- KDRLTISKDTSKNQVVL  - 
15 HC 70-82- TISKDTSKNQVVL  - 
24 HC 159-166- VSWNSGAL +  
25 HC 159-170- VSWNSGALTSGV +  
26 HC 159-177- VSWNSGALTSGVHTFPAVL + - 
27 HC 162-177- NSGALTSGVHTFPAVL +  
37 HC 238-244- LGGPSVF +  
39 HC 244-254- FLFPPKPKDTL +  
40 HC 245-254- LFPPKPKDTL +  
41 HC 245-255- FLFPPKPKDTLM +  
42 HC 246-255- FPPKPKDTLM + + 
43 HC 247-254- PPKPKDTL + + 
44 HC 247-255- PPKPKDTLM + + 
48 HC 265-278- VVVDVSHEDPEVKF +  
49 HC 265-280- VVVDVSHEDPEVKFNW +  
50 HC 266-280- VVDVSHEDPEVKFNW +  
51 HC 267-280- VDVSHEDPEVKFNW +  
16 LC 122-131- QLKSGTASV +  
 
3.3.5 Native IMS-MS method optimisation 
Gas-phase unfolding and increased peak resolution as a result of increased sample and 
trap cone voltages was reported in previous IMS-MS studies of NISTmAb RM using 
a previous generation instrument (Synapt G2) [291]. To establish source conditions 
suitable for retaining a native conformation whilst achieving maximum resolution, the 
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NISTmAb RM control was infused under a range of sample cone voltages between 
50  - 150 V (Figure 65). An increase in peak resolution is observed with sample cone 
voltage, culminating in the appearance of the individual Fc-glycan states at the highest 
sample cone voltage of 150 V (Figure 65 b), consistent with the previous study [291]. 
A single Gaussian CSD ( + 20 – 25) was evident across the whole range of sample 
cone and trap voltages, suggesting no large scale global unfolding. However there 
does appear to be a slight shift from a centroid of  + 23 value to + 24 at sample cone 
voltages in excess of 150 V suggesting a slight change in globular folding due to 
increased energy consistent with the charge state residue model [76].  Extraction of 
the IMS-MS tD for the + 23 base peak, across the voltage range (Figure 66), reveals 
the appearance of a secondary ATD peak, of increased tD ( ~ 19 ms) for the 150 V 
cone voltage confirming gas-phase unfolding of the protein at this voltage.   
Improved resolution was also observed when increasing the instrument trap voltage 
(Figure 65 b), with the appearance of glycoforms evident for trap voltages in excess 
of 55V. Similarly, gas-phase unfolding was also apparent with the a appearance of a 
secondary longer ATD at trap voltages in excess of 50 V (Figure 66) when considering 
the + 24 charge state. For cone voltages ≤ 100 V and trap voltages ≤ 40 V, it is possible 
to observe a single ATD peak. Therefore to retain the native conformation of 
NISTmAb RM moving forward sample cone voltage was maintained at 75 V and trap 
voltage at 3 V, unless states otherwise.    
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Figure 65. Comparison of the native MS spectra of NISTmAb RM acquired with 
increasing sampling cone voltages across the 50 – 150 V range. Spectra were 
acquired under native buffer conditions a) the full charge observed CSD 
observed b) MS-spectra of the + 23 charge state. Increased resolution of the 
major glycoforms is observed with increased sampling cone voltage.  
- 175 - 
 
Figure 66. Comparison of the extracted ATD of the + 23 charge state of NISTmAb 
RM, acquired with increasing sampling cone voltages across the 50 – 150 V 
range, under native buffer conditions. At sampling voltages > 100 V a second 
ATD with increased tD ~ 19ms is observed, indicative of gas-phase unfolding.   
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Figure 67.  Comparison of the native MS spectra of NISTmAb RM control acquired 
with increasing trap voltages across the 3 – 100 V range. Spectra was acquired 
under native buffer conditions a) the full charge observed CSD observed b) MS-
spectra of the +24 base peak. Increased resolution of the major glycoforms is 
observed with increased sampling cone voltage.  
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Figure 68.  Comparison of the extracted ATD of the + 23 charge state of NISTmAb 
RM, acquired with increasing trap voltages across the 3 – 100 V range, under 
native buffer conditions. At trap voltages > 40 V a second ATD with at an  
increased tD ~ 19ms is observed, indicative of gas-phase unfolding A second 
unfolded state, with further increase ATD ~ 22 ms is observed at 100 V.    
 
- 178 - 
3.3.6 Native IMS-MS measurements of NISTmAb RM and structure 
prediction 
The native IMS-MS spectra of NISTmAb RM (Figure 69 b) reveal a single narrow 
Gaussian CSD with charge states spanning from + 20 - 27, indicative of a single 
solution conformation, and a globular-like folded protein. This is corroborated by the 
single ATD observed for each charge state (Figure 69 a) .  
 
Figure 69. Native IMS-MS analysis of NISTmAb RM.  a) Drift time mobiliogram of 
NISTmAb RM IMS-MS measurements reveal a single conformational species 
for each charge state b) a single Gaussian CSD is observed for the corresponding 
mass spectra.  
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3.3.7 Native IMS-MS to identify changes in HOS induced by Fc-glycan 
variation 
IMS-MS tD measurements of the NISTmAb RM and Fc-glycan variants were 
compared for differences in HOS and globular stability Table 17. All measurements 
are expressed as an average of three inter-day measurements and the standard 
deviation given.   
The same single narrow Gaussian CSD (+20 - 27) was observed for all three samples, 
indicating no large scale unfolding due to change in Fc-glycan structure and the 
existence of a single conformation under these native-like conditions. No significant 
differences in tDs were observed across NISTmAb RM and ExoGal NISTmAb 
measurements, showing equivalent global structures between the samples.   
However under these native-like conditions, an average 3.6% decrease in ATD (across 
all charge states) was resolved for the DeGly NISTmAb relative to the NISTmAb RM, 
demonstrating a decrease in TWCCSN2 and a more compacted globular structure for 
the deglycosylated form.  
It is worth noting that though mobility is proportional to the reduced mass of the ion, 
µred , the 2.1% mass difference between glycosylation states equates to a 0.0002% 
difference in  µred which has a negligible effect on tD for these large mass proteins. 
This indicates that this decrease in ATD is indeed as a result of a change in HOS [53]. 
Measured ATDs were equivalent for NISTmAb RM and ExoGal NISTmAb under 
these conditions, revealing similar Ω values.   
The presence of a glycan structure within the cavity between the two CH2 domains 
may increase the distance between the two domains as a result of steric hindrance, 
removal of these glycans could result in the gas-phase collapse of this cavity and the 
globular Ω compaction observed for deglycosylated samples. Similarly Upon et al. 
[292] observed a ~ 3.5% decrease in ATD upon the deglycosylation of the therapeutic 
Herceptin®, suggesting this phenomenon is consistent across other IgG1s. These data 
are consistent with observations from HDX-MS analysis showing significant increase 
in flexibility within the interface of CH2/CH3 domains for the deglycosylated form, 
which may result in the gas-phase collapse described. Further still this would support 
the idea that the presence of glycosylation enhances and stabilise, the open 
conformation of CH2 domain  necessary for FcγR binding [269]. 
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Table 17. Comparison of IMS-MS measurements of NISTmAb RM control, DeGly 
NISTmAb and ExoGal NISTmAB. Average observed drift times (tD) and SDs 
expressed for triplicate, n=3,  interday measurements. *m/z values are expressed 
considering the mass of the most abundant glycoforms of NISTmAb RM 
control, G0F/G1F glycosylation state.  
 
  
NISTmAb RM 
DeGly 
NISTmAb 
ExoGal 
NISTmAb 
Charge 
state (z) 
m/z* 
tD 
(ms) 
SD 
(ms) 
tD 
(ms) 
SD 
(ms) 
tD 
(ms) 
SD 
(ms) 
20 7410.0 21.7 0.3 21.1 0.3 21.8 0.1 
21 7057.1 20.0 0.2 19.4 0.2 20.1 0.1 
22 6736.3 18.5 0.2 17.8 0.1 18.5 0.0 
23 6443.4 17.0 0.1 16.4 0.1 17.0 0.1 
24 6175.0 15.7 0.1 15.1 0.1 15.7 0.2 
25 5928.0 14.5 0.1 14.0 0.1 14.5 0.2 
26 5700.0 13.6 0.1 13.1 0.0 13.6 0.2 
27 5488.9 13.0 0.2 12.5 0.3 13.1 0.1 
 
3.3.7.1 CIU-IMS-MS comparisons 
Quadrupole selection was performed of the corresponding +24 base peak under low 
voltage native conditions, with selection made based on the criteria of ion intensity, 
compact structure [95], and CIU-IMS-MS experiments performed by ramping trap 
cell collision voltages from 3 – 100 V. At the lower collision voltage of 3 V, a single 
Gaussian ATD was observed indicating a native folded state (T1‡) (Figure 70) present 
in all samples. Similarly as stated previously the ATD of DeGly NISTmAb showed a 
~ 3.6% compaction at native conditions for a trap voltage of 3 V, measured ATDs 
were equivalent for NISTmAb RM and ExoGal NISTmAb under these conditions, 
again revealing similar Ω values, under these conditions. 
For measurements of all samples performed at voltages 3 –40 V, only the T1‡ state 
was observed (Figure 71). Increasing voltages to ~ 44 V, reveals the presence of a 
tailing peak with increased ATD, indicating the presence of a less folded species (T2‡) 
at this higher voltage, though the T1‡ state remains the predominant species. Figure 
70, displays the overlayed mobilograms measured at collision voltages of 44 - 55V 
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for all samples. Comparison of the relative proportion of T1‡/ T2‡ states between 
these voltages, reveals a higher proportion of unfolded T2‡ state for the DeGly 
NISTmAb compared to the NISTmAb RM.  A general trend of increased proportion 
of T2‡/ T1‡ is observed across DeGly > ExoGal > NISTmAb RM, presenting a 
correlation between the amount of collisional induced activation required for 
unfolding the native conformation and increased glycan structure, similar to studies 
of other IgG1s [95, 292]. This decreased stability is apparent across the whole 44 – 
55V range, corroborating the destabilisation of the CH2/CH3 domains revealed by 
HDX-MS measurements caused by deglycosylation and degalactosylation. Higher 
similarity ATD profiles across the CIU-IMS-MS experiment between the NISTmAb 
RM and ExoGal NISTmAb samples, indicates more comparabile HOS structures. 
Finally an additional more unfolded species (T3‡) was evident at higher collision 
energies ~ > 75 V for all samples (Figure 71) consistent with previous IMS-MS studies 
of NISTmAb RM [291].  
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Figure 70. Collision-induced unfolding (CIU-IMS-MS) plots of the + 24 charge state 
of NISTmAb RM (black), DeGly NISTmAb (blue) and ExoGal NISTmAb 
(red). a) A single folded gas-phase conformation (T1‡) is observed at low 
collision voltage 3 V b) increased presence of a unfolded gas-phase 
conformation (T2‡) with increased arrival time is observed as collision voltages 
are ramped from 44 – 55 V. Samples were infused using equivalent experimental 
conditions and under native buffer conditions (50 mM ammonium acetate). Data 
is displayed as arrival time (ms) versus normalised intensity.  
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Figure 71. Collision-induced unfolding (CIU-IMS-MS) plots of a) NISTmAb RM b) 
ExoGal NISTmAb and c) DeGlyl NISTmAb. Quadrupole selection of +24 
charge state was performed and trap cell activation induced using a voltage 
range of 30 - 100 V. Data are displayed in three dimensions as arrival time (ms), 
trap cell collision voltage versus normalised intensity. Arrival time distributions 
are indicated for three folded states compact (T1‡), unfolded intermediate (T2‡) 
and unfolded (T3‡). Plots were generated with use of PULSAR processing 
software [98].  
- 184 - 
3.4 Conclusions 
mAbs have revolutionised modern-day therapeutics, with their complex and tuneable 
HOS structures opening the gateway for specific targeted therapies for the treatment 
of a vast array of diseases. Current regulation supports the findings that changes in 
CQAs, such as glycosylation, of therapeutic mAbs can result in changes in HOS and 
effect safety, efficacy and potency of the therapeutic. Due to their complex nature, 
monitoring for the HOS changes of mAbs can be analytically challenging and the 
technologies employed must be both validated and demonstrated to provide adequate 
measurements. There is a need for reference datasets to support the use of the 
NISTmAb RM in method validation, QC monitoring and comparability studies of 
mAb-based biotherapeutics.  Indeed the NISTmAb RM and the protocol described 
here to generate Fc-glycan variants, has facilitated the validation of the statistical 
approach developed, in Chapter 2 using rhGH, to establish HDX-MS measurement 
thresholds, on biomolecules of increased sized and complexity, relative to rhGH RM.  
The simple enzymatic preparation of two Fc-glycan variants from the NISTmAb RM 
described here offers a candidate system for assessing the suitability of more novel 
analytical methodologies, such as HDX-MS and IMS-MS, towards the 
characterisation of small structural changes. Whilst considering the methodological 
measurement variability, localised, mainly destabilising, structural changes have here 
been characterised by HDX-MS for both Fc-glycan variants. Differences in global 
structure and decreased stability between the NISTmAb RM and fully deglycosylated 
form were also corroborated by CIU-IMS-MS experiments, with more facile CIU 
following deglycosylation validating the  destabilisation of NISTmAb RM structure 
as indicated by HDX-MS analysis. Both analytical measurements showed complete 
deglycosylation to have a larger effect on HOS relative to degalactosylation. These 
data promote the use of these Fc-glycan variants for validating analytical methods for 
the detection of HOS measurements of mAbs and also the suitability of HDX-MS and 
IMS-MS as valuable analytical methods within the biopharma toolbox.  
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Chapter 4 
Assessment of fast photochemical oxidation of proteins (FPOP) 
mass spectrometry for structural analysis of biotherapeutics 
4.1 Introduction  
MS protein footprinting methodologies have been shown to be effective tools for 
providing high resolution and highly sensitive protein HOS measurements, making 
them strong candidates for use in the analysis of protein biotherapeutics. Contrary to 
IMS-MS measurements which provide global information, both HDX-MS and FPOP-
MS provide localised structural insights into secondary and tertiary structures.  
FPOP-MS also offers its own unique advantages over alternative footprinting 
technologies, such as HDX-MS. For instance, the irreversible nature of the labelling, 
allows for the storage of labelled samples, the opportunity to use more traditional 
proteomic workflows that offer higher sensitivity, flexibility (including proteases, 
chromatography and fragmentation techniques) compared to more restricted HDX-
MS workflows. In addition samples can be reanalysed and even be subjected to 
sample clean up strategies such as solid phase extraction. These elements in particular 
open the potential of the technique towards more complex and physiologically 
relevant matrices. Indeed, FPOP-MS, in recent years, has been used to study protein-
protein interactions in-cell [189, 293] and within multi-organ systems, in vivo [294].   
This flexibility of analysis also makes quantitative downstream workflows, such as 
the use of isotopically labelled internal standards, more  applicable, opening the door 
to quantitative structural measurements. If this was achieved, this in turn could help 
bridge the traceability chain between the active folded form of a protein and the 
primary sequence of a protein. A feat that would be particularly advantageous in 
diagnostic areas such as neurodegeneration or amyloidosis, where intermediates of 
protein folding states, folded and unfolded state can be clinical biomarkers. Isolation 
and quantification of specific folding state can represent an important step in 
understanding the implications of this. So far no methods can quantify the structure 
of a protein and it is possible that FPOP-MS could bridge this gap. However, the 
technique is very much in its infancy, and though it shows potential, requires more 
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validation and standardisation of workflows in order to move from academia into an 
industrial setting to support the bio-therapeutic area. 
A “traditional” capillary flow FPOP labelling set up, involves the delivery of a sample 
through a silica capillary via a syringe pump and irradiation occurs through a 
transparent window on the capillary [182, 183, 186, 188] (Figure 72 a). This workflow 
is non-automated and at times a laborious manual task. It was hypothesised that in 
order to simplify the FPOP labelling experimental workflow, the irradiation of the 
sample could occur in a vessel, such as an Eppendorf, with the irradiation occurring 
by in a single shot of irradiation to the sample. This workflow would bypass the need 
to flow the sample via a capillary. Quenching would then occur via pipette and the 
mixture vortexed. It was also hypothesised that due to the “static” nature of the 
irradiation, the labelling would be more reproducible and easier to optimise. Figure 
72 b gives a schematic of the proposed novel labelling procedure. If effective it was 
thought that this “single-shot Eppendorf” FPOP labelling approach would be higher 
throughput and potentially more reproducible due to the simplified sample handling. 
To current knowledge, no instances of this type of FPOP labelling workflow appear 
to exist in the literature.   
In this Chapter, the applicability of FPOP-MS measurements to define protein 
structural changes was assessed using the rhGH model system developed in Chapter 
2. Two FPOP labelling strategies, capillary flow and a novel single-shot Eppendorf 
methodology,  first illustrated here, were optimised and implemented for the analysis 
of the rhGH model system at both the intact and peptidic level.  Two differing MS 
instrumental workflows were utilised for peptide level analysis and a semi quantitative 
approach applied. The results of the two labelling strategies were compared and 
discussed in order to validate the single shot Eppendorf approach. Data acquired here 
were also compared with HDX-MS and IMS-MS measurements, and the benefits and 
drawbacks of the measurements discussed. Finally, this data set provides further 
characterisation of the structural changes incurred by rhGH in the presence of zinc, 
further promoting the use of the RM and protocol for protein HOS measurements.  
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Figure 72. Schematic of two FPOP irradiation workflows. The standard a) capillary 
flow set up, introduces the sample (protein, scavenger and H2O2), into a laser 
beam path via a capillary flow. Exposure to the laser source occurs through an 
irradiation window, and the irradiated sample is subsequently quenched as it 
flows into the catalase containing quenching solution. Alternatively a novel 
labelling workflow, termed the b) single-shot Eppendorf set up, is proposed, in 
which irradiation occurs as a single shot directly into the sample-containing 
Eppendorf and the catalase quenching solution is pipetted into the sample 
immediately post-irradiation, by-passing the need for any capillary or flow 
system.  
 
4.2. Materials and Methods 
4.2.1. Materials  
All chemicals and standards were purchased as described in section 2, unless 
otherwise stated.  MS grade trypsin was purchased from Promega [Madison, USA]. 
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4.2.2. Protein sample preparation  
Prior to FPOP labelling,  7.2 µM rhGH and rhGH:Zn samples were prepared as 
described in section 2.2.1.1 to obtain rhGH control and rhGH:Zn 1:2, 1:10 and 1:20 
samples in 10 mM KPBS (pH 7.4). 28 µM protein samples were prepared using the 
appropriate scale up.  Protein solutions were left to equilibrate for 1 hour on the bench 
prior to FPOP labelling. 
4.2.3. FPOP irradiation source set up 
The FPOP laser set-up used [106, 186], consists of a Complex 50 Pro KrF excimer 
laser operating at a 248 nm wavelength (Coherent Inc, Ely, UK) and laser beam width 
of < 3 mm at point of irradiation. Two different experimental workflows for FPOP 
labelling were utilised, as described in Figure 72, one using a traditional capillary flow 
FPOP system in which the sample (protein + H202 + scavenger) is delivered into the 
irradiation path via a syringe pump and a silica capillary and the other, a single-shot 
Eppendorf workflow, in which a single shot of irradiation is delivered directly onto a 
sample held in an Eppendorf  and positioned directly into the laser beam.   
4.2.4. FPOP labelling procedures 
4.2.4.1 Capillary flow FPOP labelling procedure 
Immediately prior to irradiation, 0.93 µL 5.5% H202 (v/v) was added to 50 µL of 
protein  sample (7.2 µM rhGH) (final concentration H202 of 0.1% v/v) containing 350 
µM L-histidine in 10 mM KPBS (pH 7.4). The sample was then infused through a 
fused silica capillary (100 µm, i.d), at a flow rate of 20 µL/min. Hydroxyl radicals 
were generated by exposure of the sample (through an etched window) to irradiation 
from the laser operating at a 15 Hz frequency.  Flow rate and laser frequency were set 
so as to only irradiate the protein sample once.  Following laser irradiation, the 
capillary outflow was collected in an 1.5 mL Eppendorf tube containing 20 µL 
quenching solution (100 mM L-methionine, 1 µM catalase in 10 mM KPBS, pH 7.4), 
vortexed and immediately placed on ice. 
4.2.4.2 Single-shot Eppendorf FPOP labelling procedure 
Immediately prior to irradiation, 0.5 µL 0.5% H202 (v/v) was added to 10 µL of protein 
(28 µM rhGH) (final concentration H202 of 0.025% v/v) containing 175 µM L-
histidine in 10 mM KPBS (pH 7.4), in an Eppendorf. Hydroxyl radicals were 
generated by exposure of the sample to a single shot of irradiation from the laser 
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operating at a 1 Hz frequency.  Immediately ( ~ within 20s) following laser irradiation, 
the sample was combined with 5 µL quenching solution (100 mM L-methionine, 1 
µM catalase in 10 mM KPBS, pH 7.4), vortexed and immediately placed on ice.  
Post labelling samples (both FPOP strategies) were stored at -20 °C, awaiting intact 
LC-MS analysis or proteolysis followed by LC-MS/MS analysis.  
To account for any background oxidation that may occur due to low levels of hydroxyl 
radicals present in the H202 solution, control samples were handled in a similar 
fashion, in parallel to each irradiated sample, yet without exposure to laser irradiation.   
4.2.5 Tryptic Digestion 
4.2.5.1 Capillary flow FPOP labelled samples 
40 µL of each FPOP protein sample ( 5.76 µM rhGH) was added to 20 µL of digestion 
buffer (1 M urea, in 500 µM ammonium bicarbonate, pH 8, 0.6% SDS). Disulphide 
bond reduction was performed by addition of 2 µL of 50 mM TCEP (60 °C for 1 
hour), followed by alkylation using an addition of 1 µL of 200 mM methyl 
methanethiosulfonate (MMTS)  (RT for 10 min), before trypsin digestion (37 °C 
overnight) using a 1:50 (w/w) enzyme:protein ratio. The digested samples were frozen 
and stored at -20 °C until analysis.  
4.2.5.2 Single-shot Eppendorf FPOP labelled samples 
5 µL of each FPOP protein sample (11 µM rhGH) was added to 20 µL of digestion 
buffer (0.1 M urea, in 50 mM ammonium bicarbonate, pH 8, 0.6% SDS). Disulphide 
bond reduction was performed by addition of 1 µL of 10 mM DTT (60 °C for 1 hour, 
followed by alkylation by addition of 1 µL of 200 mM idoacetamide (IAM)  (RT for 
30 min in the dark), before trypsin digestion (37 °C overnight) using a 1:50 (w/w) 
enzyme:protein ratio.  The digested samples were frozen and stored at -20 °C until 
analysis.  
4.2.6 FPOP-MS analysis 
4.2.6.1 Intact LC-MS analysis 
The total extent of oxidation was measured at the intact protein level by LC-MS 
analysis. Chromatography was performed using an Acquity H-Class UHPLC system 
[Waters, Milford, USA]. 1.5 pmol of rhGH samples was injected onto an ACE C4 
column [2.1 x 150 mm,  3 µm, Hichrom Reading, U.K]. Chromatographic separation 
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was achieved using a 300 μL/min flow rate, 50 °C column temperature and a linear 
gradient starting from  80% A/ 20% B to 35% A/ 65% B over 6 minutes. Mobile 
phases consisted of aqueous, 0.5% formic acid (A) and 0.5% formic, CH3CN (B). 
Following chromatographic separation intact mass analysis was performed using a 
Xevo G2-XS Q-ToF instrument [Waters, Milford, USA] in positive ESI mode. 
Experimental settings were as follows: capillary voltage 3  kV, source temperature 
100 °C, sampling cone 100 V, source offset 100 V, desolvation temperature 500 °C.  
Data were acquired in MS only mode, using sensitivity mode and in the 300-3000 m/z 
range with a 0.2 sec scan time.  
4.2.6.2 Bottom up LC-MS/MS analysis 
For the localisation and quantification of oxidation modification sites, two differing 
LC-MS/MS instrumental workflows were utilised for peptide level analysis, one for 
each labelling workflows as described. 
4.2.6.2.1 Capillary flow FPOP labelled samples 
Chromatography was performed using an Acquity H-Class UHPLC system. 12 pmol 
of digested rhGH samples was injected onto an ACE Excel Super C18, (2 µm, 2.1 x 
100 mm i.d, both Hichrom Reading, U.K). Chromatographic separation was achieved 
using a 400 μL/min flow rate, 40 °C column temperature and a linear gradient starting 
from  97% A/ 3% B to 50% A/ 50% B over 19 minutes. Mobile phases consisted of 
aqueous, 0.1% formic acid (A) and 0.1% formic, CH3CN (B). 
Following chromatographic separation, MS/MS was performed using a Xevo G2-XS 
Q-ToF instrument in positive ESI mode. Experimental settings were as follows: 
capillary voltage 3  kV, source temperature 100 °C, sampling cone 90 V, source offset 
80 V, desolvation temperature 300 °C. For peptide identification and oxidation 
localisation, MS/MS experiments were performed in both DDA and MSE mode. DDA 
experiments using a Top 5 CID approach a 0.2 sec scan time, a threshold of 5000, a 4 
s dynamic exclusion window in the 50-2000 m/z range. MSE experiments were 
performed as described in section 2.2.3.2. To increase sensitivity and reproducibility, 
quantification measurement data were acquired in MS only mode, using sensitivity 
mode and in the 100-2000 m/z range with a 0.5 sec scan time. 
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4.2.6.2.2 Single-shot Eppendorf FPOP labelled samples 
Chromatography was performed using a Vanquish UHPLC system. 3.5 pmol of 
digested rhGH sample was injected onto an Acquity C18 BEH column [1.0 x 100 mm, 
1.8 µm, Waters, USA]. Chromatographic separation was achieved using a 30 μL/min 
flow rate, 50 °C column temperature and a linear gradient starting from  97% A/ 3% 
B to 60% A/ 40% B over 36 minutes. Mobile phases consisted of aqueous, 0.1% 
formic acid (A) and 0.1% formic, CH3CN (B). 
Following chromatographic separation intact mass analysis was performed on a Q-
Exactive Plus Orbitrap instrument, using a HESI-II probe source in positive mode. 
Source conditions included a 320 °C source temperature, 3 kV capillary voltage, 90 
S-lens RF, 25 a.u. sheath gas, 12 a.u. aux gas, 80 V in-source CID.  Data were acquired 
in MS/MS mode, using a Top 5 CID approach.  Full scan MS experiments: 120 ms 
maximum IT, 1E6 AGC target value, 140 K  resolution over a range of 350 – 2000 
m/z. MS/MS data were acquired in dd-MS2 mode, 80 ms maximum IT, 2E5 AGC 
target value, 3s dynamic exclusion window, 17.5 K  resolution and over a range of 
100 – 1500 m/z. 
4.2.7 Data analysis 
4.2.7.1 Oxidation quantification 
Deconvoluted mass distributions were extracted from intact protein LC-MS spectra, 
using MassLynx software v 4.1 and the MaxEnt 1 algorithm in the 18 – 25 kDa range, 
using a resolution of 0.1 Da/channel.  
Quantification of FPOP modifications was achieved by integration of modified and 
unmodified peaks generated from XIC using the following equation: 
Equation 35 
%𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑 =  
∑ 𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑𝑃𝑒𝑎𝑘
∑ 𝑢𝑛𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑 + ∑ 𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑𝐴𝑙𝑙 𝑃𝑒𝑎𝑘𝑠 
 
 
Each FPOP sample, i,  was normalised against any low levels of oxidation present in 
the irradiated control samples or introduced during sample handling using the 
following equation: 
 
- 193 - 
Equation 36 
%𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑𝑖𝑁𝑜𝑟𝑚 = (%𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑𝐹𝑃𝑂𝑃 −  %𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑𝐶𝑜𝑛𝑡𝑟𝑜𝑙)  
Samples were labelled in triplicate, and final %modified measurements expressed as 
a mean value for these normalised replicate measurements; 
Equation 37 
 
%𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑𝑁𝑜𝑟𝑚 =
1
𝑛
∑ %𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑𝑖𝑁𝑜𝑟𝑚
𝑛=3
𝑖
  
The uncertainty of these measurements was expressed as a combined uncertainty 
using the following; 
Equation 38 
𝑈 =  √
𝑆𝐷𝐹𝑃𝑂𝑃
2 + 𝑆𝐷𝐶𝑜𝑛𝑡𝑟𝑜𝑙
2
2
  
 
To determine statistically significant changes two tailed t-tests were applied, p values 
< 0.05 were determined to be statistically significant. 
4.2.7.2 Peptide oxidation identification 
Peptides were identified from Q-ToF DDA and Orbitrap dd-MS2 experiments using 
PEAKS 8.5 software [Bioinformatics Solutions Inc., Waterloo, ON, Canada], 
searching against a database containing rhGH, catalase and trypsin sequences 
including a reverse database, a precursor mass error of ± 10 ppm and a fragment error 
of 0.1 Da. Similarly peptides were identified from Q-ToF MSE experiments using 
PLGS v 3.02, using the processing parameters listed in Table A-24.   
Mass additions of + 15.99, + 31.98 and + 13.98 Da were searched to identify modified 
peptides [191]. Quantification of FPOP modifications was achieved by integration of 
modified and unmodified peaks generated from XICs using Equation 35 and Equation 
36. Modified peaks with RTs indistinguishable from that of the unmodified peaks 
were excluded from quantification due to the inability to distinguish their presence as 
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a result of in-source oxidation of the unmodified peptide and not as a direct result of 
FPOP modifications. 
XICs were generated by extracting the m/z of the base peak of each peptide isotope 
distribution, using Xcalibur software [v4.0.27.19; ThermoFisher, Bremen, Germany] 
and QuanLynx software [MassLynx v4.1; Waters, Milford, USA] for Orbitrap and Q-
ToF data respectively.  
4.3 Results and discussion 
Both the capillary flow and single-shot Eppendorf labelling strategies and MS 
workflows have been individually optimised using rhGH and utilised for the analysis 
of rhGH model system. The repeatability and sensitivity of each strategy were then 
critically assessed and results compared. FPOP-MS measurements were then used to 
provide structural insights into changes in protein HOS of the rhGH model system 
and compared with insights gained from HDX-MS and IMS-MS based measurements 
from this thesis. 
4.3.1 Capillary flow FPOP labelling 
Oxidative conditions using the capillary flow set up were first optimised, as was a 
MS-based workflow, using a high resolution Q-ToF instrument, for the peptide level 
analysis of FPOP labelled samples. This workflow was then applied to identify and 
characterise peptide oxidation sites, before finally being applied to identify structural 
differences and provide structural insights into the rhGH model system.  
4.3.1.1 Optimisation of oxidative conditions 
Using the capillary flow FPOP set-up, samples of rhGH were labelled in the presence 
of two different scavenging agents, 17.5 mM glutamine and 350 µM histamine, at 
three different H202 % concentrations; 0.02, 0.05 and 0.1%. Intact LC-MS analysis 
was used to confirm the presence of any oxidative species. Figure 73 b-d and Figure 
74 b-d, display the rhGH base peak spectra of irradiated rhGH under increasing 
concentrations of H202, peaks are labelled according to the number of oxygen 
molecules incorporated (~ +15.99 Da). At both scavenger conditions, increased 
oxidation was observed with increased levels of H202.  Glutamine and histidine 
scavenger solutions, in the presence of 0.1% H202, resulted in maximum oxygen 
incorporation of 2 and 5 oxygen molecules respectively. The increased oxidation rates 
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observed for samples incubated with the histidine scavenger, is consistent with the 
higher reaction rate constant reported for hydroxyl radicals in the presence of 
glutamine compared to the histidine (~ 5.6 times calculated using reaction rates 
constants as measured by ~ Xu and Chance[191]), facilitating lower oxidation to the 
protein sample.  
A Poisson distribution was observed for oxidation in all irradiated samples, indicating 
the absence of unwanted secondary oxidation reaction, implying oxidation levels 
observed should be indicative of the fully folded protein state of rhGH [196]. This 
reiterates that hydroxyl lifetime in the presence of histidine and glutamine scavengers 
is approximately ~ 1µs and faster than that of protein unfolding. It is beneficial to 
maximise the amount of oxidative labelling that occurs during FPOP labelling, whilst 
avoiding these secondary oxidation events, so as to increase the sensitivity of LC-
MS/MS analysis and maximise the number of amino acid residues that can act as 
potential reporter molecules towards structural changes. In light of this, the optimised 
FPOP labelling conditions were selected as 350 µM histidine, 0.1% H202 and utilised 
for all further samples labelled using capillary flow FPOP experiments . 
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Figure 73. Intact protein LC-MS spectra of the rhGH +13 base peak for FPOP samples 
in presence of 17.5 mM glutamine scavenger. Spectra represent an a) irradiated 
control sample and irradiated rhGH in varying concentrations of H202, b) 0.02% 
c) 0.05% and d) 0.1%.  Peaks corresponding to unlabelled protein sample are 
labelled 0 and oxidated peaks are labelled according to the number of oxygen 
molecules incorporated (1,2). 
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Figure 74. Intact protein LC-MS spectra of the rhGH +13 base peak from FPOP 
samples in presence of  350 µM histidine scavenger. Spectra represent an a) 
irradiated control sample and irradiated rhGH in varying concentrations of H202, 
b) 0.02% c) 0.05% and d) 0.1%.  Peaks corresponding to unlabelled protein 
sample are labelled 0 and oxidated peaks are labelled according to the number 
of oxygen molecules incorporated (1- 5). 
4.3.1.2 Optimisation of peptide oxidation analysis 
In order to obtain localised insights to FPOP-MS measurements, analysis of the 
labelled samples must occur at the peptide level, via a proteolysis step. Before 
application to the rhGH model system, oxidised rhGH samples were subjected to 
tryptic digestion and LC-MS/MS analysis, to identify and localise oxidation sites. 
4.3.1.2.1 LC-MS/MS method development [Xevo Q-ToF]  
In order to optimise the LC-MS/MS method for the bottom-up FPOP quantification 
of the rhGH and rhGH:Zn samples, a range of LC-MS/MS conditions was screened 
(Table 18) in which flow rate, desolvation temperature, elution gradient and scan 
speed were varied. Triplicate injections were made of tryptic digests of a capillary 
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FPOP labelled rhGH samples. The repeatability was assessed in terms of the RSDs of 
the extracted oxidative peak area (Figure 75) and RT (Figure 76) for four oxidated 
tryptic peptides, T2*, T4*, T11-1* and T11-2* (Table 19).  
So as to best cover the analytical space across the range of peptides in terms of 
repeatability, conditions ii, Table 18, were selected for further bottom up analysis of 
capillary flow FPOP labelled samples.  
Table 18. Range of LC-MS conditions used to screen for optimised method for bottom 
up analysis of FPOP samples 
Condition  
LC flow rate 
(µL/min) 
Gradient 
Desolvation Temp 
(°C) 
Scan 
speed 
i 300 3 - 50% 250 0.6 sec 
ii 400 3 - 50% 250 0.7 sec 
iii 400 3 - 45% 250 0.7 sec 
iv 400 3 - 50% 300 0.7 sec 
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Figure 75. XIC repeatability of four oxidised rhGH tryptic peptides using a range of 
experimental LC-MS conditions (i-iv, Table 18).  
 
Figure 76. RT repeatability of four oxidised rhGH tryptic peptides using a range of 
experimental LC-MS conditions (i-iv, Table 18).   
 
0%
5%
10%
15%
20%
25%
30%
i ii iii iv
R
el
at
iv
e 
st
an
d
ar
d
 d
ev
ia
ti
o
n
 (
%
)
LC-MS experimental conditions
Repeatability of extracted peak areas
T2* T4* T11-1* T11-2*
0.0%
0.5%
1.0%
1.5%
i ii iii iv
R
el
at
iv
e 
st
an
d
ar
d
 d
ev
ia
ti
o
n
 (
%
)
LC-MS experimental conditions
Repeatability of retention time
T2* T4* T11-1* T11-2*
- 200 - 
4.3.1.2.2 Identification and residue localisation of peptide oxidation  
To identify and localise the oxidation sites, tryptic digests of triplicate FPOP-labelled 
rhGH samples were analysed using the optimised LC-MS/MS Xevo Q-ToF method. 
A combined approach of MSE and DDA analysis was used for peptide identification 
of the tryptic digests and sequence coverage rates were in the range of ~ 95.3% and ~ 
83% for the two MS/MS methodologies, respectively.  
In total, ten oxidatively modified tryptic peptides were identified reproducibly across 
all the samples, as summarised in Table 19. A list of unmodified peptides produced 
from an in-silico digest of rhGH is found in the appendices, Table A-27. MS/MS 
spectra were manually examined to localise oxidation to amino acid resolution, and 
in total five different amino acid residues were oxidised, correlating with a mixture of 
oxidatively labelled populations in the range of 1-5 oxidation sites  revealed by the 
global analysis of FPOP labelled rhGH (Figure 74 d). These five oxidated residues 
account for ~ 18% of  the side chains within the sequence that are the most reactive 
to hydroxyl radical species ( Cys, Trp, Tyr, Met, Phe and His) [191].  
Two different oxidative species corresponding to the formation of a carbonyl moiety 
(~ +13.98 Da) and addition of an oxygen atom (~ +15.99 Da) were observed for the 
T1* peptide. Analysis of MS/MS spectra resolved these modifications to the first two 
N- terminal amino acid residues, Phe-1 and Pro-2 to give the oxygen and carbonyl 
products respectively. The coexistence of multiple forms of oxidative species for the 
T1 peptide is testament to the presence of multiple oxidisable residues in the peptide 
sequence (such as Phe and Pro) giving rise to singly modified peptide species which 
have been modified at different residues.    
There is evidence of several isobaric peaks corresponding to the XIC spectra of 
+15.99 Da modifications of several peptides, T1, T4 and T11 across the rhGH 
sequence. Several modified peaks exist for the T1 peptide, as illustrated in Figure 77, 
by the XIC for the 473.77 m/z species, correlating with a +15.99 Da modification of 
the T1 peptide. Closer inspection of the mass spectra underneath the chromatographic 
peaks T*-1, T*-2, T*-3 (Figure 77 a) revealed three isobaric peaks (RT 9.37, 9.74, 
10.06) that fulfil the correct isotope pattern and charge state for a z =2 ion, yet result 
in different RTs. MS/MS spectra revealed identical fragment spectra, consistent with 
+15.99 Da modification of the Phe-1 residue. These data suggest the presence of 
structural isomers of the oxidated T1*(+15.99) species, occurring due to hydroxyl 
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radical oxidation at the meta-, ortho- and para-positions of the benzene ring within the 
Phe-residue (Scheme 1) [110, 191, 202, 295]. It has been documented that for RP-
UPLC, the elution order of oxidised phenylalanine, both as free amino acids and as 
residues within a peptide chain, occurs in the order of para < meta < ortho, therefore 
these assignments have been made based on elution time (Table 19) [102, 295].  
Similarly three structural isomers were observed for the oxidation of the Phe-25 
residue in T4*-[1-3], as identified by identical MS/MS spectra for each corresponding 
peak, with para-, meta- and ortho- positions assigned based on elution order (Figure 
78).   
Finally inspection of the MS/MS spectra of the two isobaric T11* peaks, showed 
oxidation of the Met-125 residue for both sets of spectra (Figure 79 a).  Unlike 
aromatic side chains, methionine residues lack a ring structure and hence the 
possibility of para-, meta- and ortho- oxidative products is removed. Hydroxyl 
mediated oxidation of methionine side chain occurs directly at the sulphur atom [191, 
295]. The presence of multiple oxidated forms of Met-125 could suggest that there is 
some structural flexibility along the hydrocarbon chain which could allow multiple 
conformations and hence ultimately multiple hydroxyl radical oxidative targets for 
this methionine group. Oxidation in this instance could indeed suggest not only 
surface accessibility at this residue but also the capacity for conformational flexibility.   
The existence of these structural isomers of oxidative products could offer the 
possibility of sub-residue interpretation of oxidative data [110].   
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Table 19. Oxidatively modified  tryptic peptides (*) identified in bottom-up analysis 
of capillary flow FPOP labelled rhGH, amino acid oxidation site is indicated as 
identified by MS/MS fragment data. Due to isobaric fragment spectra, site 
specific oxidation at the meta-, ortho- and para-positions of the benzene ring 
within the Phe-residue have been assigned based on relative elution order [102, 
295].  
Peptide 
ID 
Residues Sequence 
Modification 
mass (Da) 
Oxidation 
site  
T1* 1-8 FPTIPLSR   + 13.98 Pro-2 
T1*-1 1-8 FPTIPLSR   + 15.99 Phe-1-para 
T1*-2 1-8 FPTIPLSR   + 15.99 Phe-1-ortho 
T1*-3 1-8 FPTIPLSR   + 15.99 Phe-1-meta 
T2* 9-16 LFDNAMLR  + 15.99 Met-14 
T4*-1 20-38 
LHQLAFDTYQEFEE
AYIPK 
 + 15.99 
Phe-25-para 
T4*-2 20-38 
LHQLAFDTYQEFEE
AYIPK 
 + 15.99 
Phe-25-ortho 
T4*-3 20-38 
LHQLAFDTYQEFEE
AYIPK 
 + 15.99 
Phe-25-meta 
T11*-1 116-127 DLEEGIQTLMGR  + 15.99 Met-125 
T11*-2 116-127 DLEEGIQTLMGR  + 15.99 Met-125 
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Scheme 1. Structural isomers arising from the hydroxyl-radical mediated oxidation of 
phenylalanine.  
- 204 - 
 
Figure 77. FPOP modification of the T1 rhGH peptide. XIC of the multiple +15.99 
Da modified forms (a), the single +13.98 Da modified form (b) and the 
unmodified form (c) of the peptide are illustrated, d) analysis of MS/MS spectra 
of the T1*-1, T1*-2 and T1*-3 were identical and localised the modification to 
the Phe-1 residue for all three, modification was thought to have occurred at 
para-, meta- and ortho- positions of the peaks, respectively, based on RP-UPLC 
elution times. 
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Figure 78. FPOP modification of the T4 rhGH peptide. XIC of the multiple +15.99 
Da modified forms (a) and the unmodified form (b) of the peptide are illustrated, 
c) analysis of MS/MS spectra of the T4*-1, T4*-2 and T4*-3 were identical and 
localised the modification to the Phe-25 residue for all three, modification was 
thought to have occurred at para-, meta- and ortho- positions of the peaks 
respectively, based on RP-UPLC elution times.  
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Figure 79. FPOP modification of the T11 rhGH peptide. XIC of the multiple +15.99 
Da modified forms (a) and the unmodified form (b) of the peptide are illustrated, 
c) analyses of MS/MS spectra of the T11*-1 and T11*-2 were identical and 
localised the modification to the Met-125 residue for both, illustrating two 
structural isomers of the modified peptide.  
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4.3.1.3 FPOP-MS measurements to identify HOS changes induced by zinc  
The optimised oxidative conditions and LC-MS/MS workflows were then used to 
probe the global conformational changes of the rhGH model system.   
4.3.1.3.1 Quantification of global oxidation 
Samples of rhGH and rhGH:Zn at three different ratios, 1:2, 1:10 and 1:20, were 
oxidatively labelled in triplicate using the optimised FPOP labelling conditions for 
the capillary flow set up. Intact protein LC-MS analysis was performed to probe for 
differences in global oxidation levels. Deconvolution of the resulting mass spectra 
revealed up to five oxidation states (~ +16, +32…. Da) across all samples, and the 
%modifiedNORM for each oxidative peak combined to give a total global oxidation 
measurement for each sample. Figure 80, illustrates the measured average total global 
modification levels, oxidation levels were in the range of 58-57% and indiscriminate 
for rhGH, rhGH:Zn 1:2 and 1:10 samples, indicating a consistent globular structure 
across these samples. Total global oxidation however was lower for rhGH:Zn 1:20 
samples, in the range of ~ 47%, suggesting the global structure of the rhGH-Zn 
complex to be a less solvent accessible area,  and an overall change in global 
conformation relative to the rhGH. A shift towards global compaction was alluded to 
by IMS-MS measurements in Chapter  2.  
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Figure 80. Total global modification (%) as measured from the deconvoluted mass 
spectra of FPOP labelled samples. Measurements are expressed as average 
values and error bars represent the standard deviation (n=3).  
4.3.1.3.2 Quantification of peptide oxidation 
To probe for global conformational changes between rhGH and rhGH:Zn 1:20  as 
indicated by intact protein analysis of capillary flow FPOP labelled samples, samples 
were subjected to tryptic digestion followed by bottom-up LC-MS/MS analysis and 
relative quantification. FPOP quantification was performed for capillary flow FPOP 
labelled rhGH and rhGH:Zn 1:20 samples, expressed as %modificationNORM, and 
averaged across triplicate labelled samples. 
Analysis of a triplicate injection of a single tryptic digest of a rhGH FPOP labelled 
sample was shown to be repeatable with standard deviations in the range of 0.1-0.9% 
across all ten oxidated peptide species (Table 19). Measured peptide modification 
values for each rhGH sample type are displayed in Figure 81 a. Those residues (or 
sub-level residues) that demonstrated significant changes (p < 0.05) or indeed 
similarity in %modification as a result of the presence of zinc are summarised in Table 
20. 
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Comparison of oxidation measurements across the two FPOP sample types  revealed 
differences in oxidation measurements for six out of the ten oxidated peptide species,  
corresponding to T1*, T1*-3, T4*-1, T4*-3 T11*-1 and T11*-2 peptides,  and 
specifically residues Phe-1-meta Pro-2, Phe-25-para and Phe-25-ortho and Met-125 
(Table 20). All six of these peptides demonstrated higher oxidation levels for the 
rhGH:Zn 1:20 sample relative to the control, suggesting a trend of increased surface 
accessibility at these residues upon zinc binding and a change in protein HOS for 
rhGH due to the presence of zinc at this ratio. These data are consistent with the 
general trend of increased oxidation rates observed in HDX-MS measurements in the 
presence of zinc, Table 9.   
The attributed positioning of the structural isomers for T1*-[1-3] and T4*-[1-3] + 
15.99 Da species as a result of para-, meta- and ortho- ring oxidative addition are 
highlighted in Figure 82.  For the  T1* +15.99 species, the oxidation modification is 
increased only for Phe-1-ortho site in the zinc containing sample, as the case for the 
Pro-2 residue. This suggests that this region between the two side chain sites becomes 
more exposed due to the presence of zinc. The unaffected modification extent of the 
Phe-1 meta- and para- sites however  suggested that the  positioning of the rest of the 
side chain of Phe-1, appears to be consistent in absence and presence of zinc.  This 
combined with the  relatively small change in %modification for these oxidation sites, 
is consistent with a small shift in structure and not a large structural rearrangement. 
Similarly oxidation rates increase for the Phe-25 side chain para- and ortho-sites 
(Figure 81 a and Figure 82 b), located in helix A of rhGH structure, signifying a more 
solvent exposed residue due to the presence of zinc. This residue is also localised near 
the residues involved in zinc binding of His-18, His-21 and Glu-174, though no 
oxidation of these residues were identified. In addition, increased oxidation rates were 
observed for both of the structural isomers of the oxidised Met-125 residue, located 
in helix C of rhGH structure (Figure 81 b). Modification levels for the Met-125 residue 
appear to be the most affected due to the presence of zinc, a site not located directly 
in the zinc binding sites, suggesting a long range structural change as a result of the 
presence and binding of zinc.  
Of those modified residues identified, the only residue in which oxidation levels were 
unchanged due to the presence of zinc, was the Met-14 residue, demonstrating 
structural equivalence across the samples at this residue. Overall comparison of 
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capillary flow FPOP oxidation between rhGH and rhGH:Zn 1:20 suggest small and 
localised changes in structure due to the presence of zinc occurring at the N-terminus 
and helices A and C.  
Table 20. Observed oxidations of rhGH labelled by capillary flow FPOP-MS 
experiments, sub-residue level information is listed where identified. Increases 
in oxidation levels for rhGH:Zn FPOP labelled samples relative to rhGH are 
indicated by (+), a blank input represents no relative change.  
 
The total extent of modification was generally low across all peptides and sample 
type, ~  > 25%, this combined with the low number of oxidised residues suggests both 
forms of rhGH have a protein HOS which results in a  relatively low SASA, consistent 
with the high levels of structure observed by the HDX-MS analysis (Chapter 2, section 
2.3.1.3).   
Amino Acid 
 
Relative Oxidation Change 
Type Residue Number Sub level 
 
rhGH:Zn 1:20 
Phe 1 - para 
 
 
Phe 1 - meta 
 
 
Phe 1 - ortho 
 
+ 
Pro 2 
  
+ 
Met 14    
Phe 25 - para 
 
+ 
Phe 25 - meta 
 
 
Phe 25 - ortho 
 
+ 
Met 125 isomer 1 
 
+ 
Met 125 isomer 2 
 
+ 
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Figure 81 a) Peptide level quantification of FPOP-MS measurements of rhGH (light 
blue) and rhGH:Zn 1:20 (dark blue), as labelled using capillary flow FPOP set 
up. Error bars represent the calculated combined uncertainty. Peptides 
demonstrating a significant change in %modification between the rhGH and Zn 
bound rhGH are indicated using * . b)  The XRC structure of  rhGH:Zn complex, 
in two orientations rotated around  the line (----), with the five modified side 
chain residues identified highlighted, residues demonstrating increased 
%modification due to the presence of zinc are highlighted in red (Phe-1, Pro-2, 
Phe-25 and Met-125) with Met14 indicated in blue where %modification levels 
were consistent across samples. PDB: 1BP3 [208].  
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Figure 82. Representation of the para-, meta- and ortho- positions (represented as p-, 
m- and o-)  of residues a) Phe-1 and b) Phe-25 (highlighted in green), identified 
as giving rise to the three isobaric oxidative species observed for the T1*-[1-3] 
and T4*-[1-3] modified peptides. Increased oxidation rates were observed for 
T1*-3, T4*-1 and T4*-3 sites due to the presence of zinc.  PDB: 1BP3[208].   
 
4.3.2 Single-shot Eppendorf FPOP labelling 
During the capillary flow FPOP labelling for the rhGH samples, blockages of the 
capillary during flow of rhGH samples often occurred, potentially due to aggregation 
of the protein samples in the flow system.  In these instances, re-preparation and re-
labelling of the samples were required as a result of sample loss and to ensure 
reproducibility of measurements. It was hoped that the development and optimisation 
of a single-shot Eppendorf approach, such as the one described here (Figure 72), 
would circumvent the need for a capillary, simplifying and increasing the 
reproducibility of the FPOP labelling procedure for rhGH.  
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To explore this as a potential FPOP labelling methodology, oxidation conditions were 
first optimised for the single shot Eppendorf strategy, as were MS-based workflows 
using an alternative high resolution Orbitrap instrument to that used in section 
4.3.1.2.1. Peptide level analysis was then used to identify and localise modifications, 
before finally applying the optimised workflow to gain structural insights of the rhGH 
model system. Final measurements were compared then with capillary flow 
measurements, IMS-MS and HDX-MS measurements.  
4.3.2.1 Optimisation of oxidative conditions 
It was anticipated that the laser penetration into the sample would likely be minimal 
leading to irradiation occurring only to those proteins close to the surface, (Figure 72 
b). This would result in an unmodified portion of proteins such as occurs with the 
exclusion volume in traditional capillary flow FPOP experiments, typically used to 
avoid unwarranted secondary oxidation events. Yet, it was hypothesised that due to 
the tapering shape of the Eppendorf tube and resulting bias of sample volume towards 
the irradiation source, this unmodified portion would not be excessive. However, so 
as to ensure sufficient oxidation for detection, the overall sample volume (protein + 
scavenger + H202) was reduced to 10 µL in order to compensate for anticipated 
reduction of laser exposure and in light of this protein sample concentration was also 
increased ~ 28 µM.   
As for the capillary flow FPOP set up, scavenger concentration and H202 were 
optimised to ensure sufficient  labelling. Figure 83 d demonstrates the optimised 
FPOP conditions of rhGH irradiated in the presence of 175 µM histidine scavenger 
and 0.025% H202, where up to four global modifications are observed.  Oxidation 
appears slightly less in the single-shot Eppendorf FPOP experiment compared to the 
capillary ( four vs five global modifications respectively). This could be as a result of 
an increased exclusion volume due to laser penetration, as discussed previously, or as 
a result of the increased relevant concentration of rhGH decreasing the effective ratio 
of rhGH molecules to hydroxyl radicals.   
The single-shot Eppendorf labelling procedure however was much faster ( ~ 30 sec in 
total including quenching steps) and more straight forward compared to that of the 
capillary flow ( ~ 3-4 min in total including quenching steps) with no issues of 
capillary blockages.  
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Figure 83. Intact protein LC-MS spectra of the rhGH +13 base peak of FPOP samples 
in presence of 0.25% H202. Spectra represent an irradiated rhGH in varying 
histidine scavenger concentrations of  a) 100 mM, b) 10 mM, c) 2.5 mM and d) 
175 µM .  Peaks corresponding to unlabelled protein sample are labelled 0 and 
oxidated peaks are labelled according to the number of oxygen molecules 
incorporated (1-4).  
 
4.3.2.2 Optimisation of peptide oxidation analysis 
4.3.2.2.1 LC-MS/MS method development [Q-Exactive plus]  
In hopes of higher sensitivity and greater mass accuracy, bottom-up LC-MS/MS was 
moved to an Q-Exactive plus Orbitrap MS instrument. Chromatography flow rates 
were reduced to 30 µL/min and experimental conditions, such as maximum injection 
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time and dynamic exclusion, optimised to maximise sensitivity towards low abundant 
oxidative species [110]. 
Previous quantification research performed on this instrument within LGC, has 
indicated that in order to facilitate the accurate relative quantification of low abundant  
m/z species, it must be established that the responses of both the high and low 
abundant ion species are within the linear range of the MS detector. To do this, 
increasing injection volumes, 2, 4, 6, 8, 10 µL of a tryptic digest of FPOP labelled 
rhGH were made in duplicate and analysed by LC-MS/MS. XIC peak areas were 
abstracted for the three unmodified peptides T2, T4 and T11 at each injection volume. 
Figure 84 illustrates the linearity plots of injection volume vs signal intensity for the 
three unmodified peptides in their most abundant charge states. The T11 peptide 
appears linear across the whole range ( R = 0.9969), however the T2 and T4 peptides 
appear to deviate in terms of linearity and reduced reproducibility at higher injection 
volumes,  > 6 µL, due to increased signal relative to T11 peptide ( ~ 108 vs 107 ) . In 
light of this injection volumes of 4 µL, corresponding to 1.5 pmol of rhGH, were 
selected for further FPOP quantification experiments.   
Finally, triplicate injections of a single rhGH FPOP labelled digest were made using 
the 4 µL optimised injection volume and analysis of oxidated peptides T2*, T4*-1, 
T11*-1 and T11*-2 performed. The repeatability of LC-MS/MS method was assessed 
in terms of %modifiedNORM and RT (Table 21).  
Table 21. Repeatability of LC-Orbitrap-MS/MS method, expressed as the relative 
standard deviation of %modifiedNORM and RT measurements of  series of oxidised 
peptides. Data produced from repeat injections of a single-shot Eppendorf FPOP 
labelled rhGH sample (n=3) 
 Modified peptide ID 
 
T2* T4*-1 T11*-1 T11*-2 
%modifiedNORM 2.1% 3.7% 5.3% 3.8% 
RT -0.4% -0.1% 0.2% 0.0% 
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Figure 84. Linearity of  the LC-Orbitrap MS/MS method. XIC peak areas of the T2, T4 and T11 peptides were extracted from a series of injection 
volumes ( 2- 10 µL) from a tryptic digest of rhGH FPOP labelled sample, injections were made in duplicate.
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4.3.2.2.2 Identification and residue localisation of peptide oxidation  
All the modified peptides and modification sites identified in capillary flow FPOP 
labelled digests, Table 20, were verified for single-shot Eppendorf labelled 
experiments. The lower flow rates used for the Orbitrap LC-MS/MS analysis ~ 30 
µL/min, relative to 400 µL/min used in section 4.3.1, appeared to give gains in 
sensitivity, with increased sequence coverage across all rhGH tryptic digests in the 
range of 98-100%. 
Two additional modification sites were also observed (Table 22), giving a total of 
twelve FPOP modified peptides and seven modified amino acid residues. Analysis of 
these modification species revealed a fourth additional isobaric +15.99 Da T4* 
modified peak, termed T4*-4.  Analysis of MS/MS spectra localised the modification 
site to the His-21 side chain (Figure 85).  The later elution of the histidine modified 
peptide ( ~ RT 41.95) relative to the unmodified T4 peptide ( ~ RT 40.25) is consistent 
with elution profiles observed previously for peptides with FPOP oxidated histidine 
[102].  
Furthermore, a +31.99 Da oxidation was observed for the C-terminal T21 peptide, and 
the oxidation site was localised to the Cys-189 residue (Figure 86).  The unmodified 
species T21 peptide was observed mainly in (+57.02), occurring at Cys189, as result 
of IAM alkylating agent used during tryptic digestion. Both this carbamidomethylated 
form of the unmodified T21, in addition to the XIC of non-alkylated T21 form, which 
was present in low abundance, was used for subsequent quantification of the T21*.  
Table 22. Unique oxidatively modified (*) tryptic peptides identified in bottom-up 
analysis of single-shot Eppendorf FPOP labelled rhGH, amino acid oxidation 
site is indicated as identified by MS/MS fragment data.  
Peptide 
ID 
Residues Sequence 
Modification 
mass (Da) 
Oxidatio
n site  
T4*-4 20-38 
LHQLAFDTYQEFEE
AYIPK 
 + 15.99 
His21 
T21* 184-191 SVEGSCGF  + 31.99 Cys189 
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Figure 85. FPOP modification of the T4 rhGH peptide. XIC of the multiple +15.99 
Da modified forms (a) and the unmodified form (b) of the peptide are illustrated, 
c) the TIC of bottom up analysis d) analysis of T4*-4 MS/MS spectra localised 
the modification to the H21 residue. T4*-[1-3] correspond to oxidation at Phe-
25 residue occurring  at para-, meta- and ortho- positions of the peaks 
respectively.  
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Figure 86. FPOP modification of the T21 rhGH peptide. XIC of the +31.99 Da 
modified forms (a) and the carbamidomethylated, +57.02 Da alkylated form of 
the unmodified form, and the unmodified form of the peptide are illustrated, d) 
analysis of T21* MS/MS spectra localised the modification to the Cys-189 
residue.  
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4.3.2.3 FPOP-MS measurements to identify HOS changes induced by zinc 
Samples of rhGH and rhGH:Zn at ratios of 1:2, 1:10 and 1:20, were labelled in 
triplicate using the single-shot Eppendorf FPOP labelling workflow, before being 
immediately frozen, defrosted and then digested using trypsin to allow for bottom-up 
analysis of FPOP %modification.  
4.3.2.3.1 Quantification of peptide oxidation  
Following the identification and localisation of the all twelve oxidated tryptic peptides 
and seven modified residues as listed in Table 19 and Table 22, relative FPOP 
quantification was performed in triplicate for the digests of rhGH and rhGH:Zn (1:2, 
1:10 and 1:20) single shot Eppendorf FPOP labelled samples. Data treatment and 
normalisation against an irradiated control was performed as described previously.   
Analysis of a triplicate injection of a single rhGH FPOP labelled sample revealed LC-
MS/MS quantification was shown to be repeatable with standard deviations in the 
range of 0.1-0.9% across all twelve oxidated peptide species (% modification un-
normalised against irradiated control). 
Measured peptide modification values for each rhGH sample type are displayed in 
Figure 87. For each peptide, relative comparisons were made between %modification 
measurements of rhGH and each of the three rhGH:Zn ratios, to identify similarity or 
potential changes in protein HOS.  Those residues (or sub-level residues) that 
demonstrated significant changes (p < 0.05) or indeed similarity in %modification as 
a result of the presence of zinc are summarised in Table 23. 
All three rhGH:Zn FPOP labelled samples displayed increased oxidation rates for Pro-
2 and Phe25-para and meta residue sites, indicating structural changes in the form of 
increased surface accessibility for the both N-terminal region and helix A 
respectively. These observations were consistent with measurements from capillary 
flow FPOP-MS experiments for rhGH:Zn 1:20.  
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Figure 87. Peptide level quantification of FPOP-MS measurement of rhGH (light blue) and rhGH:Zn (1:2, 1:10 and 1:20)  (increasingly darker blue), 
as labelled using single shot Eppendorf FPOP set up. Error bars represent combined uncertainty between triplicate irradiated and non-irradiated 
controls. Peptides demonstrating a significant change in %modification (p < 0.05) between the rhGH and Zn bound rhGH at each ratio are 
indicated using  (*).                                                                                                                                                    
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For samples incubated with rhGH:Zn ratios  of 1:10 and 1:20, increased oxidation was 
also observed for His-21 and Phe-25-ortho side chains, both located in helix A, further 
promoting the idea of structural changes in this region, as indicated by capillary flow 
FPOP-MS experiments. It is of note, that the His-21 is indirectly involved  in Zn2+ 
binding, via the stabilisation of the Glu-174 side chain  which bonds directly to Zn2+ 
[208], as illustrated in Figure 88 b.  Increased oxidation of this side chain in the 
presence of zinc is indicative of an increase in solvent accessibility due to the presence 
of the ligand, not reduction as may be expected for ligand binding areas. However, 
the stabilisation of the hydrogen bond between His-21 and Glu-174, appears to have 
increased the solvent exposure of the C2 site of the imidazole ring making it more 
susceptible towards hydroxyl radical attack. This would explain the increased 
modification at this site [295], Figure 88 b.  Oxidation of this His-21 side chain was 
not observed/detected in capillary flow FPOP-MS experiments, demonstrating an 
increased sensitivity towards structural changes of this model system using this 
alternative workflow.   
Table 23. Observed oxidations of rhGH labelled by single shot Eppendorf FPOP, sub-
residue level information is listed where identified. Significant increases ( p < 0.05) 
in oxidation levels for rhGH:Zn FPOP labelled samples relative to rhGH are indicated 
by (+),  no significant change is indicated by blank input.  
Amino Acid 
 
Relative Oxidation Change 
Type Number Sub level 
 
rhGH:Zn 1:2 rhGH:Zn 1:10 rhGH:Zn 1:20 
Phe 1  - para 
 
   
Phe 1  - meta 
 
   
Phe 1  - ortho 
 
   
Pro 2 
  
+ + + 
Met 14      
His 21 
   
+ + 
Phe 25  - para 
 
+ + + 
Phe 25  - meta 
 
+ + + 
Phe 25  - ortho 
  
+ + 
Met 125 isomer 1 
  
+ 
 
Met 125 isomer 2 
 
   
Cys 189 
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Finally, increased oxidation is also observed for the T11*-1 isomer of Met-125 
residue, only in rhGH:Zn 1:10 samples, suggesting an associated long range 
conformational change. Though a trend in increased oxidation is also observed for 
1:20 samples, there is increased variability of measurements for the 1:20 sample 
relative to those of other rhGH samples (Figure 87 a), therefore it this is deemed 
insignificant.  
For the residues,  Pro-2 and Phe-25, increased oxidation is observed for all zinc 
containing samples relative to rhGH, however the extent of oxidation appears to be 
unaffected by the relative ratio of zinc, suggesting surface accessibility at these sites 
to be equivalent in the presence of zinc.  
Similarly structures at residues Phe-1, Met-14 and Cys-189 appear to be equivalent 
across all samples.  As with previous characterisation of the rhGH:Zn model system, 
presented in Chapter 2, there is a trend of increased structural changes at higher zinc 
concentration, in the form of increased number of FPOP modification sites showing 
significant changes, i.e. three vs six for rhGH:Zn 1:2 and 1:10 ratios respectively, 
relative to rhGH control, suggesting the structural change of the model system is 
proportional to the amount of zinc present. 
The extent of modification was generally low across all peptides and sample type, 
with a mean total %modification across all peptides in the range of ~  > 14%, as with 
capillary flow FPOP-MS measurements suggesting high levels of protein HOS for 
rhGH.  
There is high correlation with the structural changes identified in the two FPOP 
methodologies, capillary-flow (Table 20) and single-shot Eppendorf (Table 23), 
validating the proposed latter methodology as an alternative potential workflow for 
FPOP labelling experiments.   
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Figure 88. a) Those residues modified by single-shot FPOP experiments of rhGH are 
highlighted on the XRC structure of rhGH:Zn complex (PDB: 1BP3 [208]). 
Modified residues are highlighted, sites in which %modification remained 
unchanged (blue) and increased (red) for rhGH:Zn 1:10 relative to rhGH. 
Illustration of the b) Zn2+ binding site, residues His-18 and Glu-174 directly 
involved in Zn2+ binding are highlighted (green), as is the stabilising interaction 
of the His-21 to Glu-174. Increased oxidation occurs due to the presence of zinc 
at the His-21 imidazole site indicated (*), revealing an increased surface 
accessibility of this site upon zinc binding. 
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Figure 89. Structural changes of rhGH associated with the presence of zinc (rhGH:Zn 
1:10) identified by a) HDX-MS and b) FPOP-MS measurements on the XRC 
structure of rhGH:Zn complex (PDB 1BP3, [208]); b) the primary and 
secondary (α-helices A-D indicated by bars) sequence of rhGH. Shaded regions 
illustrate those regions of increased deuterium uptake (red) and decreased 
uptake (cyan) in HDX-MS measurements, relative to free rhGH. Side chain 
residues modified by FPOP labelling experiments are modelled or indicated by 
a (*), both those that underwent no changes in oxidation (purple) and those that 
saw an increase in oxidation (red) due to the presence of zinc.  Residues His-18, 
His-21 and Glu-174 indicated in Zn 2+ binding are indicated. Sequence coverage 
missing from HDX-MS analysis are indicated by grey bars in c). 
- 226 - 
4.3.3 Comparison of FPOP-MS, HDX-MS and IMS-MS measurements 
FPOP-MS and HDX-MS can be considered complementary protein footprinting 
strategies, with FPOP-MS providing structural insights into the surface accessibility 
of amino acid side chains and HDX-MS providing insights into hydrogen bonding 
and the solvent accessibility of backbone amides within a protein structure. To better 
understand the comparability of the two footprinting techniques and to characterise 
the rhGH model system further, the structural changes and/or dynamics identified in 
the between rhGH and zinc containing samples by both HDX-MS and FPOP-MS 
measurements are here considered.  Figure 89, illustrates a summary of the structural 
changes identified in the two datasets for the rhGH:Zn 1:10 sample relative to rhGH.   
For rhGH:Zn 1:10 samples, four regions of small but localised structural changes 
associated with the presence of zinc ligands were detected by HDX-MS (Chapter 2, 
section 2.3.1.6) measurements. Increased HDX rates were localised to residues 17-32 
and 119-124,  and reduced HDX rates for residues 5-9 and 180-191, demonstrating 
both increased and decreased structural dynamics respectively.  In parallel, four amino 
acid side chains were identified as exhibiting increased oxidation/SASA by FPOP-
MS analysis, Pro-2, His-21, Phe-25 and Met-125.   
In Chapter 2, it was hypothesised that the increased HDX-MS measurements observed 
for residues 17-32,  that include residues His-18 and His-21 involved in zinc binding, 
was as a result of the outwards orientation of this hydrophobic α-helix region (helix 
A). Should this occur, then one would expect the SASA of the correlating amino acid 
side chains to increase. Indeed increased FPOP modification rates were observed for 
both His-21 and Phe-25 in the presence of zinc.  However, the third residue involved 
in zinc binding of rhGH, residue Glu-174 [208], revealed no significant structural 
change based on HDX-MS measurements. Similarly, there was an absence of 
modification for the Glu-174 side chain and surrounding residues, including Met-175, 
during FPOP-MS analysis. The very low exchange HDX rates (Figure 40) occurring 
in this region, suggest the burial of the residue within the highly hydrophobic central 
cavity of the rhGH structure. This combined with the absence of a FPOP modification 
site may tend to suggest this region to be a poor structural probe for HDX-MS and 
FPOP-MS measurements in this specific model system, highlighting some of the 
limitations of the techniques.  
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The increased HDX dynamics observed for region 119-124 (EGIQTL) in the presence 
of zinc, suggests destabilisation of this area. The lack of FPOP modification for these 
specific residues, makes commenting on structural changes on these residues  
impossible from the FPOP-MS measurements. However, FPOP-MS analysis did 
reveal increased surface accessibility for Met-125 side chain, which aligns to a very 
similar region of the primary sequence.  When interpreting data it should be 
considered, that there is an increased propensity of methionine side chains to undergo 
hydroxyl radical oxidation (Table 3), compared to surrounding residues of EGIQTL, 
which may explain a preferential oxidation site at Met-125.  
As for the increases in SASA observed for Phe-1 and Pro-2 in the presence of zinc, 
no HDX-MS data are available, as a result of the loss of N-terminal amide deuteration 
via back exchange [125]. FPOP-MS analysis in this context has offered structural 
insights unobtainable from conventional bottom up HDX-MS experiments. In contrast 
no FPOP modification was observed for the residues, 5-9 (PLSRL), a region which 
showed a decrease in structural dynamics in the presence of zinc as revealed by HDX-
MS analysis. However, the increased modification of the two N-terminal residues 
could be an associated long range structural change as a result of changes in the 5-9 
region.  This demonstrates the utility of combing measurements obtained from both 
techniques.  
Decreased dynamics for the C-terminal region, spanning residues 180-191 
(VQCRSVEGSCGF) was also indicated by HDX-MS measurements. Though no 
specific amino acid resolution could be afforded, relative comparison of overlapping 
peptidic sequences in this region indicate that structural changes occur in 180-185 
region as well as 185-191. Modification of the Cys189 residue was identified by 
FPOP-MS measurements, yet the modification was unaffected due to the presence of 
zinc. Combination of insights from both these datasets would indicate that the 
structural changes occur in 180-188 region.  Finally, the structure of residue Met-14 
appears to be unaffected by the presence of zinc in both FPOP-MS and HDX-MS data 
sets.  
Similarly for rhGH:Zn 1:2 samples, comparison of structural changes as identified by 
both HDX- and FPOP-MS analysis, relative to free rhGH, show good correlation. 
Only structural changes in the 17-32 region were identified by HDX-MS 
measurements, in the form of increased dynamics in presence of zinc, this aligns with 
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the increased oxidation of Phe-25-para and -meta sites as measured by FPOP-MS. In 
addition, increased oxidisation was also observed for Pro-2 during FPOP-MS, though 
no sequence coverage was observed for this residue as discussed, previously.   
Overall a very strong correlation exists between the localised regions of structural 
change, identified by HDX- and FPOP-MS for the rhGH model system. Both data sets 
indicate small localised structural changes in HOS for rhGH due to the presence of 
zinc, that are both specific to the binding site and alternative long range sites.   
CIU-IMS-MS measurements indicate a small increase in global stability for rhGH in 
the presence of zinc, however localised structural insights from HDX-MS and FPOP-
MS measurements showed a combination of destabilising and stabilising changes in 
secondary and tertiary structures. Though all technologies are showing to be effective 
at indicating a change in HOS, this suggests a disparity between MS HOS 
measurements at a global and localised peptidic level.  Perhaps this indicates a 
necessity to characterise or monitor changes in HOS on multiple levels, to give 
confidence and to comply with such regulation as is indicated in pharmaceutical 
guidelines.  
4.4 Conclusions 
The rhGH:Zn model system has here been successfully applied not only to validate 
and illustrate comparability of the two FPOP-MS workflows described but also to 
assess their sensitivity towards small structural changes. For the single-shot 
Eppendorf FPOP workflow, structural changes were detected and characterised at an 
amino acid level at both the lower, 1:2, and higher, 1:10 rhGH:Zn ratio, demonstrating 
comparable sensitivity to that of HDX-MS.  Additionally, the model system was used 
to explore and validate a novel FPOP-MS labelling workflow using a single-shot 
labelling approach, offering a potentially higher through-put and an alternative 
labelling strategy should protein samples be inapplicable to conventional capillary 
flow FPOP labelling strategies. FPOP-MS measurements performed in this thesis 
have been based on relative quantification between samples.  As aforementioned, the 
potential to apply established quantitative workflows within the FPOP-MS workflow 
is high, and is this an avenue which moving forward should be explored.  
A relatively new analytical platform compared to that of HDX-MS, FPOP-MS is less 
established in an industrial setting, and requires systematic validation of analysis 
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workflows to facilitate use in a regulatory context.  The data acquired here not only 
demonstrate the strong correlation and complementary structural information that can 
be gained using multiple protein footprinting techniques, but also help to validate the 
FPOP-MS technology as a whole.  The current data workflows for FPOP-MS data 
analysis are very manual and cumbersome,  but should they be more streamlined and 
robust it is possible to achieve amino acid resolution with a less data heavy approach 
compared to HDX-MS workflows.  
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Conclusions and future work
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Chapter 5 
Conclusions and future works 
The development of protein based therapeutics has revolutionised the 
biopharmaceutical industry, resulting in these biotherapeutics becoming a dominant 
drug class. Secondary, tertiary and quaternary HOS structures of these biotherapeutics 
are considered CQAs for reasons of stability, efficacy and immunogenicity. For these 
reasons protein HOS measurements are necessary throughout the product life cycle, 
used to demonstrate comparability of biotherapeutics when changes in the 
manufacturing process occur [61] or even bio-similarity between a proposed product 
and an innovator product [218].  However, many of the analytical capabilities for the 
characterisation and sufficient monitoring of changes in the HOS and/or other CQAs 
of these drug candidates, have not yet been fully validated to wholly support the 
regulations defining such drugs. Though a wide plethora of analytical technologies 
exist for the analysis of protein HOS, little is known about the suitable applicability 
or sensitivity towards small structural changes of a particular candidate drug for each 
technology.  In addition, regulators encourage the use of multiple analytical platforms 
for monitoring for changes in HOS, yet no specific guidance is provided on which 
techniques should be implemented. Nor is there guidance on how to provide data to 
regulators which establishes the sensitivity of these techniques towards small but 
reproducible changes in HOS.  
In the clinical and diagnostic area use of RMs has long since been used for method 
development, validation, uncertainty definitions and indeed harmonisation of 
quantification assays [57, 58].  Such RMs to support the utilisation of protein HOS 
measurements have, however, been absent.  
This thesis aimed to assess, develop and characterise two potential model systems of 
increasing complexity, based on protein RMs for use to support analytical method 
validation and define sensitivity of different MS–based analytical platforms towards 
small structural changes. These protein RMs were stressed to induced structural 
changes, simulating small changes which may occur during manufacturing and 
processing of a candidate drug biomolecule.  
In Chapter 2, the WHO material 98/574, an international RM based on rhGH, a small, 
relatively simple bio-therapeutic, was first used to systematically develop analytical 
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methods for HOS measurements in a robust metrological manner, defining the 
repeatability and reproducibility of HDX-MS and IMS-MS methods developed.  For 
both technologies, it was demonstrated that the inter-day reproducibility dominated 
over within-day measurements.  
Once the analytical methods were developed and their variability critically assessed, 
the sensitivity of these methods towards small structural changes was tested using a 
model system based on rhGH, in which varying amount of zinc ligands were 
introduced so as to induce structural changes of varying magnitudes. This model 
system was used as a proof-of-principle to test a statistical model developed here 
based on HDX-MS measurements, differentiating between measurement variability 
and significant HOS change by considering measurement thresholds. Both HDX-MS 
and IMS-MS measurements revealed that as the relative amount of zinc was increased 
the magnitude of structural change increased, with HDX-MS providing specific 
localised structural changes and global insights from IMS-MS measurements. These 
varying magnitudes of structural changes characterised for the model system, offer a 
valuable tool for establishing the sensitivity of an analytical platform towards 
structural changes.  
In Chapter 4, it’s illustrated, how these data can be used as reference datasets to 
develop and benchmark alternative analytical methods, such as was demonstrated for 
both an established and a novel higher throughput FPOP-MS workflow. Small 
localised structural changes associated with the presence of zinc ligands as 
characterised by HDX-MS measurements, were confirmed by orthogonal FPOP-MS 
measurements. Analogous sensitivity towards small structural changes was 
demonstrated for the FPOP-MS and HDX-MS methods developed, with IMS-MS 
providing similar sensitivity albeit at a lower resolution, though more conducive to a 
higher throughput QC type environment. Figure 90, illustrates the extensive 
characterisation of all levels of protein HOS of the rhGH:Zn model system using 
largely MS-based measurements produced in this thesis.  
Validation of HDX-MS and IMS-MS analytical methods plus the HDX-MS statistical 
model developed in Chapter 2, was illustrated using a model system, based on the 
NISTmAb RM 8761, a more complex and potentially pharmaceutically relevant 
molecule, in Chapter 3. In order to stress the protein HOS of the RM molecule, 
enzymes were used to generate differing Fc-glycan states, analogous to the type of 
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changes to a CQA that regulators state must be monitored for during manufacturing 
processes [62]. Again both HDX-MS and IMS-MS methods were demonstrated as 
being effective in monitoring for changes in protein HOS, though it was apparent that 
HDX-MS measurements demonstrated superior sensitivity towards smaller structural 
changes. The structural changes identified were analogous to previous studies of 
mAbs which show destabilising kinetics as a result of glycan structure loss [130, 279, 
287], further validating the approach and methods developed.  
One of the aims of this thesis was to develop and fully characterise model protein RM 
systems to support comparability studies to better understand analytical technologies 
for protein HOS measurements. Figure 90 and Figure 91 represent the information 
extracted from the analytical measurements produced in this thesis largely using MS-
based measurements, providing reference datasets at all levels of higher order 
structure for these model systems which can be compared with cross and with-
platform measurements performed in other laboratories.  
The comparability of several MS-based methods has been demonstrated here, 
however more data need to be produced to better understand cross comparison 
measurements. One manner in which this can be achieved is by performing inter-
laboratory comparisons such as that undertaken with NISTmAb HDX-MS 
measurements [296] though this study focuses on the comparability of absolute 
measurements and not the ability of methods to detect structural changes. In contrast, 
these model systems offer candidate systems for such studies; indeed, work has begun 
on collating the data from an interlaboratory comparison conducted outside the scope 
of this thesis based on the rhGH:Zn model system [233].  In this study analysis of the 
model system was performed across multiple platforms, including biophysical 
technologies, such as Raman, DSC, AUC, NMR, HDX-MS (multiple labs), IMS-MS 
(multiple labs) to mention but a few.  
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Figure 90. Higher order structure characterisation of rhGH RM and rhGH:Zn model system. Structural interpretation for rhGH:Zn samples are 
described relative to rhGH RM control.  
- 235 - 
 
Figure 91. Higher order structure characterisation of NISTmAb RM and deglycosylated and degalactosylated Fc-glycan variants (DeGly and ExoGal 
respectively). Structural interpretation for Fc-glycan variants are described relative to NISTmAb RM control.  
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Though the statistical model developed for defining thresholds for HDX-MS 
measurements (Chapter 2 & 3) was proven to be effective, the measurement, data 
collation and analysis was relatively cumbersome and not amenable to high 
throughput QC analysis. It is hoped that with further analysis of the data, and 
complementary datasets from the inter-laboratory comparison mentioned, the sources 
of measurement uncertainty and  their overall contribution herein can be better defined 
for HDX-MS measurements. This may allow for the definition of measurement 
thresholds for this RM model system which can be produced from a less 
comprehensive dataset, i.e. generation of fewer replicate datasets, in alternative 
laboratories. In addition by performing in depth analysis of the measurement 
uncertainties associated with HDX-MS measurements this is a step forwards to the 
standardisation of HDX-MS measurements.  
Recently, the first comparisons of FPOP-MS with HDX-MS measurements [110, 113, 
297] have validated and illustrated the potential value of the FPOP-MS analytical 
technology within the biopharmaceutical area. Yet, the lack of software and 
established data analysis  workflows  for these analysis is  likely to hold  the technique 
back  within this context. As demonstrated in Chapter 4, it is possible that these model 
RM systems can be used to drive development in this area and move towards 
standardisation. For example, analysis of FPOP-MS data showed labelling 
reproducibility to be a limiting factor for increasing the sensitivity towards structural 
changes using the FPOP-MS methods here described in this thesis. The potential 
introduction of internal standards, may allow for the reduction of such measurement 
uncertainty and hence increase the sensitivity of the technique towards small structural 
changes.  
Finally, from a metrological perspective, it is hoped that through the development and 
validation of protein HOS measurements a better understanding of the link between 
the traceable quantification of a protein based on amount ( ~ kg, often based on the 
primary structure)  and the activity of a protein in an assay (of which protein HOS can 
be a contributing factor) can be established. Disparity between these two 
measurements make establishing a traceability chain from assay measurement to a SI 
unit limited. For example, performing such studies as epitope mapping of clinical 
assay targets can assist in defining the measurands of clinical assays, which in turn 
will assist with harmonisation of clinical measurands. Alternative protein footprinting 
technologies such as XL-MS, due to their applicability to a complex biological matrix 
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and potential for introduction of traceable standards, offer a potential pathway for the 
quantification of protein HOS and hence ultimately establish a link between primary 
sequence and activity of a protein in a clinical assay. The use of such RM model 
systems as those proposed here will be pivotal in establishing these links and aid future 
development.     
As for the bio-pharmaceutical industry, structural MS platforms show great potential 
for structural characterisation of bio-therapeutics and are fast becoming established 
within the bio-analytical toolbox of these industries.  Use of appropriate standards and 
QCs will assist the standardisation of these techniques, and for IMS-MS in particular, 
the potential move away from an R&D environment and into a more high throughout 
QC type environment. As for use within the R&D environment itself, the application 
of HDX-MS either on its own and in conjunction with other structural technique, such 
as NMR[298], XL-MS[299] and native-MS[300] has been repeatedly demonstrated 
as being at the cutting edge of studying protein structure and dynamics. In recent years 
there has been an expansion of the use of XL-MS through developments in cross-
linking chemistry and software for cross-linkage identification. In their current state, 
XL-MS and FPOP-MS suffer from similar limitations of low abundance of 
modification, issues of identification and the lack of standardisation and automated 
downstream data workflows.  However if these issues are continued to be addressed 
by the community these techniques show great potential for these techniques 
providing structural insights into bio-therapeutics both in and ex vivo and on a 
potentially quantitative basis, a feat that would unique to such high resolution 
techniques.   
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Appendix  
Table A-24. PLGS workflow and processing parameters used for peptide 
identification from MSE experiments 
Workflow parameters 
Peptide tolerance 20 ppm 
Fragment tolerance 10 ppm 
Min fragment ion matches per protein 2 
Min fragment ion matches per peptide 7 
Min peptide matches per protein 1 
Maximum protein mass            250,000  
Primary digestion reagents Non-specific 
Missed Cleavages 1 
Variable modified reagents Oxidation, M 
False discovery rate 2 
    
Processing parameters 
Chromatographic peak width Automatic 
MS TOF resolution Automatic 
Lock mass for charge 2 785.8426 Da 
Lock mass window 0.25 Da 
Low energy threshold 500 counts 
Elevated energy threshold 100 counts 
Intensity threshold 750 counts 
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Table A-25. Raw differential HDX-MS measurements, S (i),  between rhGH and rhGH:Zn 1:2 and 1:10 samples. Measurement thresholds (SL) 
established for rhGH vial to vial comparability study are also stated. For comparison with rhGH:Zn samples those measurements highlighted in red 
are measurements which show a significant structural change relative to established thresholds.   All measurements were performed in triplicate and 
the error of each measurement is represented by the standard deviation (SD S) of the averaged measurements. 
 
Identifier rhGH:Zn 1:2 rhGH:Zn 1:10 Vial-to-vial rhGH Threshold SL  
Peptide, i Peptide ID   S (i) , Da SD S  S (i)  , Da SD S  S (i)  , Da SD S SL +  SL -  
1 1-9- 0.16 0.10 0.51 0.12 0.28 0.14 0.42 -0.42 
2 2-9- -0.04 0.15 0.51 0.16 0.19 0.02 0.21 -0.21 
3 3-9- 0.18 0.12 0.33 0.10 0.24 0.09 0.33 -0.33 
4 14-25- -0.19 0.08 -0.62 0.10 0.11 0.03 0.14 -0.14 
5 15-25- -0.33 0.09 -0.81 0.08 0.08 0.03 0.11 -0.11 
6 16-25- -0.16 0.08 -0.78 0.07 0.12 0.07 0.19 -0.19 
7 26-32- -0.93 0.06 -1.70 0.06 0.24 0.14 0.37 -0.37 
8 31-44- -0.17 0.24 -0.17 0.25 0.16 0.06 0.22 -0.22 
9 32-44- -0.09 0.28 -0.01 0.25 0.21 0.04 0.25 -0.25 
10 33-44- -0.39 0.21 0.15 0.26 0.31 0.06 0.37 -0.37 
11 34-44- -0.09 0.15 -0.15 0.21 0.18 0.03 0.21 -0.21 
12 35-44- -0.13 0.22 0.03 0.24 0.20 0.04 0.24 -0.24 
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13 45-51- -0.05 0.11 -0.02 0.10 0.22 0.05 0.27 -0.27 
14 45-52- -0.13 0.11 0.03 0.10 0.18 0.07 0.25 -0.25 
15 45-63- -0.81 0.62 -0.18 0.52 0.79 0.38 1.18 -1.18 
16 53-63- 0.04 0.17 -0.19 0.17 0.21 0.07 0.28 -0.28 
17 53-73- -0.03 0.43 -0.44 0.32 0.38 0.06 0.43 -0.43 
18 54-63- -0.07 0.16 -0.22 0.15 0.27 0.10 0.37 -0.37 
19 54-73- -0.32 0.35 -0.26 0.34 0.71 0.19 0.90 -0.90 
20 55-63- -0.15 0.12 -0.08 0.11 0.21 0.04 0.25 -0.25 
21 55-73- -0.16 0.31 -0.14 0.31 0.53 0.27 0.80 -0.80 
22 64-73- 0.11 0.19 -0.09 0.16 0.57 0.19 0.76 -0.76 
23 77-83- -0.05 0.05 0.09 0.08 0.17 0.08 0.24 -0.24 
24 81-87- - - - - 0.11 0.04 0.14 -0.14 
25 86-92- -0.56 0.34 -0.36 0.41 0.15 0.06 0.21 -0.21 
26 93-100- -0.22 0.10 -0.37 0.14 0.21 0.04 0.25 -0.25 
27 98-106- -0.05 0.12 -0.21 0.15 0.21 0.08 0.29 -0.29 
28 98-110- -0.07 0.18 -0.08 0.81 0.24 0.10 0.34 -0.34 
29 101-110- -0.17 0.18 -0.37 0.16 0.31 0.14 0.45 -0.45 
30 102-110- -0.02 0.10 0.16 0.12 0.14 0.03 0.17 -0.17 
31 107-113- -0.01 0.05 0.05 0.06 0.09 0.01 0.10 -0.10 
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32 111-119- 0.12 0.12 0.05 0.07 0.13 0.02 0.15 -0.15 
33 111-120- - - - - 0.14 0.03 0.17 -0.17 
34 114-124- -0.15 0.07 -0.48 0.05 0.16 0.06 0.21 -0.21 
35 115-124- -0.12 0.06 -0.40 0.03 0.10 0.02 0.12 -0.12 
36 117-124- -0.19 0.02 -0.45 0.09 0.15 0.06 0.20 -0.20 
37 125-138- 0.00 0.19 0.25 0.21 0.40 0.07 0.47 -0.47 
38 125-139- -0.15 0.32 0.28 0.29 0.30 0.08 0.38 -0.38 
39 125-146- -0.03 0.43 0.31 0.49 0.49 0.18 0.67 -0.67 
40 126-146- -0.07 0.84 - - 0.44 0.22 0.66 -0.66 
41 140-146- -0.04 0.09 0.03 0.96 0.24 0.03 0.27 -0.27 
42 140-157- - - -0.01 0.56 0.34 0.15 0.49 -0.49 
43 147-156- -0.02 0.09 0.08 0.09 0.10 0.03 0.14 -0.14 
44 147-157- 0.00 0.12 0.05 0.08 0.09 0.03 0.11 -0.11 
45 155-163- -0.09 0.11 -0.04 0.09 0.21 0.08 0.29 -0.29 
46 156-163- 0.05 0.14 0.05 0.10 0.24 0.10 0.34 -0.34 
47 157-163- -0.09 0.14 -0.02 0.13 0.19 0.08 0.27 -0.27 
48 164-175- -0.09 0.25 -0.18 0.10 0.09 0.02 0.11 -0.11 
49 167-176- -0.11 0.15 -0.18 0.08 0.16 0.03 0.19 -0.19 
50 176-182- 0.02 0.07 0.08 0.08 0.10 0.03 0.13 -0.13 
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51 178-191- - - 0.88 0.18 0.36 0.10 0.46 -0.46 
52 182-191- 0.18 0.14 0.70 0.18 0.19 0.03 0.22 -0.22 
53 183-191- -0.03 0.13 0.51 0.16 0.16 0.05 0.21 -0.21 
 
Table A-26. Raw differential HDX-MS measurements, S(i),  between NISTmAb RM and Fc glycan variants. Measurement thresholds (SL) established 
for NISTmAb RM vial to vial comparability study are stated. For comparison with Fc-glycan variants those measurements highlighted in red 
are measurements which show a significant structural change relative to established thresholds.   All measurements were performed in triplicate 
and the error of each measurement is represented by the standard deviation (SD S) of the averaged measurements. 
Identifier Degly NISTmAb Exogal NISTmAb 
Vial-to-vial 
Gly NISTmAb 
Threshold SL 
Peptide, i Peptide ID   S (i) , Da SD S  S (i)  , Da SD S  S (i)  , Da SD S SL +  SL -  
1 Heavy Chain-5-17- -0.17 0.08 0.44 0.11 0.10 0.05 0.15 -0.15 
2 Heavy Chain-5-18-  -   -   -   -  0.12 0.05 0.17 -0.17 
3 Heavy Chain-5-19- -0.27 0.08 0.40 0.14 0.14 0.04 0.19 -0.19 
4 Heavy Chain-5-20- -0.26 0.09 0.38 0.09 0.16 0.04 0.20 -0.20 
5 Heavy Chain-14-34-  -   -   -   -  0.05 0.03 0.09 -0.09 
6 Heavy Chain-21-27- -0.11 0.04 0.05 0.07 0.06 0.02 0.07 -0.07 
7 Heavy Chain-35-46-  -   -   -   -  0.05 0.04 0.09 -0.09 
8 Heavy Chain-35-50- -0.15 0.16 0.18 0.17 0.10 0.06 0.15 -0.15 
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9 Heavy Chain-36-50- -0.12 0.16 0.17 0.19 0.07 0.05 0.12 -0.12 
10 Heavy Chain-37-50-  -   -   -   -  0.07 0.02 0.09 -0.09 
11 Heavy Chain-38-50-  -   -   -   -  0.16 0.15 0.31 -0.31 
12 Heavy Chain-39-48- -0.07 0.04 0.16 0.07 0.07 0.01 0.08 -0.08 
13 Heavy Chain-39-50-  -   -   -   -  0.06 0.01 0.07 -0.07 
14 Heavy Chain-66-82- -0.14 0.07 0.38 0.11 0.07 0.03 0.09 -0.09 
15 Heavy Chain-70-82- -0.05 0.06 0.20 0.07 0.08 0.03 0.10 -0.10 
16 Heavy Chain-72-82-  -   -   -   -  0.12 0.03 0.15 -0.15 
17 Heavy Chain-83-94- 0.00 0.12 0.06 0.11 0.05 0.07 0.13 -0.13 
18 Heavy Chain-106-115- -0.13 0.06 0.14 0.04 0.11 0.09 0.20 -0.20 
19 Heavy Chain-106-117- -0.09 0.10 0.09 0.09 0.07 0.06 0.13 -0.13 
20 Heavy Chain-107-117- 0.02 0.07 0.14 0.07 0.07 0.07 0.14 -0.14 
21 Heavy Chain-118-145- -0.10 0.17 0.09 0.11 0.28 0.16 0.44 -0.44 
22 Heavy Chain-118-147- -0.27 0.23 0.00 0.15 0.43 0.22 0.66 -0.66 
23 Heavy Chain-149-158- -0.07 0.12 0.18 0.13 0.08 0.05 0.12 -0.12 
24 Heavy Chain-159-166- -0.34 0.06 0.30 0.13 0.09 0.02 0.11 -0.11 
25 Heavy Chain-159-170- -0.35 0.09 0.30 0.16 0.18 0.03 0.21 -0.21 
26 Heavy Chain-159-177- -0.45 0.09 0.30 0.19 0.13 0.10 0.23 -0.23 
27 Heavy Chain-162-177- -0.33 0.09 0.13 0.13 0.13 0.04 0.17 -0.17 
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28 Heavy Chain-165-177- -0.18 0.09 0.12 0.08 0.08 0.06 0.15 -0.15 
29 Heavy Chain-166-177- -0.12 0.04 0.14 0.08 0.07 0.03 0.09 -0.09 
30 Heavy Chain-167-177- -0.24 0.09 0.14 0.09 0.35 0.35 0.70 -0.70 
31 Heavy Chain-171-177- -0.10 0.03 0.07 0.04 0.05 0.02 0.07 -0.07 
32 Heavy Chain-183-200- -0.18 0.14 0.06 0.11 0.29 0.22 0.50 -0.50 
33 Heavy Chain-188-196- -0.07 0.03 0.04 0.06 0.05 0.03 0.08 -0.08 
34 Heavy Chain-188-200- -0.12 0.08 0.01 0.09 0.13 0.01 0.14 -0.14 
35 Heavy Chain-189-196- -0.11 0.04 0.10 0.06 0.05 0.01 0.06 -0.06 
36 Heavy Chain-189-200- -0.12 0.10 0.11 0.12 0.10 0.02 0.12 -0.12 
37 Heavy Chain-238-244- -0.79 0.03 0.03 0.06 0.02 0.01 0.04 -0.04 
38 Heavy Chain-238-255-  -   -   -   -  0.13 0.09 0.22 -0.22 
39 Heavy Chain-244-254- -0.89 0.04 -0.05 0.09 0.04 0.01 0.05 -0.05 
40 Heavy Chain-245-254- -0.77 0.22 -0.08 0.20 0.02 0.02 0.04 -0.04 
41 Heavy Chain-245-255- -1.08 0.08 -0.01 0.11 0.03 0.02 0.05 -0.05 
42 Heavy Chain-246-255- -0.85 0.05 -0.28 0.06 0.07 0.07 0.14 -0.14 
43 Heavy Chain-247-254- -0.60 0.03 -0.16 0.05 0.04 0.04 0.09 -0.09 
44 Heavy Chain-247-255- -0.75 0.03 -0.27 0.06 0.06 0.00 0.06 -0.06 
45 Heavy Chain-255-264- - - - - 0.11 0.08 0.19 -0.19 
46 Heavy Chain-256-263- -0.08 0.03 0.06 0.03 0.04 0.01 0.05 -0.05 
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47 Heavy Chain-256-265- -0.02 0.03 0.06 0.04 0.08 0.06 0.14 -0.14 
48 Heavy Chain-265-278- -1.33 0.06 0.11 0.08 0.10 0.07 0.17 -0.17 
49 Heavy Chain-265-280- -1.35 0.10 0.16 0.15 0.09 0.03 0.12 -0.12 
50 Heavy Chain-266-280- -1.28 0.05 0.15 0.11 0.13 0.08 0.22 -0.22 
51 Heavy Chain-267-280- -1.02 0.10 0.06 0.09 0.09 0.04 0.13 -0.13 
52 Heavy Chain-269-280- -0.25 0.15 0.12 0.13 0.06 0.01 0.07 -0.07 
53 Heavy Chain-310-321- -0.18 0.12 0.08 0.13 0.09 0.05 0.14 -0.14 
54 Heavy Chain-310-336- -0.42 0.07 0.27 0.16 0.14 0.07 0.21 -0.21 
55 Heavy Chain-310-359- - - - - 0.34 0.44 0.78 -0.78 
56 Heavy Chain-312-321- -0.27 0.08 0.06 0.08 0.06 0.05 0.12 -0.12 
57 Heavy Chain-322-336- - - - - 0.10 0.04 0.14 -0.14 
58 Heavy Chain-337-351- -0.04 0.06 0.27 0.14 0.10 0.03 0.13 -0.13 
59 Heavy Chain-337-359- -0.16 0.49 0.41 0.49 0.13 0.07 0.21 -0.21 
60 Heavy Chain-337-368- - - - - 0.26 0.09 0.35 -0.35 
61 Heavy Chain-352-359- 0.00 0.07 0.03 0.07 0.03 0.01 0.04 -0.04 
62 Heavy Chain-352-368- -0.24 0.13 0.18 0.12 0.10 0.03 0.13 -0.13 
63 Heavy Chain-355-368- 0.02 0.10 0.19 0.08 0.23 0.13 0.35 -0.35 
64 Heavy Chain-369-379- -0.03 0.06 -0.04 0.10 0.11 0.07 0.18 -0.18 
65 Heavy Chain-369-383- -0.02 0.14 0.08 0.11 0.11 0.01 0.12 -0.12 
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66 Heavy Chain-371-383- 0.09 0.08 0.14 0.10 0.07 0.05 0.11 -0.11 
67 Heavy Chain-372-379- 0.07 0.04 0.06 0.03 0.04 0.02 0.06 -0.06 
68 Heavy Chain-372-381- 0.09 0.05 0.03 0.13 0.13 0.16 0.29 -0.29 
69 Heavy Chain-372-382- - - - - 0.10 0.08 0.17 -0.17 
70 Heavy Chain-372-383- 0.10 0.07 0.14 0.07 0.04 0.01 0.05 -0.05 
71 Heavy Chain-380-393- - - - - 0.16 0.05 0.22 -0.22 
72 Heavy Chain-380-401- -0.11 0.15 0.23 0.18 0.15 0.13 0.28 -0.28 
73 Heavy Chain-382-401- -0.05 0.14 0.34 0.17 0.18 0.11 0.29 -0.29 
74 Heavy Chain-383-393- - - - - 0.13 0.05 0.18 -0.18 
75 Heavy Chain-384-393- -0.05 0.07 0.11 0.15 0.10 0.04 0.13 -0.13 
76 Heavy Chain-384-401- -0.13 0.09 0.24 0.15 0.08 0.08 0.16 -0.16 
77 Heavy Chain-385-401- - - - - 0.13 0.13 0.26 -0.26 
78 Heavy Chain-394-401- 0.02 0.03 0.11 0.06 0.03 0.04 0.07 -0.07 
79 Heavy Chain-395-401- 0.03 0.03 -0.02 0.05 0.05 0.07 0.12 -0.12 
80 Heavy Chain-402-408- 0.04 0.05 -0.02 0.07 0.08 0.09 0.17 -0.17 
81 Heavy Chain-414-425- - - - - 0.13 0.05 0.18 -0.18 
82 Heavy Chain-414-426- -0.19 0.08 0.33 0.14 0.07 0.02 0.10 -0.10 
83 Heavy Chain-427-449- -0.04 0.47 0.28 0.48 0.06 0.03 0.10 -0.10 
84 Heavy Chain-429-449- -0.02 0.69 0.28 0.74 0.09 0.02 0.11 -0.11 
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85 Heavy Chain-430-449- -0.21 0.06 0.18 0.10 0.07 0.01 0.08 -0.08 
86 Heavy Chain-432-449- -0.11 0.15 0.19 0.18 0.06 0.02 0.08 -0.08 
87 Heavy Chain-432-450- -0.08 0.46 0.25 0.48 0.11 0.08 0.19 -0.19 
88 Heavy Chain-434-449- -0.16 0.15 0.13 0.17 0.09 0.07 0.16 -0.16 
89 Heavy Chain-436-449- 0.18 0.08 0.29 0.15 0.05 0.03 0.08 -0.08 
1 Light Chain-5-11- 0.03 0.07 0.12 0.07 0.09 0.07 0.16 -0.16 
2 Light Chain-35-45- -0.24 0.09 0.15 0.05 0.12 0.03 0.15 -0.15 
3 Light Chain-36-45-  -   -   -   -  0.13 0.03 0.15 -0.15 
4 Light Chain-39-45-  -   -   -   -  0.04 0.05 0.08 -0.08 
5 Light Chain-46-53- -0.02 0.06 0.02 0.10 0.08 0.05 0.13 -0.13 
6 Light Chain-54-70- 0.00 0.23 0.24 0.20 0.31 0.15 0.46 -0.46 
7 Light Chain-71-81- 0.08 0.09 -0.02 0.12 0.06 0.02 0.08 -0.08 
8 Light Chain-71-82- -0.03 0.04 0.08 0.09 0.10 0.03 0.13 -0.13 
9 Light Chain-72-82- 0.00 0.13  -   -  0.19 0.06 0.25 -0.25 
10 Light Chain-74-82- -0.02 0.07  -   -  0.12 0.04 0.16 -0.16 
11 Light Chain-89-115- -0.03 0.28  -   -  0.16 0.03 0.19 -0.19 
12 Light Chain-115-121- -0.03 0.02 0.02 0.05 0.05 0.01 0.06 -0.06 
13 Light Chain-115-122- -0.07 0.03 0.04 0.05 0.09 0.02 0.11 -0.11 
14 Light Chain-115-124- -0.11 0.10 0.22 0.19 0.08 0.05 0.14 -0.14 
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15 Light Chain-116-122-  -   -   -   -  0.06 0.04 0.10 -0.10 
16 Light Chain-122-131- -0.28 0.05 0.23 0.09 0.08 0.04 0.12 -0.12 
17 Light Chain-123-131- 0.00 0.11 0.01 0.07 0.04 0.01 0.05 -0.05 
18 Light Chain-125-133-  -   -   -   -  0.07 0.03 0.10 -0.10 
19 Light Chain-131-142- -0.10 0.16 0.04 0.12 0.10 0.04 0.14 -0.14 
20 Light Chain-135-160- -0.49 0.31 0.24 0.31 0.27 0.15 0.42 -0.42 
21 Light Chain-143-160- -0.23 0.22 0.21 0.30 0.23 0.06 0.29 -0.29 
22 Light Chain-148-160- 0.03 0.11 0.14 0.20 0.12 0.06 0.17 -0.17 
23 Light Chain-161-171-  -   -   -   -  0.08 0.07 0.15 -0.15 
24 Light Chain-161-174- -0.07 0.09 0.16 0.07 0.05 0.04 0.09 -0.09 
25 Light Chain-161-177- -0.14 0.15 0.13 0.09 0.11 0.02 0.13 -0.13 
26 Light Chain-161-178- -0.16 0.16 0.03 0.09 0.14 0.02 0.16 -0.16 
27 Light Chain-172-178- -0.07 0.05 0.07 0.06 0.04 0.03 0.07 -0.07 
28 Light Chain-172-180- -0.06 0.08 0.11 0.06 0.09 0.05 0.14 -0.14 
29 Light Chain-178-191-  -   -   -   -  0.04 0.02 0.07 -0.07 
30 Light Chain-178-194- -0.07 0.21 0.14 0.21 0.06 0.02 0.08 -0.08 
31 Light Chain-179-194- 0.01 0.12 0.18 0.10 0.05 0.03 0.08 -0.08 
32 Light Chain-181-194- 0.07 0.26 0.02 0.22 0.04 0.02 0.06 -0.06 
33 Light Chain-195-213- 0.00 0.34 0.17 0.35 0.07 0.05 0.12 -0.12 
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34 Light Chain-201-213- -0.05 0.07 0.09 0.11 0.05 0.04 0.09 -0.09 
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Table A-27. Tryptic peptides from an in-silico digest of rhGH.  
Peptide ID Residues Sequence 
T1 1-8 FPTIPLSR  
T2 9-16 LFDNAMLR 
T3 17-19 AHR 
T4 20-38 LHQLAFDTYQEFEEAYIPK 
T5 39-41 EQK 
T6 42-64 YSFLQNPQTSLCFSESIPTP SNR 
T7 65-70 EETQQK 
T8 71-77 SNLELLR 
T9 78-94 ISLLLIQSWLEPVQFLR 
T10 95-115 SVFANSLVYGASDSNVYDLL K 
T11 116-127 DLEEGIQTLMGR 
T12 128-134 LEDGSPR 
T13 135-140 TGQIFK 
T14 141-145 QTYSK 
T15 146-158 FDTNSHNDDALLK 
T16 159-167 NYGLLYCFR 
T17 168 K 
T18 169-172 DMDK 
T19 173-178 VETFLR 
T20 179-183 IVQCR 
T21 184-191 SVEGSCGF 
 
 
